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Abstract 
Cigarette smoking has become one of the leading causes of preventable deaths all over 
the world, causing a serious threat to human wellbeing and a tremendous economic 
burden to governments. The currently available treatment options for smoking 
cessation are not efficient. The pulmonary delivery of drugs by methods such as dry 
powder inhaler (DPI) has been recognized as one of the most efficient routes of drug 
delivery to the targeted area. The lung delivery of nicotine in this way would be 
expected to mimic the effects of tobacco smoking and could significantly reduce the 
negative health effects of smoking that result from nicotine addiction. 
The aim of this study is to develop nanoparticles with controlled physicochemical 
properties using biodegradable polymer of chitosan (CS) loaded with nicotine salt for 
pulmonary delivery as DPI formulations. The outcomes of this project are expected to 
be a safe and effective CS-based nicotine formulation for pulmonary delivery to treat 
nicotine dependence. This thesis specially addresses the research questions: (1) how 
to develop a feasible process to manufacture the nanoparticles suitable for pulmonary 
drug delivery using biodegradable polymer of CS containing nicotine salt; (2) how to 
develop an animal model for pulmonary drug delivery from DPI formulation using a 
nose-only inhalation device.  
The current therapeutic options for treatment of smoking addiction have been 
reviewed, and current advancements of technology in pulmonary drug delivery are 
summarised. Buccal administration of drugs exhibits a low oral bioavailability, and 
sublingual tablets and chewing gums can be swallowed before being absorbed. 
Although nasal spray of nicotine is a fast way to deliver nicotine into the bloodstream, 
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the rate of absorption is still not as rapid as cigarette smoking. Therefore, it is proposed 
that delivery of nicotine with sustained drug release profile direct into the deep lung is 
likely to more effectively mimic the rapid effects of cigarette smoking on a 
physiological level, which could eliminate patient craving and allow the tapering of 
nicotine level over time to improve patients’ compliance.  
Water in oil (w/o) emulsion crosslinking method has been used to fabricate nicotine 
hydrogen tartrate (NHT)-loaded CS nanoparticles which separate as solid 
microaggregates. The physicochemical properties of particles are characterized by a 
series of techniques. Scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM) shows that the prepared particles are spherical in morphology with 
rough surface after loading CS particles with NHT. Dynamic Light Scattering (DLS) 
by Zetasizer determined nanoparticle size ranging from 167.6 nm to 411 nm, while 
DLS by Mastersizer demonstrated that the microaggregates of these nanoparticles are 
in the respirable range (<5µm). The surface positive charge as measured by zeta 
potential tends to decrease with increase of mass ratios of NHT to CS, which is in 
contrast to the increase of particle size. According to differential scanning calorimetry 
(DSC), x-ray diffraction (XRD) analysis and attenuated total reflectance-Fourier 
transform infrared (ATR-FTIR) spectroscopy, the NHT crystallinity is lost when 
encapsulated in the nanoparticles, indicating it is uniformLy dispersed as a solid 
solution. On the basis of X-ray photoelectron spectroscopy (XPS) analysis, the amount 
of NHT loaded on the surface of CS increases proportionally with increasing drug 
loading in the bulk so there is no surface enhancement. 
In vitro evaluations of drug release, aerosolization, and stability of formulations have 
been performed. In vitro drug release study through dialysis membrane technique 
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shows that NHT releases from CS nanoparticles with a prolonged drug release profile 
up to 4 days. Initial burst release occurred in the first 8 hours due to rapid dissolution 
of NHT at or close to surface of the nanoparticles, followed by a slow release because 
of penetration of the release medium into the microaggregates. A mathematical model 
is designed to correct the discrepancy during drug release measurement due to two 
barriers to diffusion through the dialysis membrane.  It is noted that all the particles 
show a smooth and rounded morphology after a 6-day release under SEM 
observations. In vitro aerosolization study is determined by twin-stage impinger 
apparatus. Fine particle fraction (FPF) of NHT-loaded CS nanoparticles is decreased 
along with increased mass ratios of NHT to CS, which is primarily dominated by the 
zeta potential of particles. The fine particle dose (FPD) of NHT-loaded CS 
nanoparticles increases from 1.7 mg to 3.2 mg, respectively from 1:1 to 3:1 based on 
the same dose of 20 mg in each capsule. In contrast, after mixing inhalable grade 
lactose with NHT-loaded CS nanoparticles, FPF is improved significantly, which is 
independent of zeta potential. In vitro long term stability test indicates NHT-loaded 
CS nanoparticles are stable under the storage condition of 25°C and 60% relative 
humidity and aerosolization of particles does not change significantly in a one-year 
storage.  
In vivo locomotor activity test has been used to investigate spontaneous activity in 
rodents, and evaluate nicotine-mediated behavioural and physiological functions in 
mice. The locomotor activity test via single subcutaneous injection (s.c.) results in an 
obvious dose-related effect in mice, with stimulant effects at the intermediate dose (0.5 
mg/kg for nicotine; 1.0 mg/kg for NHT-loaded CS nanoparticles) and depressant 
effects at the higher dose, indicating that NHT keeps bioactive effects after  loading 
into and release from the CS particles. Locomotor activity test administrated by 
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inhalation exposure using a nose-only inhalation device under the optimum parameters 
of flow rate (0.9 L/min) and exposure duration (5 minutes) shows a dose-related 
travelled distance in one hour, suggesting NHT-loaded CS nanoparticles are able to 
mediate mice locomotion behaviour. Furthermore, no allergic airway inflammation is 
observed by histological analysis of lung sections post 24 hours inhalation powder 
exposure to mice. 
In summary, this study has established a desirable w/o emulsion crosslinking method 
to fabricate NHT-loaded CS nanoparticles/microaggregates. Both in vitro and in vivo 
evaluations of NHT-loaded CS nanoparticles indicate that prepared particles in this 
study are suitable to be exploited as DPI formulations for pulmonary delivery.  It is 
proposed that the advancements of knowledge on pulmonary drug delivery from the 
mouse model will translate to humans and outcomes of this study is promising to 
provide a more targeted therapy approach for the better management of nicotine 
dependence in the future. 
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1.1 BACKGROUND 
Smoking-related disorders have become the major cause of death and mortality in both 
developed and developing countries, posing a serious threat to human wellbeing and a 
tremendous economic burden to governments. This will result in an enormous 
economic burden including direct financial loss (medications, treatments, welfare 
services and disability benefits) and indirect financial loss (lost productivity and 
income due to reduced capability or incapacity), and the estimated economic burden 
induced by nicotine addiction in Australia will exceed $36 billion (Alcohol Education 
and Research Foundation, 2010). Cigarette smoking is not going to disappear in the 
near future. Currently, there are very few effective treatment options for people who 
are suffering from nicotine-related disorders. Recent studies show that 
pharmacotherapeutic compounds currently used for smoking cessation (e.g., e-
cigarette, vareniciline, bupropion) can reduce tobacco consumption and seeking 
behaviour significantly, however, they have some therapeutic limitations: side effects 
such as nausea, depression, even suicidal thoughts and serious neuropsychiatric 
symptoms Kuehn (2009); substantial dosing is required to overcome the gut and enter 
the brain. Therefore, continued research for strategies of smoking cessation remains a 
critical priority.  
Pulmonary drug delivery is a modern and popular therapy approach which combines 
inhalation and respiratory treatments in attempt to help restore or improve breathing 
function in patients with a variety of diseases, conditions, and injuries. It delivers drugs 
directly into the deep lungs and combines with novel particle formulations to achieve 
fast and effective therapeutic effects locally and systemically as the lung provides a 
high absorption area with vast vascularization. This therapeutic strategy has been 
utilized to treat a variety of disorders and diseases such as asthma and chronic 
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obstructive pulmonary disease (COPD). In most cases, the efficacy of drugs is limited 
by their potential capability of reaching to the targeted therapeutic site. Compared to 
traditional systemic delivery methods, lung delivery therapy has many advantages, 
including reduced side effects; quicker onset of action; accurate and consistent dosing 
using an inhalation device.  
The products for dry powder inhalers (DPIs) are desirable powder formulations to be 
applied in the pulmonary delivery therapy when in combination with an efficient 
metering system and device. DPIs are inhalation devices that patients are able to 
operate easily and inhale actively. It can deliver the active drug in the dry powder form 
to the lungs to achieve local or systemic therapeutic effects through the pulmonary 
route (Islam & Gladki 2008). DPI formulations consist of three types of compositions: 
pre-formulated small particles, a carrier-based interactive mixture such as drug 
particles mixed with lactose, and loose agglomerates of drug and excipient particles. 
When patients inhale actively using a DPI device, the drug particles are separated from 
the carrier or deagglomerated, and the active pharmaceutical ingredient is delivered 
into the patient's deep lungs. A variety of factors, e.g. carrier size, surface roughness, 
shape and presence of fine excipients in the formulations can influence the efficient 
dispersion of drug from DPI formulations. The deposition site and the deposition 
patterns of the inhaled aerosol from DPIs depend on three major performance relevant 
components (a) the anatomical and physiological characteristics of the patient (b) the 
interactive powder mixture, including physical properties of the aerosol cloud and (c) 
the design of delivery devices (Stegemann et al 2013, Timsina et al 1994). 
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Scheme  1.1 Schematic diagram of DPI formulations and dispersion process: (A) pre-
formulated small particles; (B) Carrier-based formulation; (C) loose drug agglomerates or 
agglomerates of drug and excipient particles; 
 
Particulate drug delivery system via a pulmonary route, including microparticles and 
nanoparticles, plays a crucial role in the pharmaceutics and clinical medicine.  
Micro/nanoparticles is generally formed by polymers in the solid and colloidal spheres, 
and the distinction between microparticles and nanoparticles is related to their specific 
size cut-offs: diameters of nanoparticles range from 1-500nm; the dimensions of 
microparticles are in the micron range. Generally, they are composed of biodegradable 
macromolecular material formed by single or double emulsion methods and can be 
used as drug carriers (Kohane, 2007). Polymeric micro- and nanoparticles for 
pulmonary drug administration improve the therapeutic effect of drug by modifying 
the drug bioavailability. Drug encapsulation in micro- and nanoparticles leads to 
reducing drug toxicity and prolonging the biological half-life of drug (Mossaad 2014). 
As a result, the effect of the biopolymer is also an important factor for DPI 
performance. The currently most prevalent polymers in use for manufacturing 
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micro/nanoparticles are poly (lactide-co-glycolide) (PLGA), alginate and chitosan. In 
this study, we select a promising biodegradable polymer of chitosan (CS), which is 
nontoxic, biocompatible, and biodegradable polysaccharide, to develop a desirable 
particulate drug delivery system.  
Chitosan (CS) is a natural biodegradable polymer derived from crustacean shells 
(crabs, shrimps and lobsters) and it is also found in some microorganisms, fungi and 
yeast. CS micro/nanoparticles have been used extensively as drug delivery vehicles 
due to their excellent bioavailability, better encapsulation, and controlled release with 
less toxic properties. The properties of CS considerably depend on the molecular 
weight, degree of deacetylation and viscosity (Li et al 2008), which affect the particle 
size, particles formation and aggregation. Many studies have showed that several 
factors are important to affect the characteristics of CS nanoparticles, such as the ratio 
between crosslinker and polymer (Ajun et al 2009), the molecular weight of the CS 
(Csaba et al 2009), the CS concentration (Shah et al 2009) and pH (Zhang et al 2004). 
However, preparations of CS nanoparticles involve organic solvent or high shear force, 
which pose a harm to drug stability. Besides, the preparation method of emulsion 
crosslinking is complex and time consuming (Tiyaboonchai 2013). But its minor 
shortfalls can be ignored when considering its favourable biocompatibility 
characteristics. In terms of this work, we have achieved the aim of encapsulating 
appreciable quantities of nicotine within this interesting candidate of CS nanoparticles. 
It is important to evaluate the safety and efficacy of formulated inhalation products in 
animal models prior to use in humans. DPI inhalation devices require active inhalation 
to operate the devices and deliver the drug to the lungs; however, animals cannot meet 
this requirement.  Hence, the animal models of pulmonary delivery which delivers the 
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drug via their normal breathing action are necessary. Although a number of apparatus 
have been designed to evaluate a series of pharmacokinetics parameters, they are only 
modestly suitable for dry powder inhalation delivery due to limitations in dosing 
consistency between batches and subjects, excessive wastage of undelivered drug and 
inability to effectively aerosolize powders of very fine particles (Aoki, Kojo, Yamada, 
& Onoue, 2012). These apparatus need to be modified to deliver powders of small fine 
particles that would enable efficient delivery and provide consistency in dose delivery 
between subjects and between batches. 
As discussed above, it is anticipated that the treatment of smoking addiction will be 
improved with less side effects using the proposed pulmonary drug delivery method. 
Unlike gums, transdermal patches, sublingual tablets and nasal spray formulations, 
pulmonary delivery of nicotine can mimic the route of smoking and produce high 
levels of nicotine to the brain quickly, which offers a more targeted approach that will 
reduce the amount of drug required and thus reduce side effects and improve patient 
compliance. As a result, it is hypothesized that the lung delivery of nicotine would 
mimic the effects of tobacco smoking and would significantly reduce nicotine 
addiction. The currently available nicotine inhaler formulations (e.g. Nicotrol® and 
Nicorette® Inhalers) have proven to be undesirable for delivering medicaments into 
the deep lungs as they deliver nicotine into the mouth for buccal absorption. Currently 
there is no effective DPI formulation available to deliver nicotine into the deep lung.  
The aim of this project is to develop nanoparticles using the biodegradable polymer of 
CS as the carrier for nicotine for pulmonary delivery for the treatment of nicotine 
dependence with low dose and controlled release properties. It is anticipated that the 
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outcome of this study will provide novel therapeutic strategies for better management 
of patients with nicotine dependence. 
1.2 AIMS AND RESEARCH PLAN 
The goal of this project is to develop a DPI formulation of nicotine for lung delivery 
as a practicable pharmacotherapeutic strategy that reduce and prevent the development 
of smoking addiction.  This research aims to develop a novel pulmonary nicotine 
delivery system that mimics the sensory feelings associated with smoking, and at the 
same time provides a targeted approach that will find the minimal drug dose required 
for treatment and subsequently eliminate the side effects that have prevented it from 
being used more effectively as a nicotine cessation therapy. It is anticipated that the 
treatment of smoking addiction will be improved with least side effects using the 
proposed inhaled nicotine delivery that could mimic the practices of cigarette smoking. 
In addition, the potential risks of chronic nicotine inhalation are far lower than the risks 
of continued smoking. Therefore, the DPI formulation of nicotine developed in this 
study may be an effective smoking cessation appliance. 
Aim 1: To develop micro/nanoparticles using a biodegradable polymer with controlled 
surface properties (size, shape, surface free energy, surface roughness, adhesional 
properties) that contain nicotine. 
Objectives: 
 To prepare biodegradable polymer (chitosan) nanoparticles that contains 
nicotine. 
 Chapter 1: Introduction 8 
 To evaluate the influence of the polymer on the aerosolization performance of 
nicotine using a controlled water-in-oil emulsion-glutaraldehyde crosslinking 
method. 
 To understand the physicochemical properties of nicotine-loaded CS 
nanoparticles. 
 To identify the specific factors affecting the efficient delivery of prepared 
nicotine nanoparticles 
 To study the dispersibility of blank CS and nicotine-loaded CS nanoparticles  
 To study the technology of the controlled release of nicotine from CS 
nanoparticles.  
 To determine whether the process of encapsulating the nicotine nanoparticles 
has altered the activity of the compound.  
Aim 2: To construct and optimize a nose-only inhalation device for use in mouse 
models; to determine the lowest effective dose required to obtain clinically relevant 
blood levels of nicotine in mice; demonstrate its safety for administering the CS 
encapsulated nicotine nanoparticles; to test DPI formulations in mice and measure 
nicotine-mediated locomotor behaviours. 
Objectives: 
 To construct and optimize the nose-only inhalation device with the optimum 
parameters of flow rate, loading dose to achieve lowest effective dose required. 
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 To develop the animal models of pulmonary drug delivery from DPI 
formulations using a nose-only inhalation device. 
 To determine whether lung delivery of nicotine alters nicotinic receptor-
mediated locomotor behaviour in mice. 
 To evaluate the safety and efficacy in mice by administering the CS particles 
containing nicotine under conditions of inhalation exposure. 
 To determine the pharmacokinetics of nicotine-loaded CS from pulmonary 
delivery of a DPI formulation in mice. 
1.3 SIGNIFICANCE AND INNOVATION 
According to a tobacco report from the World Health Organization (WHO, 2015), 
smoking-related illness is still the single biggest cause of death worldwide, resulting 
in the death of more than 7million people a year. Despite the fact that addiction to 
nicotine, representing more than 40% of brain-related illnesses, generates a serious 
threat to human wellbeing and further increases susceptibility to other diseases, and 
poses a huge economic burden to government, there is still a dearth of innovative 
treatments, and little interest in developing new treatments in the pharmaceutical and 
biotechnology industry.  
Although the currently available drugs, varenicline and bupropion, are used for the 
treatment of nicotine dependence, both of them cause significant side effects that limits 
their efficacy. Currently available nicotine formulations include two nicotine 
inhalation products, Nicotrol® and Nicorette® Inhalers (Pfizer), which are available as 
nicotine vapour inhalers but less effective in managing nicotine addiction. The nicotine 
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vapour inhalers deliver nicotine into the buccal areas instead of the deep lungs 
(Oestergaard et al 2010, Rose et al 2010). In 1997, a DPI formulation of nicotine 
tartrate was patented using lactose powder for lung delivery; however, this has yet to 
be developed (Rose et al 1997). In comparison to cigarettes where heat, carcinogens 
and carbon monoxide produce various adverse effects, a nicotine formulation 
delivered via the same route would be superior and would offer a safer nicotine 
delivery system (Andrus PG 1999). We expected that the DPI formulation of nicotine 
might be an effective technology to reduce the craving for cigarettes and other tobacco 
products via deep lung delivery of nicotine with very low dose, contributing to an 
effective treatment for nicotine addiction with a significant reduction in side effects.  
This project specifically addresses the significant health priority goals of QUT 
(Queensland University and Technology), Australia and worldwide generally which 
comprises ageing welfare and improves Australia’s social and economic fabric by 
improving lifestyle factors that prevent the development of addiction. The outcomes 
of this research will significantly contribute to current understandings of pulmonary 
drug delivery that will offer a more targeted therapy approach for the significant 
number of Australians affected by smoking-related disorders. At the end of this work, 
it is desirable that we will have synthesized novel intelligent polymer of CS coated 
nicotine and developed a pulmonary animal model for this drug delivery system. We 
hope this project will contribute to more effective medications for substance use 
disorders, reduce direct and indirect costs to society and make improvements to public 
health and safety and health care delivery. 
The innovations of this project are to develop a novel pulmonary drug delivery system 
and pulmonary animal model and are listed as follows: 
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 The development of a micro/nanoparticles formulation of biodegradable 
polymer (CS) containing nicotine. 
 An innovative animal model for testing pulmonary delivery of the 
biodegradable polymers containing nicotine. 
 A novel delivery system using a nose-only inhalation device for an animal 
model that may result in the development of cost effective DPI formulation of 
nicotine for pulmonary delivery.  This delivery system may be applicable to 
testing a number of drugs in the future. 
1.4 THESIS OUTLINE 
This thesis is presented in a traditional monograph model.  Each chapter individually 
tells a story from development of a particulate drug delivery system through 
pulmonary route to safety and efficacy tests of formulations on animal models, as such, 
heading to a primary goal of this research: to develop a practicable 
pharmacotherapeutic strategy that reduces and prevents the development of nicotine 
addiction. 
Chapter 2 states the mechanisms of nicotine addiction with a variety of associated 
side effects, summarises the recent advances in the therapeutic options for smoking 
addiction and pulmonary delivery technology, and highlights the potential application 
of nicotine inhalers for smoking cessation based on recent literature. These provide us 
a general background about this research and highlight the knowledge gaps between 
literature and practical therapeutic strategies to improve our understanding of 
significance of treatment of nicotine dependence via pulmonary route.  
 Chapter 1: Introduction 12 
Chapter 3 develops an effective way to manufacture micro/nanoparticles of 
biodegradable polymer, CS, loaded with nicotine hydrogen tartrate (NHT) for 
pulmonary delivery of nicotine from DPI formulations. The physicochemical 
properties of particles are determined by a series of experiments such as microscopic 
study of morphology, particle sizing, surface charge, specific surface area, thermal 
characteristics and so on.  The outcomes of this chapter demonstrate the NHT-loaded 
CS particles are suitable to be applied for DPI formulation for lung delivery. However, 
aggregation between nanoparticles (nano-aggregate) is still a common challenge 
within the nano scale range due to high surface energy. 
Chapter 4 is designed to examine physical characteristics of NHT-loaded CS particles 
as DPI formulations from a series of in vitro studies, including in vitro drug release, 
aerosolization and stability. In vitro drug release study showed nicotine released from 
CS particles surface or diffusion from particles matrix in a sustained and prolonged 
profile up to 6 days. It is expected to provide the required plasma nicotine 
concentration for therapeutic effects of nicotine dependence. There is a significant 
increase in the dispersibility of particles formulations with large lactose carriers 
compared to formulations without carriers. On the other hand, further comprehensive 
studies may be needed to better understand the interactions between the charged 
particles and carriers and the impact of charged particles or agglomerates on the 
deagglomeration. 
Chapter 5 combines in vitro evaluation of efficiency of nose-only inhalation device 
and in vivo examinations of efficacy and safety of nicotine-loaded CS particles as DPI 
formulations through experiments of locomotor activity test and histological studies 
on mice. No allergic airway inflammation was observed from histological analysis of 
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lung sections within 24 hours. It suggests that formulation of nicotine-loaded CS 
particles may be applicable for exposure studies under this study design. 
Chapter 6 summarises the overall conclusions in this thesis. It concludes the main 
findings of this study, discusses the significance and limitations of this research and 
suggests future work.  
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2.1 HISTORICAL BACKGROUND  
Tobacco consumption has become one of the leading causes in preventable deaths all 
over the world, accounting for approximately 20% of all deaths (Jamal et al., 2014) 
and 90% of lung cancer cases (Stewart & Kleihues, 2003). Cigarette smoking involves 
inhaling the smoke regularly and habitually owing to the greatly addictive properties 
of nicotine (N. L. Benowitz, 1988; Aldo Leone, Landini, & Leone, 2010). Nicotine, a 
potent parasympathomimetic alkaloid and a stimulant drug, is a natural ingredient 
growing in the roots and accumulating in the leaves of tobacco (N. L. Benowitz, 
Hukkanen, & Jacob III, 2009). Physician Wilhelm Heinrich Posselt and chemist Karl 
Ludwig Reimann of Germany isolated nicotine from the tobacco plant in 1828 
(Henningfield & Zeller, 2006). Nicotine is a hygroscopic oily liquid, and it is miscible 
with water in its base form, whereas its salt form is usually solid and water soluble to 
produce its nitrogenous base (Fu et al., 2010). Nicotine has two enantiomeric forms. 
Levorotary (S)-isomer is the principal form of nicotine in tobacco; whereas only 0.1–
0.6% of total nicotine is in (R)-nicotine (Carmella, McIntee, Chen, & Hecht, 2000).  
The physiological activity of S-(+)-nicotine is less active than R- (–)-nicotine, while 
the toxicity of R-(−)-nicotine is more than S-(+)-nicotine. The salts of S-(+)-nicotine 
are usually dextrorotatory (Obaid, Koyano, Lindstrom, Sakai, & Salzberg, 1999). 
Nicotine is a weak base at pKa of 8.0. It is easy to pass through the blood-brain barrier 
and distribute all over the brain, which its uptake is achieved by active transport and 
passive diffusion (N. L. Benowitz, 1988). Tritiated S-nicotine tends to be bound in the 
areas of cerebral cortex, thalamus, hippocampus, hypothalamus, midbrain and 
brainstem (London, Waller, & Wamsley, 1985).  It is reported that the areas of high-
affinity nicotine binding showed improved metabolic activity. Short term exposure to 
nicotine could stimulate central nervous system neurohumoral pathways through 
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activation of nicotinic receptors, causing release of acetylcholine, dopamine, 
norepinephrine, serotonin (N. L. Benowitz, 1988). Exposure to nicotine develops a 
biphasic dose-response relation: low doses of nicotine cause ganglionic stimulation, 
while high dose of nicotine causes ganglionic depression (Morrison, Goodyear, & 
Sellers, 1969). The biphasic effects are noted that at low dose of nicotine, 
cardiovascular effects are mediated by increasing blood pressure and heart rate via the 
central nervous system; on the other hand, at high dose of nicotine, ganglionic 
stimulation is mediated from peripheral nervous system. However, extremely high 
level of nicotine results in hypotension and reduced heart rate intermediated by 
peripheral ganglionic blockade or central nervous system (N. L. Benowitz, 1988).  In 
addition, the tolerance of nicotine is developed after repeated doses, which may cause 
adverse effects of nausea, vomiting and pallor and so on (Moura & McMahon, 2016).  
Nicotine is only partially responsible for the detrimental effects of smoking as several 
constituents from cigarette smoke result in the development and progression of 
cardiovascular damage, particularly atherosclerotic lesions (Aurelio Leone, 2005). 
Although U.S. Food and Drug Administration (FDA) has approved some therapies 
which are designed rationally and tested effectively via a combination of numerous 
animal models for nicotine addiction (Pierce, O’Brien, Kenny, & Vanderschuren, 
2012), very few effective drug therapies for nicotine addiction can be effectively 
applied; even the currently most effective drugs,  varenicline and cytisine, can cause 
significant adverse effects such as nausea and require substantial dosing in order to 
bypass the gut and enter the brain. Therefore, from these observations, it is clear that 
a better method of pharmacotherapeutic delivery could help improve efficacy of 
currently available treatments and lead to the development of novel therapeutics. 
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2.2 ADVERSE EFFECTS OF SMOKING 
There are around 5 million smoking-related deaths annually all over the world and 
there is the expectation of up to 10 million by 2030 (Islam & Rahman, 2012). The 
positive effects of cigarette smoking include euphoria, ability to concentrate, weight 
control, and a decrease in daily tension. Nevertheless, the negative effects of smoking 
associated with high risks of stroke, cardiovascular diseases, respiratory disease and 
cancer exceed its limited positive effects. It not only shortens the life span among 
smokers, but also increases overall costs, including direct and indirect costs, and 
results in the loss of productivity during the life expectancy (Max, 2001). Both the 
deteriorating health of smokers and aggravating economic impact on society cannot 
be ignored. A large number of reports have revealed strong associations between 
tobacco smoke and various neurological, cardiovascular, and pulmonary diseases 
(Das, 2003). What is worse: cigarette smoke also causes serious health problems of 
the non-smokers. 
 
Figure 2.1 Smoking and increased health risk 
2.2.1 Smoking and Cardiovascular Diseases 
The cardiovascular system is the primary target area to be affected by smoking 
(Aurelio Leone, 1995), The main cardiovascular diseases associated with cigarette 
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smoking comprise myocardial infarction (Hay & Turbott, 1970), coronary heart 
disease (Baba et al., 2006), stroke (Burns, 2003), hypertension (Kannel & Higgins, 
1990), and abnormal cardiopulmonary function and exercise tolerance (Louie, 2001), 
all of which emerge a synergistic effect associated with smoking. Various types of 
cardiovascular damage from smoking have been identified. The first study by 
Hammond (Hammond & Horn, 1958) demonstrated smoking tended to increase risks 
of cardiovascular disease. It stated that smokers would suffer a 70% higher rate of 
death from coronary artery disease than non-smokers (Z. Chen & Boreham, 2002). 
The smokers age also affects the development of cerebrovascular disease and coronary 
heart disease (Burns, 2003). The greatest risk for developing coronary heart disease 
occurs in those under the age of 45. Risks rates increase steeply and considerable death 
is confined to the seventh and eighth decades of life. Active smoking leads to clinical 
and anatomical alterations associated with ischaemic pathology, while passive 
smoking (second-hand smoking) is more likely to trigger functional disorders 
chronically which are associated with late atherosclerotic changes (Penn, Chen, & 
Snyder, 1994). 
A variety of chemical compounds which are extracted and concentrated from tobacco 
mixtures are the source of side effects of tobacco smoke associated with the heart and 
vessels (Byrd, 1992). The tobacco plants and their leaves contain more than 4,000 
chemical substances, which results in increasing risks of cardiovascular diseases. But 
it is known that nicotine addiction contributes to selling more cigarette products. 
Nicotine is a highly addictive compound found in all tobacco products and plays a 
major role in contributing to heart and blood vessel lesions and flunk of vascular 
reconstruction especially after chronic exposure (Benowitz, 2010).  Besides, carbon 
monoxide is also another major component associated with the cardiovascular diseases 
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induced by smoking. Both of them affects the myocardial oxygen supply/ demand ratio 
and results in endothelial injury, producing atherosclerotic plaque adversely (Lakier, 
1992). Furthermore, the biochemical injury or hypoxic injury of tobacco mechanisms 
also strongly contributes to these pathogenic behaviours. 
2.2.2 Smoking and Pulmonary Diseases 
Cigarette smoking is responsible for the pathogenesis of many types of pulmonary 
diseases. Specifically, cigarette smokers have a higher prevalence in respiratory 
diseases and lung function disorders with a greater mortality rate from chronic 
obstructive pulmonary disease (COPD) in comparison to non-smokers (Pauwels, 
Buist, Calverley, Jenkins, & Hurd, 2001). Bronchodilation induced by cigarette 
smoking decreases the hyperinflated state of lung and favors smaller particles 
penetrate and depose to deeper and smaller airways via deeper inhalation of smoking. 
As well, bronchodilation facilitates uptake of carbon monoxide in the lungs. As a 
result, chronic bronchodilation increases the risk of cardiovascular disease and 
pulmonary diseases (van Dijk et al., 2010). The way of consuming tobacco is also of 
importance in the developing disease. For example: pipe and cigar smokers have a 
higher risk to develop COPD with greater morbidity and mortality rates than cigarette 
smokers (Pauwels et al., 2001). Tobacco smoke can alter the airway structures and 
functions, triggering COPD by interfering with the ability of airway epithelial cells to 
support repair processes (Hangjun Wang et al., 2001). There are many other risk 
factors for the development of COPD, for example, air pollution, occupational 
exposures, heredity, and infectious and allergic conditions. Thus, not all smokers will 
develop clinically significant COPD, but mortality rates are higher among cigarette 
smokers suffering from COPD (Matthay et al., 2003). It has been reported by some 
researchers that tobacco smoke inhalation results in a decrease in the level of lung 
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surfactant phosphatidylcholine (Subramaniam, Bummer, & Gairola, 1995). However, 
other investigators have demonstrated that no difference in lung lavage phospholipid 
concentration between smokers and non-smokers was observed (Mancini et al., 1993), 
which suggests that the effects of cigarette smoke on surfactant and surfactant-
producing cells are complicated (Haagsman & van Golde, 1985). 
2.2.3 Smoking and Asthma 
Asthma is abnormalities in airway effects involving both airway inflammation and 
impaired airflow. It is well documented that smoking or exposure to passive smoking 
among asthmatics increases the risk rate of asthma-related morbidity and disease 
severity because of the decline of lung function. It is reported that approximately 25% 
to 35% of individuals suffering from asthma are tobacco smokers, which is much 
higher compared with non-smokers (Peters et al., 1999). Also women are more 
vulnerable to the effects of smoking (M. Stapleton, Howard-Thompson, George, 
Hoover, & Self, 2011). According to a report by Beckett et al. in 4547 subjects aged 
from 18 to 30 years old stratified by sex, it is found that cigarette smokers in females 
are more susceptible to asthma incidence with decreased physical activity and gained 
weight over time (Beckett, Jacobs Jr, Yu, Iribarren, & Williams, 2001).  Asthma is less 
controlled in asthmatic patients with primary smoking compared with asthmatic non-
smokers (Schatz, Zeiger, Vollmer, Mosen, & Cook, 2006).  
On the other hand, some of the toxic gases in passive smoking contribute to the 
development of asthma (M. Stapleton et al., 2011). Environmental smoking exposure 
among asthmatic patients not only improves severe symptoms, but also lowers quality 
of life, reduces lung functions, increases health care utilization, and increases hospital 
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admissions. However, small children are the most vulnerable to tobacco smoke, 
especially maternal smoking or tobacco smoke at home. 
2.2.4 Smoking and Lung Cancer 
Environmental tobacco smoke, also referred to as second-hand smoke (SHS), has been 
classified as an important human pulmonary carcinogen (WHO, 2004). A series of 
epidemiological studies have established and shown a strong association between SHS 
exposure and lung cancer development; Lung cancer is one of the most prevalent 
diagnosed cancers and the leading cause of mortality induced by cancer in the world 
(R. L. Siegel, Miller, & Jemal, 2015). Some researchers report that only a small 
number of victim who are exposed to an environment of extensive tobacco 
consumption will suffer from lung cancer (Duan et al., 2013), while epidemiological 
evidence indicates that cigarette smoking is one of the established risk factors for lung 
cancer (Alberg, Brock, Ford, Samet, & Spivack, 2013). This controversy has made the 
mechanisms by which cigarette smoke causes lung cancer unclear. It was estimated 
that about 90% of male and 75%–80% of female deaths from lung cancer in the United 
States were due to smoking (Hecht, 2002). More than 60 chemical compounds in the 
cigarette smoke have been identified to induce cancers potentially, and these 
carcinogenic components and their metabolites such as N-nitrosamines and polycyclic 
aromatic hydrocarbons can result in lung cell transformation through activating 
multiple pathways in different ways (Patrianakos & Hoffmann, 1979). Nicotine tend 
to trigger tumour promotion and progression associated with properties of 
antiapoptotic and indirect mitogenic effects (Tonini, D'Onofrio, Dell'Aquila, & 
Pezzuto, 2013). Lung nodules are often diagnosed among smokers and can be altered 
to malignant tumours depending on the patients` persistence in smoking (Thun et al., 
1997). 
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These constituents of aromatic amines (e.g.,4-aminobiphenyl, 2-naphthylamine), 
polycyclic aromatic hydrocarbons, tobacco specific nitrosamines [e.g., 4-
(methylnitrosamine)-1-(3-pyridyl)-1-butanone] in tobacco are carcinogens that causes 
lung cancer or increases the incidence of lung cancer from experimental animals and 
human beings (Cornfield et al., 2009; Smith et al., 2006). A genotoxic mode of action 
for some of these carcinogens generates directly electrophilic species capable of 
forming covalently bound DNA lesions, known as DNA adducts, which are central to 
the carcinogenic process (Tang et al., 2001). Formation of DNA adducts can initiate 
carcinogenesis, giving rise to the incidence of mutations (Pfeifer et al., 2002). 
2.2.5 Nicotine Addiction 
Besides a variety of smoking-related diseases, addiction is one of the most notorious 
smoking-related syndromes and is mainly attributed to nicotine (N. L. Benowitz, 
1992). Nicotine withdrawal tends to perform  the many adverse effects of smoking 
cessation such as nervousness, irritability, anxiety, impaired concentration, weight 
gain and so on which makes the process of quitting smoking extremely undesirable for 
the smoker despite knowing the negative health impact of continued use (Quist-
Paulsen, 2007). 
Addiction is a repeated physical behavioural with complicated causes and effects, 
which depend on the rate and route of nicotine dosing (Polosa & Benowitz, 2011). 
Essentially, nicotine mimics the actions of the hormone epinephrine and 
neurotransmitter acetylcholine in the brain (Luty, 2007). The process of nicotine 
addiction begins with inhalation of nicotine via cigarette smoking. The lungs distil 
nicotine from the tobacco smoke and allow absorption of nicotine into the arterial 
bloodstream rapidly (Luty, 2007). This produces a transient exposure of high levels of 
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nicotine to the brain, where neurotransmitters are released, enhancing the smokers` 
feelings of pleasure. This exposure acts on nicotinic cholinergic receptors, triggering 
the increased levels  of endorphins, dopamine and other neurotransmitters e.g., 
glutamate, and γ-aminobutyric acid (GABA) (N. L. Benowitz, 2010). The release of 
neurotransmitters is particularly essential to the development of nicotine addiction 
(Vandewater, Park, Carey, & Wilkinson, 2014). Neuroadaptation and tolerance are 
developed by  altering nicotinic receptors and neural plasticity (N. Benowitz, 2008). 
As discussed above, high nicotine levels travel through body to reach brain within 10 
seconds of smoking, followed by a rapid decline only a few minutes after smoking (N. 
L. Benowitz, 2010). Nicotine from sequential cigarette smoking is capable of 
overcoming tolerance to produce further pharmacological effects (N. L. Benowitz, 
1996). Therefore, smokers have to smoke more and more to maintain the same feelings 
produced by smoking. Nicotine is metabolized to cotinine primarily by the enzyme 
CYP2A6.The rate of nicotine metabolism results in variations of tobacco dependence 
and the response to treatments of nicotine addiction (Shiffman, Ferguson, Dunbar, & 
Scholl, 2012). An recent popular mediation for treatment of smoking dependence is 
called varenicline, which  acts on specific nicotinic receptor subtypes in the brain based 
on the mechanisms of nicotine addiction (Figure 2.2) (N. L. Benowitz, 1996). 
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Figure 2.2 The mechanism of nicotine addiction 
 
2.3 CURRENT THERAPEUTIC OPTIONS FOR SMOKING ADDICTION 
 According to the clinical practice guidelines, present pharmacotherapeutics for the 
treatments of tobacco addiction divide into first-line medications and second-line 
medications. First-line medications include nicotine replacement therapy (NRT), 
bupropion (Nides, 2008) and varenicline. Second-line medications are composed of 
nortriptyline and clonidine (Polosa & Benowitz, 2011). These medications are usually 
suggested being used in combination prescriptionally. 
2.3.1 Nicotine Replacement Therapy (NRT) 
NRT is the primary medication used for the treatment of tobacco dependence. 
Available NRT formulations include nicotine chewing gums, transdermal nicotine 
patches, sublingual tablets, nasal sprays, and inhalers. All of these are now available 
to be purchased at pharmacies. 
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The basic mechanism of action is the provision of nicotine without other harmful 
chemicals via cigarette smoke, replacing partially the nicotine formerly obtained from 
tobacco smoking through activation of nicotinic receptors in the ventral tegmental area 
in the brain and trigger release of dopamine subsequently. Thus the severity of 
withdrawal symptoms and cravings are reduced when smokers try to give up tobacco 
(J. A. Stapleton et al., 2008). Concerning the safety issue of NRT, attaining nicotine 
from NRT is significantly reasonable to patients who are not exposed to the many other 
harmful products of tobacco; nevertheless, smokers absorb nicotine from cigarette. All 
NRT products appear to be efficacious, leading to a doubling of smokers’ quitting 
chances in comparison with placebo therapy (Shiffman, 2007).  However, compared 
with the route of inhalation, other delivery routes of absorption cause a slow increase 
in nicotine level in the brain and a slower brain-to-blood ratio (Le Houezec, 2003). 
However, NRT could not completely relieve all symptoms of nicotine withdrawal 
cravings because of its own limitations.  The currently available therapeutical systems 
could not reproduce the high levels of nicotine to reach the brain rapidly achieved 
through tobacco use. The efficacy of medical nicotine products relies on the 
pharmacokinetic profiles and dosage of medication. The NRT products take at least a 
few minutes to achieve lower level of nicotine via systemic venous absorption 
(Molyneux, 2004). Gum is a slow way to deliver nicotine and dosage is difficult to be 
adjusted. The plasma concentration obtained from nicotine gum is usually between 
one-third and two-thirds of that from cigarette smoking (Fagerström, 1987).  Slow 
release and passive administration of nicotine patches are not suitable for urging to 
relieve smoking craving though transdermal delivery systems ease issues of dosage 
and patient compliance. The recent nicotine patches are designed for 16h/day and 
24h/day (Ma, Kendzor, Poonawalla, Balis, & Businelle, 2016). Nicotine tablets 
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produce less reinforcement with first pass metabolism, resulting in tolerance with 
increased nicotine blood levels. Besides, different forms of formulations (nicotine 
gums, lozenges, patches, nasal sprays, and inhalers) could have different impacts upon 
withdrawal symptoms and craving. No direct evidence has proved one nicotine 
delivery system is better than another. In addition, NRT does not fully overcome the 
issue of weight gain after smoking cessation (Farley, Hajek, Lycett, & Aveyard, 2012). 
Thus, NRT is less effective for patients who are not motivated to quit or do not expect 
to experience nicotine withdrawal symptoms. NRT is generally more effective when 
offered to cigarette smoker regularly who has made a previous quit attempt in 
conjunction with behavioural support. 
It is recommended to use combination treatment such as patch and gum; or patch and 
inhaler. Combination treatment is more effective on smoking cessation with positive 
psychological intervention. A report under double blind, placebo controlled and 
randomised studies demonstrated that combined therapeutical treatments contributed 
to one year longer abstinence rates than single NRT treatment (Windle et al., 2016).  
2.3.2 Electronic Nicotine Delivery Device (e-cigarette) 
Electronic nicotine delivery systems (ENDS), also called as e-cigarettes were 
approved by US market in 2007 (Regan, Promoff, Dube, & Arrazola, 2013), followed 
by some countries worldwide as a drug delivery device for smoking cessation. 
However, it has not been approved by the Therapeutic Goods Administration (TGA) 
for use as a nicotine cessation aid in Australia. Therefore, it is illegal to sell or import 
it without a licence approval within Australia as nicotine is classed as a dangerous 
poison (Sutherland et al., 2016). 
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E-cigarettes are battery-powered devices where nicotine is suspended in propylene 
glycol or glycerine and water. They are breath activated with a micro sensor and 
produce nicotine mist via heat or ultrasound where. This aerosolizing delivery device 
is compatible with a disposable cartridge, which contains nicotine in solution of 
propylene glycol as the humectant. The devices are composed of a battery, a heating 
element, a power source, and a pressure switch (Trtchounian & Talbot, 2011). All 
these components are embedded in a tube with a mouthpiece (Figure 2.3), and the 
construction of device may vary. The newer generation e-cigarettes with high voltage 
battery power and high temperature may cause thermal breakdown of the solvents to 
produce toxic chemicals like carbonyls.  Currently, three related products are available 
on the market: delivery devices, cartridges, and refill solutions (Adkison et al., 2013). 
They still have some common characteristics with pipes, multi-dose inhalers and other 
drug delivery devices. 
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Figure 2.3 The components of e-cigarette (Cobb & Abrams 2011) 
 
In spite of launching on the market in the early stage, the safety of inhaling e-cigarette 
has not been studied in humans and thus the scientific evidence in terms of safety is 
limited. The appropriate dose of nicotine which is delivered using e-cigarette also 
remains unclear and this product has failed to regulate smoking related problems (M. 
B. Siegel, Tanwar, & Wood, 2011). The effect of long-term use of e-cigarettes is not 
known and without valid clinical data, the marketing efforts of these products may 
increase addiction to nicotine, especially in young people. Although some data 
demonstrate that e-cigarettes may be effective in reducing nicotine cessation, there are 
no such clinical data demonstrating the efficacy of these products as an efficient tool 
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to achieve the goal (Drummond & Upson, 2014). In addition the liquid dosage forms 
of these products are less stable compared to that of solid dosage form. These 
uncertainties are worrisome to the users. Although no serious adverse effects (e.g. 
deaths or events requiring hospitalisation) have been reported, most smokers who 
attempted to use e-cigarette for quitting smoking considered them ineffective (M. B. 
Siegel et al., 2011). In fact, e-cigarette has become a “bridge product”, smokers tend 
to use it in place where smoking is forbidden. On 25th April, 2011, the FDA had to 
announce that initial attempt of regulating e-cigarettes as tobacco replacement has 
failed to regulate them (I. Chen, 2013). 
2.3.3 Bupropion 
Bupropion hydrochloride was regarded to be an effective option for smoking cessation 
with non-nicotine. It is featured with sustained-release orally preferred over immediate 
release (Maccaroni, Malpezzi, & Masciocchi, 2009). It is recommended to take 
Bupropion SR (Zyban®, GlaxoSmithKline) twice daily and bupropion XL 
(Wellbutrin®, GlaxoSmithKline) once daily. As a selective reuptake inhibitor of 
dopamine and noradrenalin, bupropion could prevent and reduce craving that 
accompanies smoking cessation. It is reported that bupropion could improve the 
chances to quit smoking compared with placebo therapy although the mechanism of 
bupropion in smoking cessation is not completely understood (Huibers, Chavannes, 
Wagena, & Van Schayck, 2000). Bupropion in low doses can block brain nicotinic 
acetylcholine receptor (nAChRs) function, which could decrease the positive 
reinforcement effects of nicotine (Lerman et al., 2004). 
According to some studies comprising over four thousand subjects, it is reported that 
bupropion arouses a positive effect in smoking cessation consistently (Richmond & 
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Zwar, 2003).  Bupropion is effective to reduce withdrawal symptoms in patients who 
are motivated to quit smoking. At the same time, it is safe to be applied in patients 
with cardiovascular disease, but is limited by its occasional increase of blood pressure, 
which has been reported among smokers with hypertension. In addition, bupropion 
reduces expired breath CO levels significantly. The major safety issue is associated 
with seizures and psychosis (Strike & Hatcher, 2015). Insomnia and dry mouth are the 
other most common adverse effects with bupropion use (Tonstad et al., 2003). 
2.3.4 Varenicline 
Varenicline (Chantix/Champix®) (Figure 2.4) was introduced to market by Pfizer in 
2006. Varenicline is able to mediate the reinforcing properties of nicotine in the ventral 
tegmental area of the brain as a partial selective agonist for the α4β2 nAChR subtypes 
and improves oral bioavailability and brain penetration significantly as it is produced 
as cytosine derivative (Tutka & Zatoñski, 2006). Coe suggested that α4β2 nicotinic 
receptor partial agonists could inhibit activation of dopamine produced by smoking 
while producing relief from the smoking withdrawal syndrome (Coe et al., 2005). 
Varenicline has dual effects, that is, on the one hand, it stimulates nAChRs partially 
without producing the full effect of nicotine agonist action, and on the other hand, it 
blocks nAChRs to prevent the nicotine from tobacco approaching them (Coe et al., 
2005). That is, varenicline displays a higher affinity and less functional effect than 
nicotine resulting in a smaller release of dopamine. Therefore, varenicline can reduce 
smoking withdrawal syndrome and reduce the risk of relapse potentially. 
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Figure 2.4 Structure of varenicline 
 
Varenicline is an effective option to quit smoking with acceptable safety and 
tolerability profile. At the same time, it is a tolerated and effective option for treatment 
of patients with COPD and cardiovascular disease (Tashkin et al., 2011). More 
participants who were taking varenicline quitted cigarettes successfully than those with 
bupropion. However, there is few evidence showing that varenicline may prevent 
relapse (Cahill, Stead, Lancaster, & Polonio, 2012). The major adverse effect of 
varenicline is nausea, but in most patients nausea tends to subside over time with mild 
to moderate doses. Varenicline can also produce other side effects such as headache, 
insomnia and gastrointestinal disorders. In addition, some patients taking varenicline 
have experienced depression, suicidal thoughts, suicide, and serious neuropsychiatric 
symptoms (Kuehn, 2009). 
2.4 PULMONARY DRUG DELIVERY TECHNOLOGY 
The route of pulmonary delivery was first reported in 1967 by Herxheimer 
(Herxheimer, Griffiths, Hamilton, & Wakefield, 1967), and it was recognized as one 
of the most efficient treatments for delivering drugs to the targeted area because of  
large surface area of alveoli, small airways, low metabolism and high bioavailability. 
So far, many advances in pulmonary drug delivery have boosted drug delivery by 
inhalation locally and systemically, which offers great potential for rapid delivery of 
small-molecule therapeutics. Rapid absorption of small molecules into the systemic 
  
Chapter 2:  Literature Review 33 
circulation is due to the large surface area of the  alveoli, the highly dispersed property 
of formulation , and excellent epithelial permeability (Patton & Byron, 2007). 
Efficiencies of inhaled particles with aerodynamic diameter ranging between 1 and 2 
μm is as high as 90% if formulations are inhaled slowly and deeply (Patton & Byron, 
2007). Drug delivery through route of lung is a promising technology in which 
medications are inhaled to the lungs and enter into the bloodstream (Nanjwade, 
Adichwal, Gaikwad, Parikh, & Manvi, 2011). Aerosol delivery of reformulated drugs 
is more likely to raise the efficiency of pulmonary drugs exponentially for the 
treatment of lung disease and systemic diseases. Delivery of small molecules can 
achieve effects of rapid action, high bioavailability and low metabolism, and 
macromolecules could be delivered without injections. Pulmonary drugs are currently 
formulated as solutions, suspensions, emulsions, or micro/nano-nized dry powders, 
and formulations are aerosolized via a variety of aerosolization devices i.e., nebulizers 
are for drugs which are formulated in aqueous solution or suspension and then 
atomized into droplets through some fundamental processes. MDIs are for drugs that 
are in the forms of suspension or solution under pressure in a liquid propellant.  DPIs 
are for drugs in the form of powder that is fluidized as aerosol particles via subjective 
inspiratory efforts of patients.  
2.4.1 Nebulizers 
Nebulizers are the oldest method of delivering aerosols to the lungs via pulmonary 
drug delivery and they still play essential roles in specific diseases such as cystic 
fibrosis (Daniels, Mills, & Whitaker, 2013), dyspnoea (Boyden et al., 2015) and acute 
asthma (Cates, Welsh, & Rowe, 2013). Nebulizers are usually applied in the hospitals 
and ambulatory care settings (Watts, McConville, & Williams III, 2008), and are 
applicable for drugs which require high dose and little patient compliance and skills. 
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The new techniques of nebulization have been developed over a few decades, allowing 
some nebulizers to be portable use outside the home. A new device, Philips’ i-neb, 
incorporating vibrating mesh technology, is designed for a portable device that can be 
applied outside the home (Denyer & Dyche, 2010). Respimat is a nebulization device, 
which makes it easy for patients who have difficulties to coordinate the inhalation and 
pMDI actuation. It produces the slow-moving cloud of aerosol , reducing deposition 
rate in the mouth-throat and increasing deposition in the lung compared with pMDIs 
(Hochrainer et al., 2005). However, in many cases, nebulizers are quite bulky. It is 
suggested to acquire professional guidance to use it. In addition, the usage of it should 
cooperate with additional tubing and mouth pieces, compressed air and/or oxygen 
sources, which results in the waste of significant amounts of active medicaments. 
Besides, only about 10% of dose is actually delivered to the targeted area of the lung 
from the nebulizers (Zainudin, Biddiscombe, Tolfree, Short, & Spiro, 1990). 
2.4.2 Metered-Dose Inhalers 
Metered dose inhalers (MDI) are portable and convenient for pulmonary drug delivery 
but their use is largely limited to relatively inexpensive and potent small molecules 
that can be formulated appropriately in propellants. Ari et al. compared the efficiency 
between MDIs and nebulizers in a lung model, which is an intubated and mechanically 
ventilated adult with a tracheostomy tube quantitatively. It showed delivery efficiency 
of a pMDI is higher than that of nebulizer (Ari, Harwood, Sheard, & Fink, 2015). In 
this delivery system, drugs are dissolved or suspended in the liquefied propellants. 
Pressurised metered dose inhalers (pMDIs) are used in respiratory drug delivery 
extensively; however, pMDIs have been proven inefficient.   The deposition rate is 
only 20%-50% in chlorofluorocarbon (CFC)-propelled and hydrofluoroalkane (HFA)-
propelled pMDIs, respectively (Watts et al., 2008). Additionally, these propellants 
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negatively affect the stratospheric ozone layer making the environmental impact an 
aversive element (Islam & Rahman, 2012). Over past several decades, the new MDI 
technologies have developed rapidly in transition to new propellant systems. Isobutane 
is a commonly used flammable refrigerant, which contributes to lower global warming 
potentially compared with HFA as propellant (Myrdal, Sheth, & Stein, 2014). Vega 
group has undertaken exploring isobutane as an alternative to HFA for MDIs (Vega & 
Toneguzzo, 2012).  
2.4.3 Dry Powder Inhalers 
Dry powder inhalers (DPIs) are easier, more stable and efficient delivery system 
compared with pMDIs. They have been used extensively to deliver drugs directly to 
the site of action to achieve local or systemic treatments such as asthma, COPD, 
tuberculosis (Chan et al., 2013) and infections associated with other pulmonary 
diseases. They also have been applied for delivery of levodopa to treat Parkinson’s 
disease (Luinstra et al., 2015). Advantages of DPIs are attracting more attentions to 
boost the development of inhaled medications for pulmonary drug delivery.  
The ideal DPI should meet three requirements to achieve most effective aerosol 
performance (Hoppentocht, Hagedoorn, Frijlink, & de Boer, 2014). The DPI needs to 
deliver a consistent amount of dose to the airstream. Either the weighting of the dose 
cavity and container or the dispersion property of compartment during the inhalation 
plays a vital role in controlling the consistency of delivered dose (Hoppentocht et al., 
2014). The second demand of an effective DPI is to provide a consistent delivered fine 
particle dose (FPD), which requires a consistent amount of active pharmaceutical 
ingredients from entrained powder to be delivered into respiratory tract under an 
attainable range of flow rates (Chi Lip Kwok, 2015). The principal adhesive forces 
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such as van der Waals forces, mechanical interlocking from surface roughness, 
capillary forces, and electrostatic forces dominate powder performance during 
inhalation process (Prime, Atkins, Slater, & Sumby, 1997). In addition, the 
transportation efficiency from generated aerosol to respiratory tract by the inhaled 
airstream and deposition rate on the target area is highly important to produce an 
effective DPI product (Frijlink & De Boer, 2004).   The aerodynamic particle size 
distribution and flow rate are particularly dominant in the deposition efficiency 
(DeHaan & Finlay, 2004). Therefore, it is necessary to consider both the designs of 
powder formulations and inhalation devices to obtain an optimised inhaler 
performance.  
DPI Formulations: 
Three types of DPI formulations are currently available, including pre-formulated 
small particles, a carrier-based interactive mixture, and loose agglomerates of drug and 
excipient particles (Frijlink & De Boer, 2004). The properties of formulations are 
affected by morphology, particle size and distribution, surface charge, and surface area 
and so on, which eventually influence the dispersion property as DPI formulations.  
Optimization of flowability and dispersibility of formulations are critically important 
to develop desirable inhalation powders (Pilcer & Amighi, 2010).  Presence of lactose 
monohydrate types and sieve fractions as carriers is a strategy to improve dispersion 
properties of inhalation particles (Kaialy, Alhalaweh, Velaga, & Nokhodchi, 2012; 
Patil, Mahadik, & Paradkar, 2015).  Blending drugs with coarse lactose not only 
enhances the bulk of the formulations; also it improves separation of fine drug particles 
from formulation to improve dosing consistency of the DPI formulations (Prime et al., 
1997). A new method of excipient enhanced growth technology has been introduced 
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to overcome the limitation of particle size distribution and boost the performance of 
pulmonary delivery. In the case of this approach, submicron particles composed of 
drug and hygroscopic excipient are fabricated to minimise loss in the inhaler device 
and extrathoracic airways (Kleinstreuer, Zhang, & Donohue, 2008). Particle size 
increases significantly to the  ideal size by adjusting the ratio of excipient and drug 
once hygroscopic excipient interacts with natural warm and humid lung environment, 
which contributes to depositing particles to lower tracheobronchial and alveolar 
airways (Behara, Farkas, Hindle, & Longest, 2014; G. Tian, Longest, Li, & Hindle, 
2013). However, based on the current literature regarding the implementation of the 
excipient enhanced growth technology, the relationship between growth of particle 
size and potential deposition region has not been figured out clearly (Behara et al., 
2014).  
Several techniques of manufacture have been advanced to obtain the particles in the 
controlled particle size distribution and surface morphology. Spray-drying is an 
adequate technique to prepare submicron particles with aerodynamic characteristics 
favourable for improved dispersion, sustained release and access to deep lungs (Beck-
Broichsitter et al., 2012; Sham, Zhang, Finlay, Roa, & Löbenberg, 2004). A new 
technique of micro-moulded particles is applied to manufacture particles in a narrow 
particle size distribution with a variety of shapes (Mack, Horvath, Garcia, Tully, & 
Maynor, 2012). Other techniques for improvement of DPI formulations are based on 
the adhesive and cohesive nature of the micro-/nanosized particles, which has recently 
reached the preclinical or clinical productions of anti-asthma and COPD drugs (Begat, 
Morton, Staniforth, & Price, 2004; Muralidharan, Hayes Jr, & Mansour, 2015; Smyth, 
2006).  
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DPI designs: 
The design of DPIs on metering system and powder inhaler itself is a key factor to 
determine the effective dispersion of drug from formulations. A wide range of 
parameters, for example, material of inhaler device, geometry of the mouthpiece, air 
flow rate, drug capsule and the way of piercing, influence drug retention in the inhalers 
as well as aerosol performance of DPI formulations (Stegemann et al., 2013). DPIs are 
portable to carry, relatively affordable in price, and breath activated.  Two main types 
of DPI system, including single-unit dose and multiple-unit dose, are available to 
deliver inhaled drugs (Islam & Gladki, 2008). The single-unit devices contain a single 
dose in gelatin capsule or pre-metered single dose of DPI formulation in disposable 
blister before use (Islam & Cleary, 2012). This is a common but inconvenient DPI 
device, because patients have to load an individual dose each time. The Rotahaler® is 
one of the most familiar single unit dose devices on the market (Srichana, Martin, & 
Marriott, 1998). The multiple-unit dose devices provide a single dose from pre-
metered disposable blister, disks or tubes at each actuation, while the multi-dose 
devices enable the drugs to be stored in a bulk powder reservoir to meter an individual 
dose from the bulk (Newman & Busse, 2002). The Turbuhaler® is the first multi-dose 
example to dispense powders metered from a reservoir of inhaler (Wetterlin, 1988).  
Many inhalation devices have been employed in existing DPIs to improve delivery of 
fine particle fraction (FPF) to site of action therapeutically (Frijlink & De Boer, 2004). 
Optimisation to break up agglomeration of particles in a turbulent airstream is a feature 
of DPI devices such as Easyhaler® (Chrystyn & Niederlaender, 2012) and Turbuhaler® 
(Hirst, Bacon, Pitcairn, Silvasti, & Newman, 2001). In vivo trials demonstrate both 
Easyhaler® and Turbuhaler® have a similar whole lung deposition (18.5±7.8% vs. 
21.8±8.2%) from 200µg of budesonide (Hirst et al., 2001), while Easyhaler® tends to 
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be less sensitive to airflow in the range of 30-60 L/min with lower FPF (Chrystyn, 
2006).  Genuair® inhaler is another optimised multi-dose inhaler device with medium 
airflow resistance to improve deagglomeration of inhaled particles (Chrystyn & 
Niederlaender, 2012). In vitro studies reveal consistent emitted dose (ED) and FPF are 
achieved with reproducible aerodynamic aerosol within 45 - 95 L/min of airflow , and 
FPF is not dependent on the inhalation volume and storage conditions (Z. Xu, 
Mansour, & Hickey, 2011).  In clinical trials, more patients (110 of 123 patients, mean 
age 67.6 years) show their preference to Genuair® due to ease of inhalation than 
Breezhaler® which is a single dose inhaler (Pascual et al., 2015). Besides, design to 
strengthen the pressure drop is contributing to increase of airflow, which is beneficial 
to improve FPF deposited in the lungs (Zhou, Tang, Leung, Chan, & Chan, 2014). 
Some active devices, for example, Exubera® (Hollander et al., 2004),  have been 
combined with other techniques such as gas compression, electronic vibration or motor 
driven impeller have been introduced to produce inspiration-actuated inhalers to allow 
effective drug delivery, particularly for child or senior patients suffering from lower 
lung functions (Islam & Cleary, 2012).  
Although DPI and DPI formulations have been advancing significantly in the recent 
decades due to huge potential to be applied in treatment of respiratory tract diseases, 
wide variability of deposited FPF in the lung changes from 9% to 78.7% (Islam & 
Cleary, 2012). This may be from inefficient deagglomeration of particles, insufficient 
inspiratory force or invalid fluid-particle interaction. As discussed above, the design 
of an adequate DPI formulation requires the drug to be stored in a solid state with fine 
dispersion property and high physicochemical stability in the device. Ideally, a DPI 
device should keep drugs stable physicochemically and be able to produce a 
reproducible drug dosing (Islam & Gladki, 2008).  
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2.4.4 Soft Mist Inhaler 
Respimat® soft mist inhaler (SMI) developed by Boehringer Ingelheim (Dalby, 
Spallek, & Voshaar, 2004)  is an aerosol cloud inhaler with spring generated 
mechanical power. As the latest generation of inhalers, it is propellant-free and 
different from the traditional liquid-gas propellants. (Anderson, 2006). A precise 
engineered nozzle produces two fine jets of liquid with a metered dose of drug solution. 
A soft mist is generated from the collision of two fine jets of liquid, which results in 
approximately 65% - 80% fine particle fraction. FPF generated by SMI is much higher 
than conventional pMDIs and DPIs. As a result, a higher drug deposition in the lungs 
than oropharynx is achieved as opposed to traditional MDIs and DPIs (Dalby et al., 
2004). Respimat® SMI is a water based drug formulation that provides a reliable and 
consistent dose with each actuation. (Wu, O Adedoyin, & M Mansour, 2011). Several 
clinical studies have demonstrated that Respimat ® SMI is safe and effective in the 
application of asthma and COPD treatment in delivering bronchodilators to patients 
(E. Bateman et al., 2010; Dal Negro & Povero, 2016; Perriello & Sobieraj, 2015).  
However, Bateman investigated administration of 5 µg tiotropium once daily via 
Respimat® SMI increases the risk of deaths in COPD patients, particularly in elderly 
patients (E. D. Bateman, 2013). Thus, tiotropium Respimat® SMI has been withdrawn 
globally (Beasley, Singh, Loke, Enright, & Furberg, 2012). Regarding the unsure 
safety, decisions to use Respimat® SMI must be evidence-based carefully (Beasley et 
al., 2012).   
2.5  POTENTIAL THERAPEUTIC ROLE OF NICOTINE INHALERS 
The products of nicotine dissolution promote the transition across membrane in liquid 
found in lungs. Nicotine is the primary cause of abuse and dependence of cigarette 
smoking. It is also the prototypic agonist at acetylcholine receptor-gated ion channels 
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(Cunningham & McMahon, 2011), although little evidence is shown that nicotine is 
abused in its pure form. (Balfour, 2004). Currently chewing gums, transdermal patches 
and sublingual tablets for smoking cessation are available in the market (Lewis, 
Subramanian, Pandey, & Udupa, 2006), however, a number of practical problems are 
associated with each nicotine product. A low oral bioavailability is exhibited in the 
buccal administration of drugs, while sublingual tablets and chewing gums might be 
swallowed before being absorbed (Ìkinci, Şenel, Wilson, & Şumnu, 2004). Nasal spray 
of nicotine is the quickest way of NRT to allow nicotine to reach the brain and enter 
into the bloodstream. However, the rate of absorption still could not be comparable to 
cigarette smoking, and lack of acceptability would be caused in the small surface area 
of nasal cavity resulting from delivered high doses of nicotine (Rigotti, 2002). 
Therefore, the delivery of nicotine directly into the deep lung is more likely to 
effectively mimic the rapid effects of cigarette smoking on a physiological level, which 
could potentially eliminate patient craving and allow nicotine level to be tapered over 
time alleviating the dependence upon nicotine altogether (Buchhalter, Fant, & 
Henningfield, 2008).  
Nicotine inhaler may be an effective appliance in smoking cessation. The proposed 
pulmonary drug delivery method is anticipated to improve the treatment of nicotine 
with less side effects as the potential risks are far lower as opposed to the risks of 
continued smoking (Henningfield, Fant, Buchhalter, & Stitzer, 2005). Thus, investing 
in new approaches to develop novel nanoparticles of biodegradable polymer 
containing nicotine with controlled release profile for pulmonary delivery 
accompanied by appropriate behavioural counselling, might significantly improve 
success rates for nicotine addiction. Very recently, an inhalable nicotine formulation 
(Stenzler, Zamel, Slutsky, & Ellis, 2017) comprising nicotine, lactose, and leucine 
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applied for a patent as a potential therapeutic formulation for smoking cessation. 
Currently, no DPI/MDI formulations for pulmonary delivery of nicotine have been 
approved for the management of nicotine addiction. However, two products, Nicotrol® 
and Nicorette® Inhalers (Pfizer) are available as nicotine vapour inhaler. These two 
devices deliver nicotine into the buccal areas, rather than the deep lungs, lowering the 
maximum plasma concentration and delays the time to reach maximum concentration 
(Silagy, Lancaster, Stead, Mant, & Fowler, 2004). The current available products are 
relatively slow compared to the rapid absorption of nicotine via the lungs from 
smoking, which indicates that the pulmonary delivery method may be advantageous 
over other routes.  
A properly designed nicotine inhaler is critical to improve therapeutical effects through 
minimising the aerosol loss to the oropharynx and upper airways ensuring consistent 
dose to reach the deep lung with better dispersibility of formulations. The optimised 
nicotine inhalers can be achieved by adjusting the principal parameters of inhalation 
device such as flow rate, particle size distribution, duration of inhalation exposure etc 
(Silagy et al., 2004). An example would be a pure nicotine delivery inhaler (AERx) 
comprising a hand-held aerosol mechanical device and a single-unit discardable 
dosage strip containing nicotine salt (nicotine bitartrate) solution dissolved in water at 
pH 3.0-3.1 (Cipolla et al., 2008). The mass median aerodynamic diameter (MMAD) is 
between 2.4 µm and 2.8 µm for 10–30  mg/mL nicotine concentrations. FPF showed 
a linear relationship with a loaded dose (Moyses, Hearn, & Redfern, 2014). The 
maximum arterial blood concentration of nicotine was achieved 1 min post 
administration from inhaled nicotine of AERx Essence (Moyses, et al., 2014). It did 
not show significant lesions clinically, although mild to moderate acute adverse effects 
such as coughs and headaches were noted (Cipolla & Gonda, 2015). 
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Voke® nicotine inhaler is designed based on the MDI technology, containing 20 doses 
of formulated nicotine with propylene glycol, ethanol, saccharin, menthol, and 
HFA134a propellant in a MDI reservoir, which mimics 20 cigarettes per pack 
(Moyses, et al., 2014; Moyses, Hearn, & Redfern, 2015). The delivery of nicotine 
aerosol is actuated by a plunger within 0.5s after inhalation at a flow rate of at least 2–
3  L/min (Beard, et al., 2016), which is different from the typical flow rate of 60 L/min 
(Pharmacopoeia, 2011). Fine particle dose (FPD) ranging from 0.29 mg to 0.37 mg of 
nicotine was yielded from 0.43 mg delivered nicotine dose with MMAD less than 5 
µm (Moyses, Hearn, & Redfern, 2015). The mean maximum arterial nicotine 
concentration is achieved at 4.38 ng/mL within 6.5 min post administration from 0.67 
mg of nicotine through 6-8 puffs, which is only 5-10 % blood nicotine level after 
smoking. (Cipolla & Gonda, 2015; Moyses, Hearn, & Redfern, 2014). It indicates 
nicotine is absorbed slower from Voke® inhaler compared with cigarettes. Mild or 
moderate side effects such as dizziness, headache, dry throat and cough which are 
usually associated with cigarette smoking are reported (Moyses, et al., 2015). In the 
very recent reports, the Staccato® system is at the early stage to develop a nicotine 
inhaler, where the nicotine in the form of film layer solubilizing in the organic solvents 
such as ethanol, acetone, hexane or methanol is applied by spray processing (Cipolla 
& Gonda, 2015). However, the data of product efficacy and human safety are not yet 
available.  
2.6 NANOCARRIERS FOR PULMONARY DELIVERY 
Biodegradable polymeric nanoparticles as nanocarriers, with optimized 
physicochemical and biological properties for pulmonary drug delivery has received 
increasing attention due to their targeted deposition, enhanced drug stability and 
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absorption, ability for intracellular delivery, sustained release and reduced dosing 
frequency (Rytting, Nguyen, Wang, & Kissel, 2008).  
Various fabrication methods have been applied to produce polymeric nanoparticles. 
Generally, the drug molecules are either adsorbed or bound to nanopartical surfaces as 
nanosphere or encapsulated into nanoparticles as nanocapsules (Figure 2.5) (Kumari, 
Yadav, & Yadav, 2010).   Spray drying is the primary particle engineering to 
manufacture nanoparticles (Chow, Tong, Chattopadhyay, & Shekunov, 2007). This 
technique applies jets of dissolved or suspended drug in an aqueous or other fluid 
phases that produces a fine mist through a high pressure nozzle (Bailey & Berkland, 
2009). Kuar has reported  gum-based porous nanoaggregates containing isoniazid and 
rifampicin were prepared via spray drying, which is suitable for anti-tubercular 
pulmonary drug delivery with sustained drug release pattern (R. Kaur et al., 2016). Al-
Qadi investigated this process successfully to produce microencapsulated protein-
loaded CS nanoparticles as DPI formulation (Al-Qadi, Grenha, Carrión-Recio, Seijo, 
& Remuñán-López, 2012). However, after spray-drying, the production yield of 
particles is relatively low (~ 47–50%) (Sosnik & Seremeta, 2015) due to the loss of 
liquid droplets inside the wall of the drying chamber (Cevher et al., 2006). Besides, 
the ineffective separation capacity of cyclone and the insufficient forces of liquid 
atomization affects the formation of appropriate submicron particles, which influences 
the size and size distribution in the development of the pulmonary drug delivery 
system (Oliveira, Guimarães, Cerize, Tunussi, & Poço, 2014). Double 
emulsion/solvent methods have been studied for preparation of polymeric particles, in 
which droplets of the dispersed phase are emulsified into the continuous phase with 
surfactants under vigorous homogenization (Iqbal, Zafar, Fessi, & Elaissari, 2015). 
Multiple emulsions of water-in-oil (w/o) are more widely applied than the oil-in-water 
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(o/w) (Chu, Utada, Shah, Kim, & Weitz, 2007). The o/w method is usually used to 
encapsulate insoluble or poorly water soluble drugs such as 5-Fluorouracil (Khang et 
al., 2001)  and  Lignocaine (Chung, Huang, & Liu, 2001), while w/o is able to 
encapsulate most hydrophilic drugs (Iqbal et al., 2015). Although double emulsion 
systems present a number of advantages, this process of manufacture is complicated 
and time-consuming (Lambrich & Schubert, 2005). In most cases, organic solvents are 
involved (Lambrich & Schubert, 2005). The technique of ionotropic gelation 
crosslinking to prepare nanoparticles is reported extensively in the recent literature 
(Bailey & Berkland, 2009; Bugnicourt, Alcouffe, & Ladavière, 2014), particularly the 
use of sodium tripolyphosphate (TPP) as an ionic agent to form the CS nanoparticles 
(Bugnicourt & Ladavière, 2016). The characters of formed nanoparticles are affected 
by a series of factors such as size of droplet, stirring speed, viscosity of solution (Rao 
& Geckeler, 2011).   
 
 
Figure 2.5 Schematic diagram of types of biodegradable nanoparticles: nanocapsule, and 
nanosphere. The drug molecules are either entrapped inside or adsorbed on the surface.  
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Poly-D, L-lactide-co-glycolide (PLGA) is one of the most popular biodegradable 
polymers and has been used extensively for development of nanosystems such as 
proteins and peptides nanomedicine, nano-vaccines, nanoparticles, as it is metabolised 
to monomers, lactic acid and glycolic acid in the body with less toxicity. The common 
methods to prepare PLGA nanoparticles include solvent emulsion-evaporation 
(Raichur, Nakajima, Nagaoka, Maekawa, & Kumar, 2014), interfacial deposition 
(Fonseca, Simoes, & Gaspar, 2002) and emulsification-diffusion (Terry, Salaam, 
Nyairo, Thomas, & Dean, 2014).  Gomes et al. demonstrated that entrapped eugenol 
and trans-cinnamaldehyde with PLGA nanoparticles prepared by emulsion 
evaporation method could inhibit specific pathogens effectively, which can be used in 
food systems potentially as antimicrobial delivery (Gomes, Moreira, & Castell‐Perez, 
2011).  Cardoso et al reported that doxorubicin-loaded galactose-conjugated PLGA 
nanoparticles could be recognised by human hepatoma cellular carcinoma cells 
specifically, which has the potential to be used in liver-targeted drug delivery 
(Margarida Cardoso et al., 2016). However, due to the acidic nature of PLGA 
monomers, it is recommended to blend with alginate, chitosan, pectin (L. Liu et al., 
2004) to overcome this limitation. Arya group investigated and found that topotecan-
loaded composite particles of PLGA-chitosan had a synergistic effect on non-small 
cell lung cancer, which is promising for the treatment of lung cancer (Arya & Katti, 
2015).  
Nanoparticles of Poly (lactic acid) (PLA) and its copolymers have widely been used 
as delivery systems for local and systemic applications (Rancan et al., 2009). PLA 
undergoes scission in the body to monomeric units of lactic acid, which is a natural 
intermediate in carbohydrate metabolism. The rate of degradation depends on the 
degree of crystallinity and can be tailored by grafting (Tyler, Gullotti, Mangraviti, 
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Utsuki, & Brem, 2016). It eases the issue of safe elimination, which has been approved 
by FDA for use in vaccines, sutures, bone implants and screws (Tyler et al., 2016). In 
recent decades, formulations incorporated with PLA for targeted and sustained drug 
delivery has been widely demonstrated. Chen el al. study showed that drug uptake in 
targeted leukaemia cells could be improved by nanocomposite of nano-TiO2 and PLA 
nanofibers incorporated with anticancer drug of daunorubicin (C. Chen et al., 2007).  
Musumeci et al. investigated that docetaxel-loaded PLA/PLGA nanoparticles prepared 
by a solvent deposition method for intravenous administration could improve drug 
solubility and achieve sustained release (Musumeci et al., 2006).  Montiel-Eulefi et al 
reported copper-loaded PLA nanoparticles can be applied in the gastric cancer, which 
showed a cytotoxic effect and increased apoptosis on the gastric cancer cell line MKN-
54 (Montiel-Eulefi, Jara, Toro, Garces, & Leal, 2014).   
Alginate is an anionic polymer with less toxicity and good biodegradability. It has been 
employed extensively in the fabrication of particles and bulk gels (Paques, van der 
Linden, van Rijn, & Sagis, 2014). Nanosystem of alginate, including nanoaggregates, 
nanospheres and nanocapsules are mostly prepared by complexation (Lertsutthiwong, 
Noomun, Jongaroonngamsang, Rojsitthisak, & Nimmannit, 2008) and w/o 
emulsification (T. Chen, Yan, Li, & Tang, 2012).  Zahoor et al. prepared alginate 
nanoparticles, which were 235.5 ± 0 nm in size by cation-induced gelation. 
Pharmacokinetic and chemotherapeutic performance of encapsulated isoniazid, 
rifampicin and pyrazinamide with aerosolised alginate nanoparticles were evaluated 
via the aerosol route in guinea pigs, which showed inhalable alginate nanoparticles are 
suitable to be applied as a controlled release of antitubercular drug carrier (Zahoor, 
Sharma, & Khuller, 2005).  
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2.7 CHITOSAN NANOPARTICLES AS A PULMONARY DELIVERY 
SYSTEM 
Chitosan (CS) (Figure 2.6) is a natural biodegradable polymer derived from crustacean 
shells such as crabs, shrimps and lobsters, microorganisms, fungi and yeast (Kumar, 
2000). It is a modified cationic polyaminosaccharide polymer which is the N-
deacetylated derivative of chitin (Kumar, 2000). The primary unit of CS is a linear 
polysaccharide formed by β-(1-4)-linked D-glucosamine (deacetylated unit) and N-
acetyl-D-glucosamine (acetylated unit) randomLy,  so they are readily available for 
cross linking (X. Wang, Chi, & Tang, 2008). Due to advantages of CS such as 
extensive availability, low cost, high biocompatibility, biodegradability, better 
stability, low toxicity, mild preparation method, ease of chemical modification and 
versatile routes of administration (Sonia & Sharma, 2011), CS has been used 
extensively in many fields such as medicine, food and agriculture (Elena Udrea, 
Hritcu, Popa, & Rotariu, 2011; Sanyakamdhorn, Agudelo, & Tajmir-Riahi, 2013). The 
properties of CS considerably depend on the viscosity and molecular weight of CS 
which are dominated by the degree of deacetylation (Li, Liu, Wu, Wu, & Ran, 2008), 
and its properties affect the particle size, size distribution and particle aggregation. 
During the past two decades, a substantial amount of work has been published that this 
polymer is very suitable for preparation of nano- and microparticles for controlled drug 
release and offers valuable advantages as a drug delivery carrier for both small 
molecular drugs, like nicotine (Hui Wang, George, Bartlett, Gao, & Islam, 2017), 
paclitaxel (Majedi et al., 2014), and macromolecules, such as RNA (Ragelle et al., 
2014),  DNA (Gan, Wang, Cochrane, & McCarron, 2005). A wide range of drug 
formulations including gels, capsules, tablets, inhalations have been manufactured by 
CS. (Jonassen, Kjøniksen, & Hiorth, 2012). For example, glycol CS nanoparticles have 
achieved promising applications in both diagnosis  and therapy for cancer (Lee, 2011). 
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Many studies have showed that several factors are important to achieve the desired 
characteristics of CS nanoparticles, including the proportion of crosslinking agent and 
polymer, the molecular weight of the CS, the CS concentration and pH (Agnihotri, 
Mallikarjuna, & Aminabhavi, 2004). Meanwhile, polymeric micro/nanoparticles for 
pulmonary drug administration improve the therapeutic effect of drug by modifying 
the drug bioavailability; in addition, encapsulated drugs in  the micro- and 
nanoparticles contributes to reducing drug toxicity and prolongs the drug release 
profiles (Mossaad 2014). 
 
Figure 2.6 Structure of Chitosan (CS) 
 
CS nanoparticles have been used extensively as drug delivery carriers due to their 
variety of advantages, which were mentioned before. Further studies could involve the 
use of derivatives of CS to provide better control of properties. Application of CS and 
its derivatives in lung delivery of various drugs has been extensively reviewed (Islam 
& Ferro, 2016). Currently most studies focus on the modifications of C2 position 
which is amino groups , while less attention is paid on the potential application of C6 
modification (Islam & Ferro, 2016).  In the near future, more modified CS with 
encapsulated drugs or other conjugated excipients at C6 or both C2 and C6 could be 
prepared for more practicable pharmacotherapeutic strategies. In addition, toxicities of 
derivatives of CS in different human organs have not been completely understood 
although a lot of studies have been reported based on in vivo animal models (Archana, 
Dutta, & Dutta, 2013; Liang et al., 2014). However, there is no doubt that translation 
  
Chapter 2:  Literature Review 50 
from animal models to humans is still difficult to achieve due to large differences of 
anatomical structures between animals and humans. Biodegradability is another safety 
issue to consider in long term human health applications. In particular, the most current 
techniques involved in organic solvents and use chemical crosslinkers as well as high 
shear force (Tiyaboonchai, 2003). However, its minor shortfalls can be ignored when 
considering its favourable biocompatibility characteristics.  
2.8 ANIMAL MODELS FOR PULMONARY DISPOSITION 
With advancements of aerosol and inhalation technology in development of inhalation 
medications, it is essential to evaluate the efficacy of drug delivery and its bio-activity 
following encapsulation and release as well as potential toxicity of formulated 
inhalation products in animal models prior to application in humans. Although several 
in vitro apparatus such as twin-stage impinger (Haghi, Traini, & Young, 2014), multi-
stage liquid impinger (Zhou et al., 2013) and cascade impactors (M. Chen, Romay, Li, 
Naqwi, & Marple, 2016) have been used to evaluate the particle deposition according 
to the size of particles, these methods could not totally imitate structures of upper and 
lower respiratory tracts. Rodent models such as rats and guinea pigs are usually 
employed for pulmonary dosing; however, mice are a greater technical challenge in 
lung dosimetry and collection of multiple blood samples due to smaller body size and 
limited volume of body blood. 
2.8.1 Intratracheal Instillation 
Intratracheal instillation is a pioneering work reported by Schanker group (Enna & 
Schanker, 1972). The rats are placed on a surgical board in a supine position under 
anesthesia. An insulation blanket is used to maintain 37 °C consistently. The trachea 
is exposed carefully, following inserting an endotracheal tube between the tracheal 
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cartilaginous rings. A microsyringe of aqueous tested solutions or suspensions instils 
into the airways via tube. Then, the lung tissues are removed and homogenized to 
determine the levels of drug concentration quantitatively using HPLC or LC-MS. 
Although a substantial number of data for the lung tissue kinetics have been produced 
from this model (Enna & Schanker, 1972; Lanman, Gillilan, & Schanker, 1973; 
Schanker & Burton, 1976), a large number of animals are sacrificed to produce a data 
point due to the destructive tissue sampling. The technique of intratracheal instillation 
is only applicable to liquid instillation although a variety of more sophisticated and 
custom-made dosing devices (Hasegawa-Baba, Kubota, Takata, & Miyagawa, 2014; 
Zhang et al., 2016) have been applied for use in rodent models. Based on the 
advancement on the tracheostomy, the new techniques such as direct injection to the 
lung or spray of drug solutions in the lung through orotracheal intubation was applied 
(Brain, Knudson, Sorokin, & Davis, 1976),  but it is still limited for powder 
administration. 
2.8.2 Dry Powder Insufflation 
As deep lung delivery from dry powder formulations has attracted increasing 
attentions in the recent years, powder insufflation technique as well as insufflation 
devices with precise dosing and reproducibility have been employed. In most cases, 
tracheal access via tracheotomy is essential and it is required 3-5 mL compressed air 
to insufflate 0.2-5.0 mg powders from devices into the lung (Sakagami, 2006). Penn-
Century produced a hand-operated dry powder insufflatorTM to aerosolize dry powders 
and deliver fine particles for small rodent applications (Codrons, Vanderbist, Ucakar, 
Préat, & Vanbever, 2004). Molina et al. (Molina et al., 2016) compared CeO2 (cerium 
oxide) nanoparticles distribution from intratracheal instillation and powder 
insufflation using Penn-Century device. It is found that inhalation insufflation caused 
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a more significant deposition in the trachea and a more uniform particle distribution 
within lungs than instillation. In order to achieve deep lung delivery to maximize drug 
deposition, ventilated administration of aerosol exposure with positive pressure has 
been employed. However, a substantial amount of test material is required to pursue a 
desirable biological effect with relatively high dose deposition from powder 
insufflation due to low ventilation rate of rodents. Furthermore, this technique of 
powder insufflation relies on the physicochemical characterzations of powder and the 
way of aerosolization.  
2.8.3 Inhalation Exposure 
Much effort has been made to design devices for inhalation exposure in animal models 
because neither anaesthesia nor surgery is required. Currently, there are two main 
options for delivering particles to animals to achieve inhalation exposure, including 
whole-body exposure and nose-only inhalation exposure (Hu, Adamcakova-Dodd, 
LehmLer, Gibson-Corley, & Thorne, 2015). Mainelis reported a nose-only exposure 
chamber with four inhalation ports that was employed to deliver anticancer drug and 
small interfering RNA to the lungs in mice. The aerosol deposition rate under the size 
of 130  nm of liposomal nanoparticles was 1.4% at each port after 60 minutes 
aerosolization (Mainelis et al., 2013). Sinha and his group developed a nose-only 
inhalation chamber as either nebuliser or DPI depending on the experimental setup for 
mice (Sinha & Mukherjee, 2012). In vitro evaluation test showed drug deposition from 
DPI was higher than nebulizer (42-57 % vs. 11-26 %) and in vivo test demonstrated 
80-130 µg/g of voriconazole was found in mice lung tissues from DPI while 40–68 
µg/g  was detected from nebulizer (Sinha & Mukherjee, 2012). In contrast, a whole-
body inhalation exposure apparatus was constructed by Yi group and used for delivery 
of titanium dioxide nanoparticle aerosol with stable mass concentration, uniform 
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composition and consistent particle size distribution (J. Yi et al., 2013). This inhalation 
chamber from whole body exposure requires animal to inhale the drugs from the 
animal body surface instead of nose administration, which prevents measurement of 
the oral dose efficiency. Interestingly, a very recent study reported both whole-body 
inhalation and nose-only inhalation exposure results in the same efficiency in particle 
deposition under the same administration conditions (Oyabu et al., 2016). 
However, it is still a challenge to design the adequate inhalation devices for use in 
animal models to test the efficacy of inhalation products. The currently available 
inhalation devices designed for DPI studies require tracheal intubation under ambient 
pressure or positive pressure, which results in large amount of inhaled particles being 
deposited by physiological breathing rather than spontaneous respiration.  On the other 
hand, they require whole body exposure to achieve inhalation by spontaneous 
respiration, while the absorption routes are through percutaneous absorption or orifices 
other than the nasopharynx. Some test material is toxic if it deposits on the fur of the 
animals. The nose-only exposure devices seem favourable for animal model studies, 
however, the duration of exposure is critical to consider carefully with variation of air 
flow rate, air pressure, aerosol concentration (Lebedová et al., 2016).  A large fractions 
of aerosols deposit nasal cavity as rodents are nose-breathing animals, which results 
in over-estimation of lung’s  absorption capacity because plotted blood concentration 
profiles are the sum of absorptions  from nose, gastrointestinal tract and lung (Wolff 
& Dorato, 1993). Furthermore, a large amount of test material is wasted due to the low 
efficiency of powder delivery.  
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2.8.4 In Vivo Imaging Technique 
In vivo imaging technique is an approach to assess lung and oropharyngeal depositions 
in the direct ways to track particle or drug carriers by taking images of lungs, which 
allows evaluating lung-regional deposition of particles qualitatively and quantitatively. 
Various options based on the theories of radionuclides, nonionizable radiation and 
fluorescent dye have been applied to determine particle deposition by capturing 
pictures of lungs tissues or by autoradiographic technique after sacrificing animals and 
separation of animal lungs such as gamma scintigraphy (Bennett, Xie, Zeman, Hurd, 
& Donaldson, 2015), single photon emission computed tomography (SPECT) 
(Gervais, Poussier, Bardin-Monnier, Karcher, & Thomas, 2014), positron emission 
tomography (PET) (Barth et al., 2014), magnetic resonance image (MRI) (Abdukayum 
et al., 2014) and fluorescence imaging (Abdukayum et al., 2014). The images of 
SPECT and PET are presented in the pattern of 3D, allowing more details on regional 
lung deposition to be shown, in comparison to the 2D images technique produced by 
gamma scintigraphy (Nahar et al., 2013). Specifically: (1) Formulations applied to 
gamma scintigraphy are labelled with gamma ray emitting radioisotopes. It is possible 
to measure lung deposition regionally via this method. However, due to 2D images 
from this method, structures of interest maybe overlayed and scanned, which is 
possible to fail to distinguish among alveoli, small and large airways (Nahar et al., 
2013);  (2) Formulations applied with SPECT are radiolabelled and subjects are rotated 
scanned by gamma camera, structures of interest with better anatomical are produced 
by radionuclide in the 3D construction. Therefore, accuracy is improved significantly 
by this method (Perring, Summers, Fleming, Nassim, & Holgate, 1994). Nevertheless, 
the conditions such as redistribution of radiolabelled aerosol, coughing and absorption 
of radiolabelled signals into blood stream may be associated with this method as it 
takes as long as 30 minutes to complete scan of regional deposition. (3) The drugs 
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applied with PET are labelled with positron emitting radioisotopes, which produce 
high energetic photos by annihilating with electrons and emit spontaneously. The drug 
of interest is able to be seen as radioactive tracer when merging positron emitting 
isotopes such as 11C, 13N, 15O and 124In, which contributes to progress in pathology, 
biochemistry, inflammation and cellular response. However, availability of positron 
emitting radionuclides is primary limitation to applying this technique widely (Saha, 
MacIntyre, & Go, 1992).  In addition, this method is unable to provide lung deposition 
of inhaled formulations quantitatively. (4) The method of MRI not only offers a way 
to measure particles deposition in animals quantitatively, but also enables 
quantification of particles deposited regionally in animals and in vitro human airways 
(Thompson & Finlay, 2012). Richard et al. reported MRI contributed to increase of 
concentration of particle deposition when drugs are loaded with iron oxide 
nanoparticles in the application of targeted delivery (Richard et al., 2004). (5) Test 
drugs tagged with fluorescent particles can be tracked and detected during drug 
deposition in animals by fluorescence imaging.  The limitation associated with this 
method is that biological tissues could scatter, reflect and absorb emitted fluorescent 
light, causing interference of light capture by detector and determination of the number 
of molecules. In addition, most tissues appear to auto-fluoresce, which enhances 
heterogeneous background signal (D. Yi, Price, Panoskaltsis-Mortari, Naqwi, & 
Wiedmann, 2010). Currently the common options to overcome this problem are to 
subtract auto-fluorescence from blank tissue and select emitted light in the region of 
near infrared  of the spectrum (Adams et al., 2007; Diao et al., 2015).  
Imaging technique could provide a real picture of drug deposition in the animal lungs 
locally and regionally. However, the techniques mentioned above are challenging with 
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expensive cost, high dose required for radiation, safety hazards of radioactivity and 
specific expertise in handling of radio labelled isotopes.   
As discussed above, the author hypothesises that the delivery of pure nicotine to the 
deep lung using a DPI device with better formulation would be comparable to cigarette 
smoking and hence would alleviate cravings and nicotine withdrawal with reduced 
dosage and potential side effects. At the same time, it is anticipated that the polymer 
encapsulated nicotine delivery will also reduce nicotine craving with controlled 
formulation.  Very recently, Wang et al. demonstrates using the biodegradable polymer 
of CS as carriers for nicotine hydrogen tartrate (the salt form of nicotine) as DPI 
formulation, which is able to deliver FPD of nicotine between 1.7 mg and 3.2 mg into 
lungs with sustained release profiles. It suggests encapsulation of nicotine into CS 
nnaoparticles may be exploited for sustained release nanoparticulate DPI formulation 
for treatment of nicotine addiction potentially (Hui Wang et al., 2017).   
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The aim of this chapter is to develop micro/nanoparticles of biodegradable polymer of 
chitosan (CS) loaded with nicotine hydrogen tartrate (NHT) for pulmonary delivery of 
nicotine from dry powder inhaler (DPI) formulations. The physicochemical properties 
such as particle size, flowability, specific surface area etc. of particles are understood 
by a series of techniques.  The NHT-loaded CS (NHT-CS) micro/nanoparticles are 
prepared using water-in-oil (w/o) emulsion crosslinking method. The morphological 
studies are characterized using scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM). Particle size analysis is determined by Zetasizer and 
Mastersizer. According to differential scanning calorimetry (DSC), x-ray diffraction 
(XRD) analysis and Attenuated total reflectance-Fourier transform infrared (ATR-
FTIR) spectroscopy, the NHT crystallinity is lost when encapsulated in the 
micro/nanoparticles, indicating it is uniformLy dispersed as a solid solution. On the 
basis of X-ray photoelectron spectroscopy (XPS) analysis, the amount of NHT loaded 
on the surface of CS increases proportionally with increasing drug loading in the bulk 
so there was no surface enhancement. 
3.1 INTRODUCTION 
Novel particle technologies have assisted the advancement of inhalation therapy. The 
size of particles should be small enough to escape from the mouth, throat and 
conducting airways and targeted to the deep lung. The performance of the particles 
deposited is characterized by the aerodynamic diameter, Da. Generally, the particles 
with large sizes (Da >5 µm) are deposited in the mouth and upper airways; particles 
with small size (Da =1-5µm) are deposited in the lungs; the particles with very small 
size (Da <1µm) are able to deliver the drug to the lung epithelium, while mostly they 
are suspended or exhaled driven by diffusion (Labiris & Dolovich, 2003; Sung, 
Pulliam, & Edwards, 2007). When the particle-particle aggregation is created, it causes 
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difficult handling of nanoparticles physically (Grenha, Seijo, & Remunán-López, 
2005) as it requires high energy for their deaggregation in dry powder form. To 
overcome these limitations, nanoparticles incorporating micron carriers such as coarse 
lactose of different morphologies has been reported (Kho & Hadinoto, 2013; Ungaro, 
d'Angelo, Miro, La Rotonda, & Quaglia, 2012). Jafarinejad (Jafarinejad et al., 2012) 
prepared lactose and mannitol micro-scale dry powders containing itraconazole-
loaded nanoparticles by spray drying to improve the physical and aerosolization 
properties.   Large biomolecules are not able to cross the alveolar epithelium when 
they reach it, while nanoparticles are the ideal vehicles for drug transport to the deep 
lung, avoiding unwanted mucociliary clearance and phagocytic mechanisms (Grenha, 
et al., 2005).  Over the last few decades, nanoparticles have been extensively 
recognized as valuable drug carriers for pulmonary delivery through dissolving, 
entrapping or encapsulating to active substance due to its a variety of advantages. 
Furthermore, nanoparticles are able to deliver drug in the prolonged and sustained 
period in the lung tissue and systemic circulation, which is beneficial for patients 
compliance with reduced dose required (Beck-Broichsitter, Merkel, & Kissel, 2012; 
Colilla, Baeza, & Vallet‐Regí, 2015). The nanoparticles are usually composed of 
biodegradable polymer, which is degraded in the body and excreted through natural 
metabolic pathways (Sung, et al., 2007). A variety of molecules have been for systemic 
and local therapeutic nanoparticles from pulmonary delivery. 
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Figure 3.1 Molecular structures NHT (A) and glutaraldehyde (B) 
 
In this study, nicotine hydrogen tartrate (NHT) (Figure 3.1A) was selected as the 
model drug to prepare the NHT-loaded CS nanoparticles for pulmonary delivery. The 
targeted size of NHT-loaded CS nanoparticles would be within 500 nm, while the size 
of micro-aggregate occurred between nanoparticles due to high surface energy are 
ideal within 5 µm, which is in the respirable range.  NHT is more stable than nicotine 
base, which is a very unstable and hygroscopic oily liquid, causing difficulties in 
conventional packaging materials (Chauhan, Lin, & Madan, 2012). NHT is a 
hydrophilic powder, aqueous solubility up to 50 mg/mL and it melts at 89°C (Chauhan 
et al., 2012).   
The aim of this chapter was to demonstrate a strategy to fabricate NHT-loaded CS 
micro/nanoparticles by using water-in-oil emulsion crosslinking method. 
Glutaraldehyde (Figure 3.1B) is used as a crosslinking agent for primary amines. The 
mechanism of this method is to utilize the Schiff base reaction where the 2 units of 
amine group of CS is crosslinked with one aldehyde molecule, forming a characteristic 
imine (N=C) bond between aldehyde  carbon and primary amine (Agnihotri et al., 
2004) (Scheme  3.1).  
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Scheme  3.1 Mechanism of crosslinking of glutaraldehyde with CS (Agnihotri et al., 2004) 
3.2 MATERIAL AND REAGENTS 
Low molecular weight (LMW) CS with the degree of deacetylation of 92% was 
purchased from Sigma-Aldrich, Australia. 50% aqueous glutaradehyde was purchased 
from Merck, Australia as the crosslinker for the preparation of nanoparticles. Span 80 
was obtained from PCCA, Australia as the emulsifier. Nicotine hydrogen tartrate 
(NHT) salt powder (≥98%) was purchased from Sigma-Aldrich, Australia. All other 
chemicals and reagents used were analytical grade.  
3.3 METHODS 
 W/O Emulsion Crosslinking  
 
Preparation of blank CS nanoparticles 
Blank CS nanoparticles were prepared by using W/O emulsion-glutaraldehyde 
crosslinking method (Hui Wang et al., 2017). In order to fabricate blank CS 
nanoparticles, LMW CS powder was dissolved in 2 w/v% acetic acid to obtain the 
final concentration 2% CS solution with pH 3.5. About 1mL span 80 was mixed into 
about 100 mL paraffin oil under vigorously stirring to form a fine dispersion. 3mL of 
2% CS solution was added to paraffin oil drop-wise, with the homogenization for 5 
minutes  using ultraturrax (IKA®) to obtain the W/O emulsion. Then, the mixture was 
continued stirring at 5000 rpm (IKA® Works (Asia), Inc). After 10 minutes, the stirring 
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speed reduced to 3000 rpm and the liquid mixture was continued to mix for 3 hours 
with the addition of 0.2 mL 50% glutaraldehyde every hour for a period of three hours. 
Finally, the whole mixture was stood for 1 hour, after washing in hexane once and 
diethyl ether three times. The blank CS nanoparticles were obtained by freeze drying 
at −80 °C. 
Effect of amount of crosslinking agent on formation of nanoparticles 
 
Different types of blank CS nanoparticles were prepared with a series of different 
levels of crosslinking agent (i.e. 0.3mL, 0.6mL, 0.9 mL 50% glutaraldehyde solution 
in total). All other conditions were same as above. The detailed conditions and results 
were shown in the Table 3.1. In the following sections and chapters, all the blank CS 
nanoparticles used for general physicochemical properties tests were prepared by 0.6 
mL 50% glutaraldehyde solution, except for emphasizing volume of glutaraldehyde 
solution used during manufacture process. 
Preparation of NHT-loaded chitosan nanoparticles 
For preparation of NHT-loaded CS nanoparticles, 2 mL of NHT solution in milli-Q 
water at different concentrations (i.e., 2%, 4%, 6% w/v) was added into 2 mL of 2% 
CS solution (dissolved in 2% acetic acid) before adding to paraffin oil. This gave 
loadings which are referred in the following studies as 1:1; 2:1 and 3:1 ratios of NHT: 
CS. All other conditions were same as above. The detailed conditions and results were 
shown in the Table 3.1 
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Table 3.1 Conditions to prepare blank CS and NHT-loaded CS nanoparticles 
 
Products name Volume of 2% CS 
in 2% acetic acid 
(mL) 
volume of 50% 
glutaraldehyde (mL) 
Concentration of 
NHT solution (%) 
Blank CS NPs 3 0.6 0 
Blank CS NPs-0.3 3 0.3 0 
Blank CS NPs-0.9 3 0.9 0 
NHT-CS 1:1 2 0.6 2 
NHT-CS 2:1 2 0.6 4 
NHT-CS 3:1 2 0.6 6 
 
 Morphological Studies  
The morphological examination of the freeze dried CS nanoparticles and NHT-loaded 
CS nanoparticles were observed by Scanning Electron Microscopy (Zeiss Sigma VP 
Field Emission SEM). A tiny amount of freeze dried powder was dropped onto a 
silicon wafer adhered with an aluminium stub through carbon adhesive tape. The air 
dried specimen stubs were coated with a conductive layer of sputtered gold (argon gas 
pressure of 0.5 mbar, current of 30 mA, and coating time of 75 s), followed by 
observing  morphological characterizations of secondary electron images under a high 
vacuum with an accelerating voltage of 5 kV and a working distance  of 6.8 mm. A 
variety of photomicrographs with different magnifications were captured for blank CS 
nanoparticles and NHT -loaded CS nanoparticles. 
To understand more about individual nanoparticles, the samples were analysed by a 
TEM. A small amount of powder was suspended in water and TEM analysis were 
obtained by dropping 6 µl of the prepared suspension onto a copper grid, and dried 
overnight at room temperature. The examinations were carried out at the accelerating 
voltage of 200 kV without any further modification or coating. 
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 Particle Size 
The particle size and size distribution of the blank CS and NHT-loaded CS 
nanoparticles were determined using Zetasizer (Nano ZS 90, Malvern Instruments, 
UK) by DLS measurements. Lyophilized powder of nanoparticles was dispersed in 
mineral oil with 1% span 80, and sonicated for 10 minute. Size measurements were 
performed under a detector angle of 90° at 40°C. All the measurements were 
performed in triplicate. Reported values were the mean diameter ±SD.  Particle sizes 
and data acquisition were analysed by Malvern Zetasizer Software. 
A laser diffraction instrument (Malvern Mastersizer 3000, Malvern Instruments, 
Malvern, UK) was utilized for measuring the size of micro-aggregates as seen in the 
SEM images. A 10 mg of NHT-CS and CS powders were suspended in 50 mL of milli 
Q water with 2 drops of 1% Tween 80 as surfactant. NHT-CS/blank CS suspensions 
were then added to an automated dispersion unit (Hydro MV, Malvern Instruments, 
Malvern, UK) to reach an obscuration value of 20  ±  1% and recorded particle sizing 
in a cycle of 5 measurements over 120 s. Size distribution was determined  as relative 
volume density versus size distribution curves (Malvern Mastersizer 3000® Micro 
Software v 3.10). Parameters obtained in particle size distribution of mean particle 
volume D [v, 50] are shown in Table 3.3.  
 Zeta Potential 
Using this DLS, surface charges (zeta potentials) on nanoparticles were determined at 
measured pH after freeze drying and a fixed pH (pH=6) to get a clear understanding 
on the effect of pH on zeta potential. The nanoparticle powders were dispersed in 0.1 
mM KCl, following 10 mins sonication and the zeta potential measurements were 
repeated in triplicate. 
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 Particle Density and Flow Property 
 
Bulk density, tap density, Carr’s index and Hausner ratio 
 
The bulk density (𝜌
𝑏
 ) and tapped density( 𝜌
𝑡
 ) of particles were determined by the 
graduated cylinder measurement (Pilcer, Vanderbist, & Amighi, 2009) as Eq. 3.1 and 
Eq. 3.2. A certain amount of test samples ( 𝑚
0
) were introduced into a dry graduated 
10 mL cylinder, after  the agglomerates formed during storage were broken up gently 
to avoid changing the nature of the particles. Apparent volumes ( 𝑉
0
 ) without 
compacting were noted to calculate the bulk density (g/mL). Then, the formulations 
were tapped 100 times mechanically by tapped density tester (ERW-SVM101201, 
ERWEKA, Germany) and the volumes (𝑉
1
) of cylinder were read to calculate the 
tapped density (g/mL). Furthermore, Carr’s index (CI) and Hausner ratio (HR) were 
calculated (Varshosaz, Taymouri, & Hamishehkar, 2014) using the Eq. 3.3 and Eq. 3.4 
below. All the measurements were performed in triplicate. 
                                                          𝜌
𝑏
=
𝑚0
𝑉0
                                                            Eq.  3.1 
                                                          𝜌
𝑡
=
𝑚0
𝑉1
                                                            Eq.  3.2 
𝐶𝐼 =
100(𝑉0−𝑉1)
𝑉0
                                              Eq.  3.3 
𝐻𝑅 =
𝜌𝑡
𝜌𝑏
                                                           Eq.  3.4 
Where 𝜌𝑏represented the bulk density; 𝜌𝑡was tapped density; CI was Carr’s index and 
HR was Hausner ratio.   
Angle of repose 
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The angle of repose (θ) is an important macroscopic parameter in evaluating the 
flowability of particles (Varshosaz et al., 2014) as Eq.3.5. It is the angle formed by the 
horizontal base and the edge of a cone-like pile of granules. A glass funnel of diameter 
18 mm and orifice 2 mm was used. The height from the beginning of funnel to end of 
orifice was 50 mm. The funnel was fixed by in a stand 3 cm above the beaker surface. 
The cone was built through glass funnel using around 0.50 g of NHT-loaded CS 
nanoparticles. The height (h) and the diameter (d) of the base of the cone formed by 
the granules were measured and used to determine θ using the following equation. 
                                               θ = tan−1(
2ℎ
𝑑
)                                            Eq.  3.5 
 Differential Scanning Calorimetry (DSC) 
The thermal characteristics of pure NHT, NHT-CS nanoparticles and blank CS 
nanoparticles were investigated using differential scanning calorimetry (DSC) in a TA 
Instruments DSC (model Q100). 1.2 mg samples were accurately weighed in a 
standard aluminum pan, sealed and taken through a heat-cool-heat cycle between 25°C 
and 180°C at a constant speed of 10°C/ min under continuous purging of nitrogen 
atmosphere (10 mL/min). An empty sealed pan was used as a reference. All samples 
were measured in triplicate.  
After DSC test, the aluminium pan of NHT was cut by scissors and observed under 
microscope. The product inside of aluminium pan subsequently was analysed by 
attenuated total reflectance Fourier transform infrared (ATR-FTIR). 
 X-ray Diffraction (XRD) 
Powder X-ray diffraction diagrams of blank CS nanoparticles and NHT-loaded CS 
nanoparticles were performed with PANalytical X'Pert PRO MPD Powder X-ray 
Diffractometer. Powder samples were finely ground into XRD sample holders to create 
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flat surfaces. The X-ray source was CuKα radiation over the range of 4-75° (2θ) at 40 
kV and 80 mA. Angular speed was 4°/min. 
 X-ray Photoelectron Spectroscopy (XPS) 
The XPS analysis of chitosan and the NHT was performed using a Kratos Axis Ultra 
Spectrometer (Kratos Analytical, Manchester, UK) equipped with monochromatized 
aluminium X-ray source (powered at 10 mA and 15 KV), 165 mm radius 
hemispherical analyser (HSA) and 8-channel electron multiplier (channeltron) 
detection system. Powder samples were mounted onto stainless steel sample holders 
using double-sided adhesive tape and the spectra were collected using an analysis area 
of 700 x 300 µm. Low-resolution wide scans (survey spectrum) in the binding energy 
scale (0–1200 eV with 1.0 eV steps) were collected at an analyser pass energy of 160 
eV. High-resolution narrow scans (multiplex spectra) were collected at 20 eV pass 
energy with 0.05 eV steps for O1s, N1s and C1s. The data were processed using Casa 
XPS software Version 2.3.14 and binding energies of the various elements were 
referenced to the C1s line at 285.0 eV. 
 Attenuated Total Reflectance -Fourier Transform Infrared (ATR-FTIR)  
Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectra was 
conducted with a Nicolet Nexus 870 FTIR spectrometer equipped with a single 
reflection diamond crystal attenuated total reflectance (ATR) accessory. External 
reflection FTIR accessory with an angle of incidence 40° and a mercury cadmium 
telluride (MCT/A) detector were employed for all ATR spectral acquisitions. NHT, 
blank chitosan nanoparticles and NHT-loaded chitosan (1:1-3:1) nanoparticles were 
analysed by ATR. The tiny amount of samples were dropped on the top of a diamond 
crystal and secured with a high-pressure clamp. The product after DSC measurement 
of NHT was detected by ATR as well. All spectra were collected at a resolution of 8 
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cm-1 and 64 scans in the range of 4000-600 cm-1 and analysed using the spectral 
analysis software OMNIC (Nicolet Instrument Corp.). 
 BET Specific Surface Area 
BET nitrogen adsorption is one of the most common used methods to acquire 
information about the pore size and specific surface areas of powders consisting of 
agglomerates of smaller particles. The specific surface area of powders can be 
evaluated through BET equation, which assumes that the gas volume of monolayer 
adsorption can be obtained by measuring the adsorbed gas quantity. In this study, the 
specific surface area of CS nanoparticles and NHT-loaded CS nanoparticle powders 
were determined by BET surface area measurement. Nitrogen adsorption 
measurements were carried out at 77 K using an ASAP 2010 volumetric adsorption 
analyser from Micromeritics (Norcross, GA). Before the measurements, the samples 
were degassed under vacuum overnight at 473 K. 
 Drug Incorporation 
Drug loading was calculated based on the ratio of amount of drug entrapped in the 
nanoparticles to the total amount of nanoparticles obtained after lyophilisation, which 
was calculated using Eq.3.6, 
                 𝐷rug loading(%) =
total drug−free drug
nanoparticle weight
× 100                        Eq.  3.6 
As the drug loaded nanoparticles were washed with diethyl ether, the amount of 
washed drug in diethyl ether was calculated to obtain the actual drug loading in 
nanoparticle. Initially the nanoparticles were separated from the oil phase by 
centrifugation, free drug was extracted into an excess of PBS (1:5) solutions and 
quantified by UV spectrophotometry (Beckman Coulter DU 800UV/Vis 
Spectrophotometer, USA) at the maximum absorbance wavelength of 258 nm. There 
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was a possibility that a small amount of non-entrapped NHT leached into diethyl ether 
during washing. To calculate this amount, a 4 mL diethyl ether supernatant after 
centrifugation was mixed with excess amount of PBS (1:5) under vigorous shaking 
and kept it an open air at 30°C for 20 minutes for complete removal of diethyl ether. 
Finally the amount of free drug was measured by UV spectrophotometry. All the free 
drugs during the diethyl ether three times wash were collected and recorded.  The final 
total free drug was the sum of the free drug in the oil supernatant and ether 
supernatants.  Each sample was repeated three times.  
3.4 RESULTS AND DISCUSSION 
 Preparation of Nanoparticles 
W/O emulsion crosslinking method was applied to prepare blank CS and NHT-loaded 
CS nanoparticles. Glutaraldehyde was used as a crosslinking agent for primary amines. 
The mechanism of this method is to utilize the Schiff base reaction where 2 units of 
amine group of CS is crosslinked with one aldehyde molecule, forming a characteristic 
imine (N=C) bond between aldehyde carbon and primary amine (Scheme  3.1). The 
mixture of NHT and CS solution at a series of mass ratios (NHT: CS) from 1:1 to 3:1 
at similar fixed conditions was added into the paraffin oil under vigorously 
homogenization.  During this process, it was observed that a clear emulsion changed 
to opalescent visually upon adding water phase solution into oil phase, which indicated 
formation of a suspension of nanoparticles. Flocculation was reported to occur on 
addition of high molecular weight polymer into a dilute dispersion (Abdelwahed, 
Degobert, Stainmesse, & Fessi, 2006; Gan et al., 2005), so we chose  LMW chitosan 
to improve physical stability and reduce aggregates among nanoparticles. The 
nanoparticles were dried by freeze-drying through sublimation and desorption under 
vacuum. Primary physical and chemical characteristics of nanoparticles, were 
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maintained from freeze-drying, which can also keep the nanoparticles samples under 
acceptable relative humidity and benefit long-term stability (Abdelwahed et al., 2006).    
Both the blank CS nanoparticles and NHT-loaded CS nanoparticles obtained in this 
experiment showed a light yellow coloration of the powder. In this study, volume 
ratios of 2% CS solution and glutaraldehyde was 5:1, producing the size of  
nanoparticles that was below 200 nm and polydispersity <1 (Table 3.2). Weak acid 
solution is expected to produce the lowest diameter CS nanoparticles (J. Xu et al., 
2012). Thus, inter- and intra-molecular cross-linkages of CS and negatively charged 
glutaraldehyde (Sawyer et al., 1987) were processed in a weak acidic environment of 
2% acetic acid. The mean diameter of the blank CS nanoparticles obtained from this 
work was 167.6±10.2 nm (Table 3.2).  
Emulsification behaviour of surfactants mainly relies on their chemical structure 
especially the hydrophilic-lipophilic balance (HLB). It has been reported that the 
average diameter of particle increases with increasing HLB value (Kobiasi, Chua, 
Tonkin, Jackson, & Mainwaring, 2012). Span 80 was selected in this study because of 
its HLB value of 4.3 (as it is constituted of a small hydrophilic group and one 
hydrophobic oleate chain), which is favourable for producing desired particle size in 
paraffin oil.  Small hydrophilic group increases steric hindrance and curvature, 
stabilizing the smaller droplet sizes by reducing surface tension and favoured the 
formation of stable CS droplet size. We chose the fastest stirring speed (5000 rpm) in 
this study to obtain the desired size of nanoparticles as there is a relationship between 
stirring speed and particle size (Ajun, Yan, Li, & Huili, 2009). The relationship 
between pH and formation of the nanoparticles showed that the mean diameter of the 
blank CS nanoparticles tend to decrease with increase in pH (J. Xu et al., 2012), and 
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the CS nanoparticles prepared in weak acid solution were expected to have a minimum 
diameter. Final nanoparticles were obtained by freeze-drying owing to the advantages 
of drying samples through sublimation and desorption under vacuum. It not only 
maintains the primary physical and chemical characteristics of nanoparticles, it also 
keeps acceptable relative humidity for nanoparticle samples and benefits long-term 
stability (Abdelwahed et al., 2006).    
In order to obtain less aggregated and uniform size of NPs, we anticipated that the 
application of ultrasonic agitation during homogenization may overcome aggregation 
and produce narrow particle size distribution. Homogeneity is believed to be a process 
of equilibrium between aggregation and mixing. Theoretically, homogenization is 
slower than the process of aggregation, which results in larger nanoparticles; on the 
other hand, if the time scale of homogenization is faster than aggregation, the 
nanoparticle size is supposed to be smaller and less aggregated (Karnik et al., 2008).  
We tended to use ultrasonic agitation to extend the time scale of aggregation during 
homogenization (Figure 3.1). The application of ultrasonic agitation obtained 
consistent blank CS particles with diameters around 30 nm, however, the emulsion 
was too stable to recover the blank CS nanoparticles. We were interested in exploring 
reasons for this phenomenon. During the ultrasonic emulsification of two immiscible 
liquids, coalescence occurred, which probably contributed to the collision of small 
droplets and formation of the continuous phase (Gaikwad & Pandit, 2008). As a result, 
it was impossible to collect nanoparticles from continuous emulsion phase. 
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Figure 3.2 Picture of manufacturing of nanoparticles using ultrasonic agitation during 
homogenization 
 
 SEM & TEM 
SEM was applied to observe the shape and surface morphology. Both formulations of 
blank CS and NHT-loaded CS (1:1) showed nearly spherical shape and smooth surface 
(Figure 3.3A-B), which suggested that w/o emulsion crosslink technique is successful 
to obtain a large quantity of nanoparticles. However, the rougher surface was noted on 
the particles when the weight ratios of NHT and CS were over 2:1 (Figure 3.3 C, D), 
suggesting that NHT was accumulated on the CS nanoparticle surface with 
aggregation or adhesion among nanoparticles to some extent. All the size of 
nanoparticles from SEM images were found to be <1 µm. The similar results were also 
obtained from TEM that blank CS nanoparticles showed nearly spherical shape and 
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smooth surface. NHT-loaded CS nanoparticles had a rougher surface (Figure 3.4B) 
compared with those of blank CS nanoparticles. 
A shortcoming of nanoparticles was that serious aggregation occurred among 
nanoparticles, which is also a common challenge within the nano-scale range due to 
high surface energy. Additionally, freeze drying made nanoparticles size increase after 
drying according to the report by Dudhani (Dudhani & Kosaraju, 2010) because of 
aggregation from the strong inter- and intra-molecular hydrogen bond.  
 
 
Figure 3.3 SEM images of different ratios of drug and CS (A) Blank CS nanoparticles; (B) 
Drug-loaded CS nanoparticles (1:1); (C) Drug-loaded CS nanoparticles (2:1); (D) Drug-
loaded CS nanoparticles (3:1) 
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Figure 3.4 TEM images of (A) blank CS nanoparticles; (B) NHT-loaded CS (3:1) 
nanoparticles 
 
 Particle Size and Size Distribution 
Figure 3.5 and Table 3.2 showed the mean particle size and size distribution of CS 
nanoparticles and NHT loaded CS nanoparticles from the DLS. DLS analysis of CS 
nanoparticles from 1:1 to 3:1 showed unimodal size distribution. The average diameter 
of the blank CS nanoparticles was 167.6±10.2 nm with PDI of 0.084±0.03. Mean 
particle size of NHT-loaded CS nanoparticles increased with the increased mass ratios 
of NHT and CS as increased solids within increased concentration of the NHT 
contribute to a larger droplet during the formation of nanoparticles under other same 
conditions. Specifically, the average particle size of NHT-CS (1:1) nanoparticles was 
198.3±7.5 nm with PDI of 0.161±0.05. The average size of NHT-CS (2:1) 
nanoparticles increased moderately to 204.4±3.9 nm with PDI of 0.106±0.071, while 
NHT-CS (3:1) nanoparticles demonstrated a maximum particle size of 411.2±63.4 nm 
with a PDI of 0.393±0.526. It indicated individual particles were in the nano range (<1 
µm) obtained in this work, which were suitable for administration of delivery to deep 
lungs. It should be noted that the sizes of nanoparticles determined by DLS (Table 3.2) 
were different from those measured by SEM (Figure 3.3) due to two different methods 
being applied. DLS is based on laser light scattering to give a particle size 
measurement, while SEM is based on direct imaging using back-scattered electrons. 
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The size observed from SEM images was slightly higher than the size measured by 
DLS. It is possible that aggregation as seen in Figure 3.3 and Figure 3.4 arising from 
the strong inter- molecular hydrogen bonding was not broken because we used dry 
powder of nanoparticles during sample preparation for SEM analysis. CS is a hydrogel 
polymer, so CS nanoparticle clusters tend to be formed by self-adhesion through 
Brownian motion among nanoparticles themselves. In addition, intra- or 
intermolecular hydrogen tends to lead intra- or intermolecular aggregation of particles 
in polar solvent (Berger, Reist, Mayer, Felt, & Gurny, 2004) (X.-G. Chen, Lee, & Park, 
2003). The formation of CS self-aggregates was confirmed by SEM and TEM (Figure 
3.3, Figure 3.4).   
 
Figure 3.5 Comparable particle size distribution between blank CS nanoparticles and different 
weight ratios of NHT to CS nanoparticles from 1:1 to 3:1 (n=3) 
 
Table 3.2 Characteristics of nanoparticle prepared by different ratios of NHT and CS (n=3) 
 
 z-average size (d.nm) PDI Zeta potential (+ mV) pH 
blank 
chitosan  
 167.6±10.2 0.084±0.03 20.1±1.4 5.83 
NHT-CS 
(1:1) 
198.3±7.5 0.161±0.06 19.0±1.2 4.55 
NHT-CS 
(2:1) 
204.4±3.9 0.106±0.07 14.2±0.7 3.83 
NHT-CS 
(3:1) 
411.2±63.4 0.393±0.52 12.2±0.4 3.81 
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As the aggregates of nanoparticles are above one micron (seen by SEM), the actual 
size of them cannot be measured properly by the DLS and therefore, the size of 
aggregates was determined using a Mastersizer. The median diameter (D [v,50]) of the 
aggregates varied between 3.7 and 4.7 µm (Table 3.3), which are within the respirable 
range (<5µm) and suitable for DPI formulations.  Therefore the particles prepared in 
this study are the mixture of both individual nanoparticles and agglomerates of 
nanoparticles.  
Table 3.3 Aggregate size distribution, represented by volume fractions 50%, D (v, 50) 
 
 D(v,50)  (d.µm)  
blank CS  3.73±0.01  
NHT-CS (1:1) 4.23±0.04  
NHT-CS (2:1) 4.20±0.04  
NHT-CS (3:1) 4.73±0.03  
 
 Zeta Potential 
Zeta potential is associated with the stability of nanoparticles as well as the appropriate 
dispersion in vivo. The surface charge measured by Zetasizer showed all nanoparticles 
(blank and NHT loaded) were highly positively charged and the amount of charge 
decreased with increasing NHT concentration in the nanoparticles (Table 3.4). The 
linearity trend (Figure 3.6, r2= 0.8783) in decreasing surface charge with increased 
drug loading indicated that the increasing surface coverage of CS nanoparticles with 
NHT caused the positive charge on nanoparticles to reduce. The reduction of surface 
charge with drug loading at 1:1 ratio was not significant compared to the blank CS 
nanoparticle; however, it was highly significant (P<0.05) with higher concentration of 
drug loading (2:1 and 3:1), which implied that the nanoparticle surface positive 
charges were masked (Muhsin et al., 2016) due to the increased accumulation of NHT 
on the surface. Although the adhered NHT on the particle surface could not be visible 
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at 1:1 ratio, higher concentrations of NHT showed a significant amount of drugs are 
adhered on the particle surface confirmed by SEM images. In addition, as the NHT 
has a negative charge due to the presence of the tartaric acid salt, the positive charge 
of the CS amino groups was reduced with increased concentration of NHT in the 
formulation. Meanwhile, as presented in Table 3.4, surface charges of nanoparticles 
reduced with increased concentration of NHT and shifted to negative charge at a fixed 
pH 6. This result suggested that under conditions of reduced protonation of the CS the 
nanoparticles containing NHT would tend to agglomerate since it is regarded that a 
low zeta potential (in this case -1.5 to -4.5 mV) would not favour dispersion of the 
nanoparticles.  
Table 3.4 Comparison of zeta potential of nanoparticles prepared at different conditions at 
pH=6 (n=3) 
 
Nanoparticles Zeta potential (mV) at pH 6 
blank CS 18.9±0.3 
blank CS-0.3 12.8±0.7 
blank CS-0.9 8.4±0.1 
CS NHT (1:1) -1.50±0.3 
CS NHT (1:2) -3.1±1.1 
CS NHT (1:3) -4.5±1.9 
NB: blank CS-0.3 means CS particles prepared by 0.3 mL glutaraldehyde; blank CS-0.9 means 
CS particles prepared by 0.9 mL glutaraldehyde; the rest of particles were prepared by 0.6 mL 
glutaraldehyde. 
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Figure 3.6 The relationship between zeta potential and drug loading 
 
To further study the role of pH on the nanoparticles, we measured the zeta potential of 
blank CS nanoparticles at different pH levels and the data are presented in Figure 3.7. 
Blank CS nanoparticles were applied to test the effect of pH on the particle surface 
charge. The zeta potential was measured in 0.1 mM potassium chloride solution 
adjusted with 0.1 N NaOH or 0.1 N HCl. A good linearity with a coefficient of 
determination of 0.9840 was observed where the zeta potential of nanoparticles 
reduced with increased pH when pH was between  3 and 6 (Figure 3.7). A fixed amount 
of glutaraldehyde was used for crosslinking, so the number of available amino groups 
on the CS for protonation was constant. The decrease in zeta potential therefore 
follows the reduction in the protonation as pH increases. The positive surface charge 
of CS in acidic medium due to protonation of the amine groups in CS showed repulsive 
forces (Kiang, Wen, Lim, & Leong, 2004) between nanoparticles, which support these 
findings. The large amount of drug accumulated on the particle surface resulted in 
reduced surface positive charge favouring agglomeration. It clearly demonstrated that 
the pH has a significant effect on the surface zeta potential. In addition, as presented 
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in Table 3.4, when different amount of glutaraldehyde was used for crosslinking, the 
zeta potential at fixed pH of 6 varied with the degree of crosslinking. The higher 
intrinsic surface positive charge  on the blank CS particles rendered less agglomeration 
(Gazori et al., 2009) due to the repulsive forces and this resulted in higher FPF of blank 
CS particles. As a result, the amount of 0.6 mL glutaraldehyde was selected for 
preparation of CS nanoparticles in this study because of higher postive surface charge 
on the blank CS nanoparticles. As discussed above, both the effect of pH and degree 
of crosslinking could affect the zeta potential, which eventually affected the 
dispersibility of nanoparticles. Therefore, it could be concluded that the surface charge 
on the CS nanoparticles are highly mediated by an electrostatic interaction in addition 
to hydrogen bonding or hydrophobic interactions involved in the association process. 
The positive surface charge of CS in acidic medium due to protonation of the amine 
groups in chitosan showed repulsive forces (Kiang et al., 2004) between nanoparticles, 
which support our findings. 
 
Figure 3.7 The Zeta Potential of blank chitosan nanoparticles under different pH 
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 DSC 
The DSC thermograms of the blank CS, pure NHT and NHT-loaded CS with different 
drug to polymer weight ratios from 1:1 to 1:3 are shown in Figure 3.8. A broad 
endothermic peak of CS nanoparticles found to be onset at 82.1°C (peak at 89.04°C), 
corresponding to loss of bound water from CS nanoparticles (Dudhani & Kosaraju, 
2010; Zhang, Yang, Tang, Hu, & Zou, 2008). Pure NHT showed a sharp endothermic 
peak at 91.0 °C due to a crystalline melting point. However, this peak disappeared 
during the cool/reheat circle. The deep changes in drug thermal behaviour were found 
in thermograms of NHT-loaded CS nanoparticles, as the typical peaks of NHT 
disappeared in terms of NHT to CS mass ratios between 1:1 and 3:1 (Figure 3.8).  The 
endothermic peaks, which were similar to the peaks from CS transition, shifted to a 
lower temperature with the NHT-loaded CS nanoparticles. It is considered that this is 
a proof of incorporation of NHT into the matrix of CS nanoparticles, but NHT was 
also loaded onto the surface of CS nanoparticles as SEM images (Figure 3.3) show. 
The possible reasons for absence of NHT endothermic peak were: 1) NHT was 
dissolved into CS nanoparticle matrix as a solid solution and did not crystallize; 2) 
NHT was converted to its amorphous form within nanoparticles (Chauhan, et al., 
2012); 3) the characteristic peaks of NHT and CS were overlapped, so the combined 
peaks shifted to lower temperature with increasing NHT content. The same 
phenomenon of disappearance of NHT melting peak from drug loading formulation 
was also reported by Sneha (Chauhan, et al., 2012).   
Inspired by DSC results, the aluminium pan of NHT was cut to be observed under 
microscope. It was noted that there was a sticky brown gel in the aluminium pan 
instead of white powder which is the original status of NHT (Figure 3.9). The NHT 
after heating appears to be liquid rather than crystalline under the microscope. This 
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explains why there is no crystallization exotherm when cooling from the melt and the 
endothermic peak of NHT disappeared after first heating cycle. In order to obtain more 
knowledge of this product, the FTIR was conducted and demonstrated in the following 
section (3.4.8). 
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Figure 3.8 DSC (exothermic up) during heat, cool, heat runs of (A) blank CS particles; (B) 
NHT-loaded CS particles (1:1); (C) NHT-loaded CS particles (2:1); (D) NHT-loaded CS 
particles (3:1); (E) pure NHT powder  
 
A B 
C D 
E 
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Figure 3.9 The image of NHT under the microscope after DSC heat/cool/heat test 
 
 XRD 
Figure 3.10 shows X-ray diffraction patterns of blank CS and NHT-loaded CS 
nanoparticles. There was only a broad peak in the diffractogram of blank CS at 2θ at 
19.04°, which was characteristic of CS as an amorphous polymer. The region under 
the broad peak was associated with the amorphous phase. In the X-ray diffractogram 
of pure NHT powder, several sharp identical peaks were observed at the angle of 2θ at 
17.50°, 22.96°, 26.06° and 33.24°, indicating that the NHT was existing as the 
crystalline material. After NHT loading, the diffraction intensities were becoming 
weaker, which suggested decreased crystallinity within the nanoparticles.   
Interestingly, the same conclusion was reached from DSC. No characteristic peaks of 
crystalline NHT were recorded in the XRD spectra of NHT-loaded CS nanoparticles 
with regards to three different ratios of NHT formulations. Several researchers also 
reported similar phenomenon ie. the absence of drug XRD peaks after encapsulation 
of drugs with polymers (Papadimitriou, Bikiaris, Avgoustakis, Karavas, & 
Georgarakis, 2008). It may be explained that NHT formed an amorphous dispersion 
within nanoparticles due to interactions that occurred between NHT and drug carriers. 
This case commonly occurred with amorphous polymers as drug carriers (Karavas, 
Georgarakis, & Bikiaris, 2006), such as CS. Another potential reason is that NHT 
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converted to amorphous form attributed to the intermolecular interactions between 
NHT and CS.  
 
 
 
Figure 3.10 The X-ray powder diffractions of (A) NHT; (B) blank CS nanoparticles and NHT-
loaded CS nanoparticles 
 
 XPS 
As XPS is a surface-specific technique (typically measuring the atomic composition 
of the first 5 nm) it has been used to determine if there was enrichment or depletion of 
the NHT at the surface of the CS nanoparticle. Such surface segregation or depletion 
would affect the release properties of the NHT. The XPS spectra in the C1s, N1s and 
O1s regions of CS, CS particles, NHT and the particles after loading with NHT at the 
ratios of 1:1, 2:1 and 3:1 (with respect to the mass of CS) have been analysed and 
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Table 3.5summarizes the atomic concentrations from these spectra. These can be 
compared with calculated values from the materials based on composition for all atoms 
other than hydrogen (which is not detected by XPS). In principle it is difficult to 
distinguish between CS and NHT based on survey scan data that generate atomic 
compositions of C, N and O as there are only small differences between the 
compositions (comparing the calculated values in row 1 and row 4 of Table 3.5). 
However, when the expanded N1s multiplex spectral data were collected it was found 
that there was a major difference between CS and NHT due to the ability of XPS to 
distinguish N+ from N due to a binding energy shift of 2.5eV. It may be seen from 
Table 3.5 that [N+] is very low in CS from both the starting material and the particle 
whereas it constitutes, in theory, all of the [N] in NHT and 80% in the actual samples. 
The concentration of 0.8% [N+] from the original CS and 0.4% [N+] from the particle 
arise from protonation in the course of extraction from chitin and in subsequent 
dissolution in acetic acid for particle preparation. It has been noted that solubilisation 
of CS of MW 295 kDa requires a degree of protonation of 0.5, but this will be lower 
for the CS studied here which has a MW of 50 to 195kDa.  
The composition of NHT has been studied and comprises a single molecule of nicotine 
which is complexed with two molecules of tartaric acid. One carboxylic acid group 
from each tartaric acid molecule is hydrogen bonded to the other, leaving one 
carboxylic acid group to bind to the protonated pyridine and N-methyl pyrrolidine 
units of nicotine (Perfetti, 1983). The measured value of 0.8 for the ratio [N+]/[N1s] 
indicates that not all nicotine groups are associated with two tartaric acid molecules 
and examination of the N1s multiplex spectrum shows the presence of a weak band at 
399.2eV which was consistent with an uncharged pyridine. It must also be recognized 
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that the NHT may have undergone slight decomposition under the X-ray conditions so 
the theoretical value is not attained.  
In the particle, the surface concentration of NHT compared to the CS may be measured 
by the ratio of [N+]/[N1s]. If the surface were to be totally covered with NHT then the 
ratio would be 0.8. When there is no NHT on the surface then it would be given by the 
value for CS particles i.e., 0.18. The relative amount of charged nitrogen to total 
nitrogen [N+]/[N1s] may therefore be used as a comparative measure of surface versus 
bulk composition of NHT in the particle and this was shown in Figure 3.11. In this 
figure, the value for the blank CS particle has been subtracted, resulting in a linear plot 
indicating that the surface concentration of NHT is consistent with the bulk 
concentration i.e., there is no preferential surface segregation of the drug. Thus in the 
SEM micrograph Figure 3.3D (NHT: CS = 3:1) where there was apparently complete 
surface coverage of the CS by NHT, the XPS result indicated that there was still 34.4% 
CS at the surface (i.e. within the first 2nm). Thus the particle is a true solid solution of 
the two components at all three concentrations studied with neither component acting 
as an encapsulant. This is consistent with the absence of any crystalline NHT in the 
particles. This morphology is important when considering the process of in vitro 
nicotine release since NHT is instantly accessible to the PBS solution. 
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Table 3.5 Calculated and measured atomic concentrations from XPS analysis 
 
Sample C1s N1s O1s [N+] [O-C=O] [N+]/[N1s] 
Chitosan 
calc. 
54.8 8.9 36.3 0.0 0.0 0.0 
Chitosan 
meas. 
63.0±3.1 7.3±0.4 28.6±1.4 0.8±0.04 0.0 0.11±0.01 
Chitosan 
NP 
69.4±3.5 2.2±0.1 28.4±1.4 0.4±0.02 1.5±0.07 0.18±0.01 
NHT calc. 56.2 6.3 37.5 6.3 12.5 1.0 
NHT meas. 59.1±3.0 5.4±0.3 35.5±1.8 4.3±0.21 10.5±0.53 0.80±0.04 
1:1 NP  71.2±3.6 2.3±0.1 26.4±1.3 1.1±0.06 2.8±0.14 0.48±0.02 
2:1 NP  66.0±3.3 2.5±0.1 31.5±1.6 1.6±0.08 4.7±0.23 0.64±0.03 
3:1 NP  65.0±3.2 2.8±0.1 32.2±1.6 2.0±0.10 5.2±0.26 0.71±0.04 
 
 
 
Figure 3.11 Plot of the XPS atom ratio of charged nitrogen [N+] to total nitrogen signal [N1s] 
from the NHT-loaded particles after subtraction of the signal from a blank CS particle versus 
the analysed bulk concentration of NHT in weight %. 
 
 ATR-FTIR 
Several characteristic bands of CS raw material can be identified from absorbance 
FTIR spectra (Figure 3.12A) of the original material. The overlapped peaks of the O-
H and N-H stretching were recorded at 3400 cm-1. At 2870cm-1, the peak of CH2 
stretching vibration was recorded, which corresponded to pyranose ring. The 
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characteristic peaks of CS were at 1656 cm-1 and 1565 cm-1 with high intensity which 
were attributed to the vibration of amide I (C=O) band and amide II (N-H) band, 
respectively from the residual N-acetyl groups of chitin. The peak of asymmetric 
stretching of C-O-C bridge at 1109 cm-1 and skeletal vibration involving the O-C-O 
stretching at 1059 cm-1 and 1026 cm-1 were assigned to its polysaccharide structure, 
which is agreement with reports (Peniche et al., 1999).  For crosslinked CS 
nanoparticles, 2 units of amine group of CS is crosslinked with one aldehyde molecule 
to form a characteristic imine (N=C) bond between aldehyde carbon and primary 
amine based on the Schiff reaction. However, the characteristic absorbance of C=N 
stretching, usually ranging between 1600-1700 cm-1, was not seen, and this may be 
associated with overlapping with amide I band. The absorption band at 1715 cm−1 was 
aldehyde group, which results from the polymerization and subsequent crosslinking of 
glutaraldehyde or possibly from one residual aldehyde of glutaraldehyde that did not 
react with two amino groups in the CS. These reactions are competitive with the Schiff 
reaction for crosslinking, indicating that the chemistry of the resulting CS network is 
complex as recently reported by Liu et al. (C. Liu, Thormann, Claesson, & Tyrode, 
2014). The FTIR spectra for NHT (Figure 3.12B) showed an absorption band at 1716 
cm-1, which was the characteristic band (C=O) of –COOH from NHT.  The presence 
of -COO- caused a specific band at 1565 cm-1. The absorption bands of 1461 cm-1, 
1268 cm-1 1192 cm-1 and 1131 cm-1 were associated with O-H bonding and C-O 
stretching.    
The entrapment of NHT into CS nanoparticles was also investigated by FTIR analysis 
of NHT-loaded nanoparticles with mass ratios between 1:1and 3:1. The obtained 
spectrum was presented in Figure 3.12B as well. It showed carboxyl peaks of NHT 
slightly shifted after encapsulation with CS, which was obscured with aldehyde group 
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at 1719 cm-1. In addition, the distinctive absorption bands of amide I, amide II from 
CS nanoparticles were compromised with NHT, causing a merged absorption band at 
1597 cm-1 with different intensities affected by the mass ratio of entrapped NHT.   
Both DSC and XRD profiles showed that NHT converted to an amorphous form or 
was present as the nanodispersion in CS nanoparticles.  In order to confirm the 
significant change of NHT in the nanoparticle, FTIR was also employed to detect any 
possible physicochemical interaction that occurred between the NHT and CS or 
glutaraldehyde crosslinks from the frequency shifts or splitting in absorption peaks. In 
this study, we only used one NHT-loaded CS (3:1) nanoparticles formulation as an 
example. Theoretically, NHT-loaded CS (3:1) nanoparticles were constituted with CS, 
NHT and glutaraldehyde. The subtraction spectrum (Figure 3.12C) of unloaded CS 
nanoparticles from the spectrum of NHT-CS (3:1) nanoparticles containing 66% NHT 
should be comparable to the spectrum of pure crystalline NHT. Surprisingly, it was 
found that subtracted IR spectrum of blank CS nanoparticles from NHT-CS (3:1) 
nanoparticles showed a big difference from the IR spectrum of pure NHT. At the same 
time, the product of NHT after DSC test was also measured by FTIR to distinguish the 
possible change in chemical structure that occurred to NHT when it experienced heat-
cool-heat DSC cycle.  Compared with pure NHT powder, FTIR spectrum (Figure 
3.12C) of NHT after DSC kept the characteristic peaks of -COOH and -COO- at 1773 
cm-1 and 1601 cm-1, respectively. The bands of O-H and C-O stretching were shifted 
to lower frequency. However, IR spectrum of unloaded CS subtracted from NHT-CS 
(3:1) coincided with the spectrum of NHT after DSC test, which strongly confirmed 
our previous assumption that NHT was encapsulated with CS nanoparticles 
successfully but some physicochemical changes occurred during this process.  Based 
on the facts discussed above, we concluded that NHT existed as the solid solution in 
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the CS nanoparticles after encapsulation.  This conclusion was consistent with the 
results from DSC, XRD and ATR-FTIR, as well as supported by the microscope 
picture of NHT after DSC test (Figure 3.9) which showed the crystalline NHT did not 
form again on cooling. 
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Figure 3.12 Comparisons of FTIR spectrum of (A) CS nanoparticles and CS raw material; (B) 
NHT-loaded/unloaded CS nanoparticles and NHT; (C) NHT; subtraction of unloaded CS 
nanoparticles from NHT-CS (3:1) and NHT after DSC test.  
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 BET Surface Area 
Specific surface area of CS and NHT-loaded CS nanoparticles was determined by 
multipoint BET analysis based on the method developed by Brunauer, Emmett and 
Teller (Brunauer, Emmett, & Teller, 1938). BET surface area is defined as the ratio 
A/m of the surface area A to the particles’ mass m which is derived from the particles’ 
gas adsorption characteristics shown Eq. 3.7. 
                                        𝑆𝐵𝐸𝑇 =
𝐴
𝑚
=
4𝜋𝑟2
𝜌∙
4
3
 𝜋𝑟3
=
3
𝜌∙𝑟
                                             Eq. 3.7  
This indicates that specific surface area increases with the inverse of the particle radius 
and density, assuming all the particles were spherical. In terms of NHT-loaded CS 
nanoparticles in this study, the density of particles increased with concentration of 
NHT (Table 3.7), so it is understandable that BET surface area decreased with 
increased mass ratios of NHT to CS from 1:1 to 3:1 as in Table 3.6. However, blank 
CS showed smallest BET surface area with 2.5135 ± 0.0202 m²/g suggesting that 
serious aggregation occurred between CS nanoparticles compared to those containing 
NHT. This may have resulted from the smooth surface, which increased cohesion 
forces among CS nanoparticles.  
Table 3.6 BET surface area of blank CS nanoparticles and different weight ratios of NHT to 
CS nanoparticles from 1:1 to 3:1 (n=3); 
 
Formulation BET surface area (m²/g) 
Blank CS  3.4222 ±  0.0334 
NHT-CS 1:1 7.2644 ± 0.0650 
NHT-CS 2:1 4.6497 ± 0.0493 
NHT-CS 3:1 2.5135 ± 0.0202 
 
  
Chapter 3:  Preparation and Characterization of NHT-loaded CS nanoparticles 93 
 Flow Property  
Powder flowability is a critical factor to influence dry power inhalation performance. 
The flowability of blank CS and different NHT-loaded CS nanoparticles are 
summarized in Table 3.7. The bulk and tapped density values obtained from the 
formulations of the blank CS and NHT-CS (1:1) nanoparticles were lower than those 
obtained from NHT-CS (2:1; 3:1). In terms of NHT loaded nanoparticles, as expected, 
the more NHT contained into a same amount of formulation, the higher was the 
density.  
CI and HR are two indications to evaluate the powder flowability and respirable 
fraction. The CI value of < 25% indicates good flowability, while > 25% means poor 
flowability which is cohesive powder characteristic. In addition, HR value which is 
less than 1.25 is considered to be good flowability, on the contrast, greater than 1.25 
is taken as poor flowabilitly. Either CI or HR is not an absolute number to determine 
the property of a material; their values would vary depending on the methodology 
applied to measure them. The CI values of freeze dried nanoparticle powders ranged 
from 15.4% to 38.9% and HR values were between 1.18 and 1.62. Both formulations 
of NHT-CS (2:1) (3:1) showed <25% CI and 1.25 HR values, indicating a fluid 
powder. However, blank CS nanoparticles showed the highest CI and HR values 
(38.9±0.01%, 1.62±0.01 respectively) with a severe aggregation due to small size, 
exhibiting poor flowability from cohesive powder. Consequently, the flow properties 
resulted in this study suggested that higher concentration of NHT to the same amount 
of CS would reveal better powder flowability, which benefits aerosolization of 
powders for DPI formulations.   
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Table 3.7 Physical properties of all CS/NHT-loaded CS nanoparticles tested (mean ± S.D., n 
= 3) 
 
 Blank 
chitosan 
NHT-CS (1:1) NHT-CS 
(2:1) 
NHT-CS (3:1) 
Bulk density 
(g/mL) 
0.329±0.01 0.364±0.02  0.459±0.01 0.484±0.01 
Tap density (g/mL) 0.533±0.01 0.539±0.01 0.572±0.01 0.573±0.01 
Carr’s index 38.9±0.01 31.6±0.01 20.0±0.01 15.4±0.01 
Hausner ratio 1.62±0.01 1.48±0.01 1.25±0.01 1.18±0.01 
 
The results of angle of repose measurements of nanoparticles with and without 10% 
lactose carriers were shown in Table 3.8. Angle of repose is another general indication 
for evaluation of the flow properties of powders. The values of angle of repose from 
nanoparticles without carriers were in the range of 39.9° –50.8°, which was out of the 
normal acceptable range of 20°–40°. It was observed that the angle of repose reduced 
with the increased mass contents of NHT to CS nanoparticles.  On the other hand, 
angle of repose decreased significantly after coating 10% lactose carriers, which 
showed better flow properties compared with corresponding blank CS/NHT-loaded 
CS nanoparticles without carriers and all the values showed potential good flowability 
in the range of 26.4°-39.9°. 
Table 3.8 Angle of repose of CS/NHT-loaded CS nanoparticles and nanoparticles with 10% 
lactose carriers (mean ± S.D., n = 3) 
 
Drug-loaded chitosan θ1 10% nanoparticles with 
lactose 
θ2 
Blank chitosan 
nanoparticles 
50.8±0.5 Blank chitosan 39.9±0.9 
Nicotine-loaded chitosan 
(1:1) 
49.4±0.3 Nicotine-loaded chitosan (1:1) 34.9±3.0 
Nicotine-loaded chitosan 
(2:1) 
44.0±0.9 Nicotine-loaded chitosan (2:1) 33.4±0.1 
Nicotine-loaded chitosan 
(3:1) 
39.9±0.9 Nicotine-loaded chitosan (3:1) 26.4±0.6 
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 Drug Incorporation 
In this study, the drug loading was measured indirectly by measuring the amount of 
drug remaining in the supernatant (Gomathi et al., 2014). UV spectrophotometry was 
applied for quantitative analysis of drug loading because direct UV spectrophotometry 
is applicable to the determination of nicotine quantitatively and its related compounds 
(Swain et al., 1949; Al-Tamrah, 1999). It is reported that spectrum of nicotine from 
UV spectrophotometry is characterized by a strong and sharp absorption maximum 
near 260 nm in water solution, and 259 nm in acidified. The UV spectrum of NHT 
with different concentrations in PBS showed that the maximum absorbance 
wavelength (λ max) was 258 nm (Figure 3.13). A zero intercept linear calibration 
equation for NHT in PBS was obtained to be Y=0.0064X (r2= 0.99745), where X is 
the drug concentration in μg/mL and Y is the UV absorbance at 258nm (Figure 3.14). 
The amount of free drug in the supernatant of paraffin oil was determined from the 
absorbance at the wavelength of 258 nm. Drug loading of NHT-loaded CS 
nanoparticles were calculated using Eq. 3.6, and the results were calculated in the 
Table 3.9. The drug loading increased from 30.67±0.84% to 65.59±3.24% as drug-CS 
mass ratio increased. This suggested the capacity for drug loading decreased as the 
amount of drug increased.  
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Figure 3.13 UV Scan of maximum absorbance wavelength of NHT in PBS with different 
concentration ranging from 10-50 μg/mL 
 
 
Figure 3.14 Beer-Lamber’s calibration curve of nicotine hydrogen tartrate in PBS (n=3) 
 
Table 3.9 Drug loading of different ratios of NHT-loaded CS nanoparticles (n=3) 
 
 Drug loading (%) 
Blank chitosan NPs - 
NHT-CS (1:1) 30.67±0.84 
NHT-CS (2:1) 45.61±4.41 
NHT-CS (3:1) 65.59±3.24 
 
  
Chapter 3:  Preparation and Characterization of NHT-loaded CS nanoparticles 97 
3.5 SUMMARY 
In this chapter, an effective and feasible way to prepare NHT loaded CS nanoparticles 
for lung delivery has been established by w/o emulsion crosslinking method.  The 
morphological observations (SEM & TEM) showed that all the particles were 
spherical and the surface roughness of the particles increased with increased drug 
loading. The individual particle size and size distribution of blank CS and NHT loaded 
CS formulations was in the nano range by DLS measurement, showed an increase in 
diameter with increased NHT content. On the other hand, nano-aggregates were 
formed among nanoparticles due to high surface energy, while all the aggregates were 
in the respirable range (<5µm) by laser diffraction determination. The NHT loading 
depended on the drug/ polymer ratio i.e., the higher the ratio between NHT to CS, the 
higher the drug loading. Positive surface charge of CS/NHT-loaded CS nanoparticles 
was reduced with increased concentration of NHT. BET surface area was governed by 
a variety of combined effects such as particle size, surface charge and 
cohesion/adhesion forces between particles.  In terms of NHT-loaded CS 
nanoparticles, smaller particle size and higher zeta potential favoured higher BET 
surface area, which will be beneficial to the powder aerosolization from DPI 
formulation. In contrast, strong cohesion forces among blank CS nanoparticles are the 
predominant effect in controlling BET surface area. FT-IR, XRD and DSC indicated 
that the NHT altered to an amorphous form entrapped in the CS nanoparticles. On the 
basis of XPS analysis, the amount of NHT loaded on the surface of CS increased 
proportionally with increasing drug loading in the bulk so there was no surface 
enhancement. The outcomes of this chapter demonstrated the NHT-loaded CS 
nanoparticles are suitable to be exploited for DPI formulation for lung delivery, which 
needs to be confirmed and verified in the following chapters. 
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This chapter will evaluate a series of physical characteristics of NHT-loaded chitosan 
(CS) and blank CS nanoparticle formulations, which were described in Chapter 3. First 
of all, the in vitro drug release studies are determined indirectly by way of a dialysis 
membrane technique. A mathematical model is introduced to correct the discrepancy 
during drug release measurement due to two diffusion barriers of the dialysis 
membrane. The morphology of particles post-release is investigated by SEM. The 
second part of work in this chapter is to evaluate in vitro aerosolization of the 
formulations by using a twin-stage-impinger (TSI) apparatus. The aerosolization of 
nanoparticles is related to the surface charge, and the relationship between surface 
charge and aerosolization of nanoparticles as DPI formulations is first to be reported 
in this study. It is also noted that the dispersibility of nanoparticle formulations with 
large lactose carriers is increased significantly compared to formulations without 
carriers. Finally, the long term stability of NHT-loaded CS nanoparticles is tested 
under controlled conditions of 25°C and 60% relative humidity (RH) for one year and 
formulations were found stable without significant change of FPF during this period.  
4.1 INTRODUCTION 
Aerosolization, controlled release and stability of formulations are three critical 
efficacy and safety issues to achieve practical drug product in order to develop reliable 
DPI formulations.  
Controlled drug release technology from nanoparticles is one of the most researched 
areas in the fields of chemical engineering and drug delivery in the recent decades to 
allow delivery of a variety of drugs to different targeted areas of body with sustained 
release over a prolonged period of time. Compared with conventional dosage forms, 
this delivery system is featured with higher efficiency, lower toxicity and better patient 
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compliance (Uhrich, Cannizzaro, Langer, & Shakesheff, 1999). CS is one of the most 
widely used polymers for manufacturing nanoparticles. The absorption enhancing 
effects of CS nanoparticles with small size and marked positive zeta potential were 
showed to be promising carriers for improving the pulmonary absorption (Chan et al., 
2013). CS nanoparticles prepared by cross-linking with glutaraldehyde (Gaspar et al., 
2015; Park et al., 2013; Hao Wang, Xu, & Zhou, 2014) have demonstrated sustained 
drug release from lung delivery.  
The release rate of drug from controlled release nano-sized dosage formulations are 
estimated by several techniques such as direct way of sample and separate (SS) and 
indirect way of dialysis membrane method to predict the drug release performance in 
physiological systems.  SS provides a simple and direct way to assess the drug release 
through sampling of the release media, which usually requires high energy separation 
techniques like centrifugation, ultracentrifugation and ultrafiltration. However, several 
challenges are involved in the physical separation with high energy separation 
techniques. Continued drug release occurs during the separation process (Hua, 2014). 
Additionally, after sampling, a same amount of fresh release media or release buffer is 
replaced into the release system to maintain the sink condition during drug release 
study, which results in drug loss during sampling process and increase the discrepancy 
of concentration between solid phase (nanoparticles) and liquid phase (release 
medium). The dialysis membrane is used to separate nanoparticles from the 
released/dissolved drugs, which diffuse through the membrane for quantification, so 
separating the nanoparticles from the solvent containing the drug to be analysed (Hua, 
2014). Drug release from the nanoparticles through the dialysis bag depends on the 
solubility of the drug from the nanoparticles as well as the diffusion of the dissolved 
drug through the dialysis membrane, which gives an apparent delay of release of drug 
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from the nanoparticles. During drug release testing by dialysis bag, the concentration 
profiles in the acceptor phase are used to assess the release kinetics of drug from 
nanoparticles. In this process, it is assumed that a steady state concentration gradient 
of drug is achieved instantaneously in the acceptor phase. The rate limiting properties 
of the dialysis membrane i.e., small molecular weight cut-off (MWCO), are one of the 
major obstacles to the steady state diffusion of the dissolved drug as well as the 
quantification of the diffused/released drug in the acceptor phase (Moreno-Bautista & 
Tam, 2011). Incomplete release data is likely to be collected with absence of sink 
condition or high equilibration time (Heng, Cutler, Chan, Yun, & Raper, 2008). Also, 
dialysis technique is not suitable for drugs which bind to the dialysis membrane (Hua, 
2014).  The thickness and permeability of membrane is another rate limiting factor that 
controls the diffusion of the released drug from the nanoparticles. In some references 
(M.-M. Chen et al., 2015; Khdair et al., 2016; X. Tian et al., 2014), it is assumed that 
the rate of diffusion across the membrane is faster than the rate of release, so the 
permeability coefficient of the membrane is ignored and the change in acceptor 
concentration with time mimics the release rate from the particles. This cannot be 
generally assumed. One obvious limitation from the general dialysis technique is the 
accurate quantification of drug release in vitro, as the sample is analysed from 
receiving compartment after it has diffused from nanoparticles through the dialysis 
membrane. Due to two diffusional barriers, the measured drug release kinetics may be 
slower than the actual release that would occur in vivo. However, in this chapter, the 
mathematical model modified from a report by Xie et al. (Xie, Beyer, Vogel, Wacker, 
& Mäntele, 2015) is used to overcome the discrepancy of equilibration times due to 
diffusion barrier from a dialysis membrane.   
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For the efficient pulmonary delivery of a drug aerosol particles with an adequate 
aerodynamic particle size (1 ~5 μm) need to reach the alveolar region of the lungs. 
However, aggregation among nanoparticles (nano-aggregate) is a common defect 
within the nano scale range due to high surface energy, which lowers the respirable 
fractions (Bosquillon, Lombry, Preat, & Vanbever, 2001). Therefore, optimization of 
aerosolization with an adequate range of particle sizes is still a challenge for 
development of DPI formulation system. Various strategies have been exploited to 
reduce aggregations between nanoparticles and improve flowability of dry powders in 
an attempt to prompt aerosolization performance of inhalation powder particles. In 
most cases, large coarse lactose carrier are blended with micronized drug particles to 
improve flowability, reduce aggregation and aid in dispersibility (Bosquillon et al., 
2001).  
Stability of formulation is another essential characteristic to be considered to produce 
practical DPI formulations. Storage conditions such as humidity and storage 
temperature affect the physical and chemical stability of DPI formulation, which 
results in a significant influence on the aerosolization of formulations. Long term 
stability test is to provide evidence of how the quality of an active pharmaceutical 
ingredient varies with time under the variables of a variety of environmental factors 
such as temperature and humidity. For a formulation to be suitable, physicochemical, 
pharmaceutical and microbiological characteristics are required to keep stable during 
its entire shelf-life. During formulation development or feasibility studies, 
physicochemical and pharmaceutical properties of the formulation are analysed at 
fixed time intervals of at least 6 months or longer.  The other approach to evaluate the 
stability of formulation is stress testing by exposing the formulation to accelerated 
humidity and/or temperature without any protective measures.  
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Overall, a number of factors such as moisture content, particle size, morphology, 
excipients and storage conditions affect the powder flowability.  The aim of this 
chapter was to evaluate in vitro drug release profile, aerosolization performance and 
long-term stability of DPI formulations of NHT-loaded CS particles.  It is expected 
that the outcome of this chapter will guide the development of in vivo evaluations of 
DPI formulations of NHT-loaded CS particles.  
 Theories and Models of Drug Release 
Zero-order model 
Zero-order release model is an ideal drug delivery model. It is assumed that drugs 
maintain the constant levels in plasma across the delivery period.  The applications of 
this model can be used to explain the drug dissolution of various classes of modified 
release pharmaceutical dosage forms, such as oral osmotic tablets, transdermal systems 
and matrix tablets with low soluble drugs (Freitas & Marchetti, 2005).  
Zero order release represents a process of constant amount of drug release from a drug 
delivery system. The equation can be represented as: 
                                                        Qt = Q0+k0t                                                Eq.4.1 
Where Qt is the amount of drug dissolved or released in time t, Q0 is the initial 
amount of drug in the system (most often, 𝑄0=0), and k0 is the zero order release 
constant with the unit of %/h. To study the release kinetics, the release profile is 
plotted as cumulative % drug release versus time. 
First order model 
First order release model assumes the rate of release process is proportional to the drug 
concentration based on the different mechanisms of dissolution both alone and in 
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combination, so the initial rate of process depends on the initial concentration.  It is 
supposed to take place at a constant proportion of the drug concentration available at 
that time and process never comes to an end. The applications of this model can be 
used to describe the absorption, distribution and metabolism of dosage forms.  The 
earliest equation of dissolution rate in a linear kinetic process was proposed by Noyes 
and Whiteney (Noyes & Whitney, 1897) as 
                                                
dC
dt
= k1(Cs − Ct)                                                Eq.  4.2 
Where dC/dt is the rate of concentration change with respect to time, k1 is the first 
order release constant with the unit of (time)-1.  The solution to Eq. 4.2 is: 
                                             ln[Cs/(Cs − Ct)] = k1t                                         Eq.  4.3 
or  
                                                    log C = log C0 − k1t/2.303                                      Eq.  4.4 
Where C0 is the initial concentration of drug and t is the time. To study the release 
kinetics, the release profile is plotted as log cumulative % of drug remaining versus 
time. 
Higuchi model 
Higuchi release model was proposed by Higuchi in 1961, aiming to describe a model 
for the drug’s release from a matrix system. This release model was proposed based 
on the hypotheses: (a) higher drug concentration than drug solubility in the matrix 
initially; (b) drug diffusion in only one dimension; (c) smaller drug particles compared 
with system thickness; (d) negligible matrix swelling and dissolution; (e) constant drug 
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diffusivity; (f) sink conditions in the release environment. Simplified Higuchi model 
can be represented as: 
                                                       Q = kH ∗ t
1 2⁄                                               Eq.  4.5 
Where kH is the Higuchi dissolution constant. To study the release kinetics, the release 
profile is plotted as cumulative % of drug versus square root of time.  
Hixson-Crowell model 
Hixson and Crowell proposed this drug release model in 1931 to describe the 
proportional relationship between particles’ regular area and the cube root of its 
volume.  It is assumed surface area and diameter of particles or tablets is changed 
during the drug release in the system. The equation is represented as: 
                                                               Q0
1/3
− Qt
1/3
 =  k1/3t                                     Eq.  4.6 
 
Q0 is the initial amount of drug in the dosage form, Qt is the remaining amount of drug 
in the dosage form at time t; k1/3is a release rate constant. To study the release kinetics, 
the release profile is plotted as cube root of drug percentage remaining versus time. 
Korsmeyer-Peppas model 
Korsmeyer and Peppas proposed a release model to describe drug release from a 
polymeric system in 1983. This release model can be represented as: 
                                                            Q = ktn                                                   Eq.  4.7 
Where Q is the fraction of drug release at time t. k is the release rate constant and n is 
the release exponent. The release mechanism is dependent on the values of n. n≤0.45 
represents a Fickian diffusion mechanism, 0.45<n<0.89 means non-Fickian 
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mechanism; n≥0.89 corresponds to case II transport. To study the release kinetics and 
determine the value of n, the release profile is plotted as log cumulative percentage 
drug release versus log time. 
4.2 MATERIAL AND REAGENTS 
LMW chitosan (CS) and NHT powder were purchased from Sigma-Aldrich, Australia. 
Phosphate buffered saline (PBS) tablets were obtained from Sigma-Aldrich, Australia. 
All other chemicals and reagents used were analytical grade.  
4.3 METHODS 
 Preparation of NHT-loaded CS Nanoparticles and Mixing Nanoparticles 
with Large Carriers 
 
Preparation of NHT-loaded CS nanoparticles 
The details of processes to prepare micro/nanoparticles as DPI formulation were same 
as section 3.3.1 (See Chapter 3). 
Preparation of mixing nanoparticles with large carriers 
The lyophilized NHT-loaded CS and blank CS nanoparticles were  mixed (10%W/W) 
with inhalation grade lactose monohydrate (Inhalac® 120) microparticles to make 
binary interactive mixtures using a previously reported hand mixing technique (Liu & 
Stewart, 1998). The nanoparticles were placed between two layers of lactose particles 
in a glass test tube together with 3 ceramic beads of approximately 10 mm diameter 
and shaken vigorously for 5 minutes to ensure adequate mixing. The ceramic beads 
provide a ball milling effect for breaking up the agglomerates formed during the 
mixing process. 
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 In Vitro Drug Release Study by Dialysis Membrane 
 
Dialysis membrane system set up 
To overcome the limitation of loss of samples during physical separation from the 
direct way of sample and separate (SS), a system of UV-visible spectrometer and 
temperature controlled water bath was designed to study the in vitro release of NHT 
from CS nanoparticles from the modified dialysis bag diffusion technique (Pilcer et 
al., 2009). A dialysis membrane (MW 3500 Da, Yuanye Biotech Ltd, China) was pre-
prepared at least 24 hours in advance in deionized water. Dialysis pouch with NHT-
loaded CS nanoparticles was mounted into a wide mouth glass reaction flask. Two 
small stirrer bars were put into donor and acceptor compartments respectively to 
maintain uniform mixing of media during the process of release. Stirring rate of both 
acceptor and donor phases was set to gentle stirring at 100 rpm under magnetic stirrer. 
The dialysis system was kept at the constant temperature thermostatically at 37 ◦C (set 
up as Figure 4.1). The volume of acceptor phase (Va) was at least 5 times as much as 
that of donor phase (Vd) to ensure sink conditions. PBS was used as release medium. 
UV spectrophotometry analysis was carried out at 258 nm to evaluate the 
concentration of NHT during drug release. At time t = 0, a certain amount of 
nanoparticles, obtained as described under Section 3.4.1 was placed into donor 
compartment. The measured volume, Vd of PBS was then added into the acceptor 
compartment. Aliquots of 5 mL were taken from receiving compartment for UV 
spectrophotometry and the released drug concentration was determined at fixed time 
intervals (0.5, 1, 2, 4, 8, 12, 24h and every 24h until 6 days). After analysis, the liquid 
was poured back to the acceptor flask immediately.  To determine the permeability 
constant of the dialysis membrane, a plain 1 mg/mL NHT solution dissolved in PBS 
was placed in the donor compartment and the procedure was repeated using the same 
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dialysis membrane. All measurements were repeated in triplicate (n=3) and the drug 
release profile in the acceptor phase was determined directly through linearity 
(r2=0.9992) of concentration and UV absorbance graph. Cumulative release profiles 
were determined by a mathematical model in the following section to construct the 
plots of the cumulative (%) drug release versus time.  
The drug release data in this study were obtained under sink conditions, where the 
back diffusion from receiving to donor phase can be considered negligible, and the 
thermodynamic activity of permeant in the receiving phase was also negligible 
compared to that in the donor. The volume enclosed in the dialysis bag was 
significantly smaller than the receiving phase, so sink conditions were achieved 
throughout the experiment.  
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Scheme  4.1  Diagram of NHT released from CS nanoparticles 
 
 
 
 
 
Figure 4.1 Drug release study using dialysis membrane set-up 
 
 
Mathematical model for drug release correction 
During dissolution testing by dialysis membrane, the concentration profiles in the 
acceptor phase are generally employed to estimate the release kinetics of drug from 
nanoparticles. However, the dialysis membrane diffusion technique has some 
limitations. The rate limiting properties of the membrane are one of the major obstacles 
to the quantification of the released drug in the acceptor phase. In order to reduce the 
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discrepancy of delayed drug release due to diffusion from the dialysis bag to the 
acceptor compartment and limited membrane permeability, a modified mathematical 
model (Xie et al., 2015) was used to obtain the corrected release profiles of the model 
drug used in this study. Although a number of factors such as temperature and pressure 
affect the diffusion rate, in this study, a simplified mathematical model is based on an 
optimal condition that only drug permeability constant and concentration gradient 
between two compartments govern the diffusion rate (Xie et al., 2015). Fick’s law (Eq. 
4.8) is applicable to describe the rate of change in concentration of acceptor phase 
(Pedersen, Østergaard, Larsen, & Larsen, 2005) if the system was well stirred. 
                                        
dCa
dt
= (
k
Va
) [Cd(t) − Ca(t)]                                       Eq.  4.8 
Where k refers to a dialysis membrane’s permeability coefficient, which is associated 
with the pore size, thickness and soaked surface area of the dialysis membrane. Cd , Ca 
are the NHT concentration in the donor and acceptor phases, respectively at time t. Va  
is the volume in acceptor compartment.  
Determination of permeability of dialysis membrane 
To determine the permeability coefficient of membrane, the concentration profile of 
pure NHT passed through dialysis membrane was carried out. The NHT concentration 
in donor phase can be obtained from Eq.4.9 when a certain amount of pure NHT is put 
into the donor compartment.               
                                                   Cd(t) =
Q0−Ca(t)∗Va
Vd
                                         Eq.  4.9 
Where Q0 refers to the amount of pure NHT in the donor phase initially; V𝑑  is the 
volume in donor compartment. 
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If Eq.4.9 is merged into Eq.4.8, Eq.4.8 can be expressed as: 
                                                 
dCa
dt
= (
k
Va
) [
Q0−Ca(t)∗Va
Vd
− Ca(t)]                     Eq.  4.10 
Then, it is solved analytically as:                                                 
                                           Ca(t) = [
Q0
Vd+Va
] {(1 − exp (
kt(Vd+Va
VdVa
)}                  Eq.  4.11 
Eq.4.11 is simplified as: 
                                                  Ca(t) = C∞[1 − exp(km ∗ t)]                        Eq.  4.12 
Where C∞ =
Q0
Vd+Va
 represents final concentration when the system achieved 
equilibrium; which was measured by UV directly during the process; km=
k(Vd+Va)
VdVa
 is 
defined as total permeability coefficient. The results of pure NHT release data can be 
applied to Eq.4.10 to obtain km, after which k was fitted analytically. 
Determination of total permeability coefficient of NHT-loaded CS nanoparticles 
In terms of the NHT-loaded CS nanoparticles, k varied proportionally with the volume 
of donor phases used during the drug release process. 
The parameters of C∞, C𝑎, t from the drug release of NHT-loaded CS nanoparticles 
were known, thus, the Eq. 4.10 can be fitted by plotting the experimental data of Ca(t) 
versus t using software MATLAB®. 
To determine the rate of change of concentration in the acceptor phase at each time 
point, derivative of Eq.4.12 was required as Eq.4.13  
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dCa
dt
= −C∞km ∗  exp(km ∗ t)                              Eq.  4.13 
Cd can be written as Eq.4.14 according to Eq.4.8: 
                                               Cd(t) =
Va
k
∗
dCa(t)
dt
+ Ca(t)                                 Eq. 4.14 
It is noteworthy that k is a constant only if the soaked area does not change. As the 
different volumes of donor phases have been used, the value of soaked area changes 
and therefore it is required to correct the k  value accordingly. In this way, the 
concentration of NHT in the donor phase (Cd) was obtained. 
Cumulative drug release of NHT-CS nanoparticles 
At any time point t, the total amount of released NHT in the system was accumulated 
as: 
                                             Qr(t) = Cd(t)Vd + Ca(t)Va                                Eq.  4.15      
Therefore, the cumulative release fraction of NHT from CS nanoparticles was 
determined by the Eq.4.16 
                                          Fr(t) =
Qr(t)
m(NPs)∗drug loading(%)
∗ 100%                   Eq.  4.16 
Where m(NPs) was the amount of NHT-loaded CS nanoparticles in the dialysis 
membrane; the value of drug loading regarding different mass ratios of NHT to CS 
was shown in Table 3.8. The release profiles of NHT from nanoparticles were 
determined using both the general method (before correction without mathematical 
model) and modified mathematical models (after correction) to obtain a clear 
understanding on the drug release from the nanoparticles.  
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Release kinetic models  
To understand the mechanism of NHT release from nanoparticles, the release data (up 
to maximum drug release) were fitted to different kinetic models i.e, zero order, first 
order, Higuchi model, Hixson-Crowell model and Korsmeyer-Peppas model. The 
kinetics of drug release from nanoparticles is presented in Table 4.1 and Table 4.2.  
SEM after drug release 
After drug release study, the nanoparticle powders were collected onto the 0.22 µm 
membrane through repeated filtration and dried overnight in the oven at 60°C. The 
morphology of fully dried blank and NHT-loaded CS nanoparticles after drug release 
for 6 days was observed by SEM. All the experimental details of SEM were same as 
section 3.4.2. 
 In Vitro Aerosolization Study 
Formulations without large carrier  
The aerosol performance of DPI formulations of blank CS nanoparticles and NHT-
loaded CS nanoparticles were evaluated by applying the twin-stage impinger (TSI, 
Copley Scientific, Nottingham, UK).  Prior to testing, 7 mL and 30 mL of PBS were 
dispensed to Stage 1 and Stage 2 of the TSI, respectively. The ﬂow rate through the 
TSI was adjusted to 60±5 L/min by a vacuum pump (D-63150, Erweka, Germany) 
through a calibrated digital flow meter (Fisher and Porter, Model 10A3567SAX, UK). 
20±1 mg of nanoparticle formulations were filled into size 3 hard gelatin capsules 
(Fawns and McAllan Pty., Australia) which were subsequently inserted into a 
Rotahaler®. NHT-loaded formulations were aerosolized into the body of DPI device 
by twisting the capsules at 60±5 L/min for 5 s. After each experiment, Rotahaler, 
Stage1 (S1) and Stage2 (S2) were washed with PBS separately into suitable volumetric 
ﬂasks. Washings collected from each stage were filtered through pre-dried and pre-
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weighed 0.20 µm pore size filter membrane (Phenomenex, USA). The same filtrations 
were repeated at least five times until the filtrate was clear without any sign of 
turbidity. Finally, the particles filtered on the filter membrane were dried overnight at 
60 °C until they reached a constant weight and the mass of the nanoparticles were 
determined gravimetrically. As the NHT is soluble in PBS and the drug-loaded 
nanoparticles were washed 3 times, the NHT-loaded CS nanoparticles were evaluated 
both gravimetrically and spectrophotometrically. Initially, the mass of nanoparticles 
were measured by the method described above.  During washing the drug-loaded 
nanoparticles, the filtrate solutions were collected and the amount of NHT in the 
solution was determined by UV analysis. Finally, the determined respective amount of 
NHT was added with the mass of nanoparticles and the actual experimental data was 
obtained. Therefore, the dispersibility data presented here in this study are the 
summation of both gravimetric and spectrometric methods. Five capsules were 
repeated in this procedure.  
The aerosolization of DPI formulations was evaluated by four parameters: recovered 
dose (RD), emitted dose (ED), fine particle fraction (FPF) and fine particle dose (FPD). 
RD is calculated as the total amount of drug collected from inhaler, S1 and S2. ED is 
calculated as a percentage of the total amount of particles emitted from the inhaler into 
S1 and S2 out of RD (Eq. 4.17). FPF is calculated as a percentage of the amount of 
particles as well as encapsulated/adhered drug deposited in Stage 2 out of RD (Eq. 
4.18), which represents a respirable fraction of the delivered dose, and FPD is the mass 
in milligrams of NHT deposited in the Stage 2 of TSI.         
                                                       ED =
S1+S2
RD
× 100                                     Eq.  4.17 
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                                                        FPF =
S2
RD
× 100                                       Eq.  4.18 
Formulations with large carrier  
Aerosolization of the drug-loaded CS and mixing nanoparticles (10% W/W) was 
tested. The freeze-dried nanoparticles were mixed with inhalation grade lactose 
monohydrate (Inhalac® 120) microparticles as carriers to make binary interactive 
mixtures using a previously reported hand mixing technique (J. Liu & Stewart, 1998). 
The dispersibility of this formulation was carried out using the TSI as explained above.  
To compare the dispersibility behaviour of micronized NHT, the commercially 
available NHT was ground to inhalable size, mixed with large carriers and the FPF 
was measured. The NHT in the DPI formulation was analysed using a validated UV 
spectrophotometric method.  
 Long Term Stability Test 
A long term stability study for the NHT-loaded CS nanoparticles was carried out over 
one year under controlled conditions of 25 °C/60 % relative humidity (RH). The DPI 
formulations were filled into size 3 hard gelatin capsules, which were stored in stability 
chambers under the specified conditions of temperature (25 ± 2 °C) and RH (60 ± 5 
%). An acceptable RH was maintained by saturated magnesium nitrate slurry. The 
samples appearance, morphology and FPF were evaluated at different time intervals 
(1st, 2nd, 12th month) for its chemical and physical stability.  
 Statistical Calculations 
All statistical analysis (one-way ANOVA with Bonferroni post hoc) was performed 
using statistical software of SPSS. MATLAB® was applied to analyse and plot drug 
release experimental data. 
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4.4 RESULTS AND DISCUSSION 
 Controlled Drug Release Study by Dialysis Membrane 
 
Drug release study by dialysis membrane 
Figure 4.2 presents the normalised data of pure NHT diffused through dialysis 
membrane from the donor compartment to the receiving compartment. According to 
the experimental results, NHT achieved equilibrium (0.1 mg/mL) between donor and 
acceptor phases in seven hours, which confirmed the system setup and dialysis 
membrane used in this study are reasonable to be applied in this drug release study. 
The relationship: Ca(t) = 0.1(1 − e
−0.6713t)  (r2=0.9981) was obtained by plotting 
experimental results to fit Eq. 4.12 analytically. Total diffusion coefficient 
(km=0.6713h
-1) was known through fitted equation. The diffusion constant of dialysis 
membrane (k=30.2085) was resolved by replacing the values of Va, Vd, km into km =
k(Va+Vd
VaVd
), which was kept constant in the following calculations of NHT-loaded CS 
nanoparticles since data were collected from the same dialysis membrane. 
 
Figure 4.2 Concentrations measured in acceptor phase with time from pure NHT release. 
(Q0=50 mg, Va=450mL, Vd=50mL, C∞=0.1 mg/h, km=0.6713h
-1) 
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Figure 4.3 showed the normalised concentration profile in the acceptor phase for 6 
days. As shown in the figure, pure NHT diffusion reached equilibrium in 7 hours, 
while the NHT-loaded nanoparticles took longer time to achieve constant 
concentration. This was because the drug was distributed in the matrix uniformLy and 
the release took place via diffusion through the matrix. Then, the rate of drug release 
gradually went down and a longer diffusion time to release was required as drug 
molecules had to travel a longer distance with the release continuing. In this study, 
release was terminated at 6 days when the concentrations in the acceptor phases were 
almost stable. Meanwhile, the concentrations of the donor phases and acceptor phases 
were measured to be fairly close to each other. Thus, released NHT was considered to 
be balanced between two phases.  C∞ is the concentration in the acceptor phase by the 
time of equilibrium. The experimental run of pure NHT was as a control group to 
obtain dialysis diffusion constant (k), which was constant in the same dialysis system. 
All the other corresponding values of km from NHT-loaded CS nanoparticles were 
determined by fitting experimental data to the mathematical model (Eq.4.12).  
 
Figure 4.3 Concentration fraction (%) profile in the acceptor phase (data presented as mean ± 
SD., n = 3) 
 
  
Chapter 4:  In Vitro Evaluation of NHT-loaded CS Formulations 119 
After determination of km and with regards to different weight ratios of NHT-loaded 
CS nanoparticles respectively, the numerical value for 
dCa
dt
can be acquired by replacing 
the derivatives using Eq. 4.13. A series of numerical value of derivatives could 
describe the rate of change of concentration in the acceptor phase at the point of time 
t. 
Figure 4.4 shows the concentration profiles both in the donor phase (Cd) and acceptor 
phase (Ca). The corrected numerical value of Cd(t) was acquired according to Eq. 
4.14, with all the known parameters obtained from last two steps.  As shown in Figure 
4.4 (a, b, c, d), the concentration in the acceptor phase increased continuously, the time 
to reach equilibrium increased along with increase of mass ratios of NHT to CS.  Pure 
NHT reached equilibrium within 8 hours, while the formulations of NHT-loaded CS 
(1:1) and (2:1) achieved balance between two compartments in the 12 and 24 hours, 
respectively. However, the concentration gradient of NHT-loaded CS (3:1) 
nanoparticles kept increasing until around 12 hours after the start of the drug release 
test, and two compartments attained the same concentration in 144 hours. It is expected 
that pure NHT did not share the same release rules with NHT-loaded CS nanoparticles. 
NHT was dissolved into the PBS the moment it was put into the donor phase, followed 
by diffusion across the dialysis membrane. On the other hand, NHT on the CS 
nanoparticles surface was dissolved into PBS at first, and then entrapped drug was 
released from inside nanoparticles due to drug diffusion following matrix swelling. It 
was reported the swelling of CS membrane crosslinked by glutaraldehyde reached a 
stable equilibrium water content in about 15 minute, and  the swelling curves remained 
stable with time under the test condition of 37°C and pH of 7.4 (Gupta & Ravi Kumar, 
2000; Silva, Silva, Coutinho, Mano, & Reis, 2004). Thus, the longer equilibrium time 
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was required with higher drug loading.  However, compared with the NHT-CS (1:1; 
2:1) groups, NHT-CS (3:1) took longer time to reach equilibrium. The possible 
explanation for this might be the entrapped drug was gradually released from the CS 
nanoparticle within the 12 hours.  The rate of entrapped drug release slowed down 
over time, which resulted in a longer drug diffusion time. In this study, the main 
mechanism of NHT released from chitosan nanoparticles may depend on the drug 
diffusion within the first release stage considering swelling of CS nanoparticles was a 
slow process.  
 
Figure 4.4 The concentration profiles in the donor phase (Cd(t)) and acceptor phase (Ca(t)) of 
(A) pure NHT (Va=450mL, Vd=50mL); (B) NHT-CS (1:1) (Va=130mL, Vd=20mL); (C) NHT-
CS (2:1) (Va=250 mL, Vd=40 mL); (D) NHT-CS (3:1) (Va=130mL, Vd=20mL) 
 
The percentage of cumulative drug release corrected by the mathematical model from 
the nanoparticle formulation was plotted as shown Figure 4.5. The total cumulative 
amount of released NHT in the system was determined by Eq. 4.15, and the cumulative 
drug release (Fr) was calculated according to Eq. 4.16. In terms of the pure NHT 
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release as a control group, the cumulative release percentage of NHT in the system can 
be seen constant (100%) during the experiment due to its high solubility and immediate 
dissolution in the aqueous release medium, which was in accordance with release 
mechanisms and practical condition as well. According to the drug release profiles 
(Figure 4.5), the drug was rapidly released from the nanoparticles initially, followed 
by slight slow release. Initial burst release was attributed to the rapid dissolution of 
surface or close to surface of adhered/entrapped drug, while the later slow release was 
because of the penetration of the release medium into the nanoparticles and dissolution 
of the entrapped drug. Compared with control group, it was obvious that entrapment 
of NHT in the CS nanoparticles can effectively sustain NHT release. Short-term 
release profiles (right bottom corner of Figure 4.5) of NHT-loaded CS nanoparticles 
showed that NHT-loaded CS nanoparticles (3:1) experienced slowest release rate in 
the initial two hours, achieving a highest cumulative burst release of about 60% in the 
eight hours when the corresponding values for 2:1 and 1:1 were at 53% and 47%, 
respectively. At the same time, NHT-loaded CS (3:1) nanoparticles experienced most 
cumulative release in the duration of 6 days. All the features of release from our study 
were in accordance with report from Hans (Hans & Lowman, 2002), which indicated 
that the higher drug loading led to the greater fractional release of drug from the 
nanoparticles, but the larger particle size resulted in a slower initial burst release and 
longer sustained release since less area of contact with the release medium contributes 
to slower dissolution of drug compared with smaller size of nanoparticles. At the end 
of the period (6 days), all of three drug-loaded CS nanoparticles (weight ratios of 1:1-
3:1) achieved the maximum cumulative % release (around 58 ± 3%, 62 ± 1%, and 72 
± 5% respectively). Nicotine-loaded CS nanoparticles as DPI formulations in this 
study achieved prolonged controlled release from nanoparticles compared with current 
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nicotine transdermal patch to release accumulative 90% nicotine within periods of 12-
24 hours (Lewis et al., 2006; Sha, Zhang, Li, & Shen, 2014).  However, not all the 
drug was released from the nanoparticles within 144 hours. It is estimated that the drug 
may be associated with vestiges of the positively charged nanoparticles through 
electrostatic interactions, so lower surface charge favored higher cumulative drug 
release in PBS, i.e. cumulative drug release of NHT-CS (3:1) was higher than those of 
NHT-CS (1:1) and NHT-CS (2:1) (Lim et al 2000).  
 
Figure 4.5 Corrected cumulative drug release over a period of 6 days and initial release in the 
12 hours (right bottom) (data presented as mean ± SD., n = 3) 
 
Figure 4.6  demonstrated the differences of numerical results of the cumulative drug 
release between general calculation method and this mathematical model. The general 
way of dialysis diffusion is based on the assumption that the concentrations of acceptor 
phase and donor phase are at equilibrium at any point. One obvious limitation from 
the traditional dialysis technique is the accurate quantification of drug release in vitro, 
as the sample is analysed from receiving compartment where it has diffused from 
nanoparticles through dialysis membrane. Due to two diffusional barriers, delayed 
effect happened during this process, and the measured drug release kinetics may be 
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slower. However, in this study, a mathematical model based on the approach of Xie 
(Xie et al., 2015) was set up to overcome the discrepancy of equilibration times due to 
diffusion barrier from a dialysis membrane. As shown in Figure 4.6,  although the 
corrected cumulative release values did not show significant differences from 
traditional calculations, especially at ending period (>12 hours) as the systems were 
under equilibrium conditions, the designed model offered the possibility to measure 
accurately drug release with time. It can be used to predict real-time release of drug-
loaded nanoparticles in order to achieve desired release profiles.  
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Figure 4.6 Comparisons of before and after corrected drug release (A) NHT-CS (1:1); (B) 
NHT-CS (2:1); (C) NHT-CS (3:1) (data presented as mean ± SD., n = 3) 
 
Kinetics of drug release 
Before the mathematic modelling correction of two-barrier delayed diffusion of 
dialysis membrane, the original data obtained from acceptor phase of dialysis 
membrane was fitted to various models, which results referred as before correction. 
The release data were analysed by linear regression and the highest r2 values were 
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considered to the best fit model to demonstrate the behaviour of drug release. The rate 
of release was divided into an initial phase (0-8 hrs) and a terminal phase (8-144hrs) 
based on a modified report by Lim (S. Lim, Martin, Berry, & Brown, 2000) as it is 
understandable that the release rate in the burst release stage is faster than that of in 
the sustained release phase. In an attempt to explore the characteristics of drug release 
profile, the data were fitted to four different mathematical models, i.e., zero order 
model, first order model, Higuchi model, and Hixson-Crowell model. The results 
before mathematic model correction of release rate constants (k) and coefficients of 
determination (r2) were shown in Table 4.1. The initial phase of release of NHT was 
faster than that of the terminal phase due to the higher concentration gradient, and this 
was because of the adherence of the drug on the nanoparticle surface and the defects 
of pores or cracks within the matrix (S. Lim et al., 2000). As shown in Table 4.1, it 
indicated that NHT-loaded CS nanoparticles were best characterised by first order 
model (r2=0.9116-0.9680) and Higuchi model (r2=0.9796-0.9998) with high linearity. 
The other models were not considered regarding the lower coefficients of 
determination. 
The release data of NHT from all combinations strongly fitted (r2 =0.9567-0.9897, 
Table 4.1) with Korsmeyer-Peppas model, which demonstrates the release exponent 
(n) obtained from the slope of a plot of log % cumulative release against log time. For 
spherical particles if n is 0.45, the release mechanism is considered to follow Fickian 
diffusion (Siepmann & Peppas, 2001), where drug release occurs through usual 
molecular diffusion because of a concentration (or chemical potential) gradient. 
Higher values of n between 0.45 and 0.89 indicate non-Fickian or anomalous transport, 
where release is controlled by a combination of diffusion and polymer 
relaxation/erosion. In this study, the drug release exponents (n values) for NHT-CS 
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(1:1) was less than 0.45, suggesting that the drug release was Fickian diffusion. 
Whereas, the n values for NHT-CS (2:1) and NHTCS (3:1) were above 0.45 (0.50-
0.54), which is an indicative of non-Fickian diffusion due to the higher drug 
concentration in the nanoparticles.  
All data in this report were obtained under sink conditions, where the back diffusion 
from receiving to donor phase can be considered negligible, and the thermodynamic 
activity of permeant in the receiving phase was also negligible compared to that in the 
donor. The volume enclosed in the dialysis bag was significantly smaller than the 
receiving phase, so sink conditions were achieved throughout the experiment. There is 
no doubt that dialysis membrane is not suitable for drugs that bind to the membrane. 
To this purpose the drug concentration in the donor, free from binding, was calculated 
from dialysis data, as illustrated in Sections 4.3.1, and compared with the concentration 
in the receiving phase at the corresponding time.  
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Table 4.1 Release rate constants and correlation coefficients of NHT release from CS 
nanoparticles before correction 
 
models 1:1 2:1 3:1 
 Initial 
phase 
Terminal 
phase 
Initial 
phase 
Terminal 
phase 
Initial 
phase 
Terminal 
phase 
 0-8 
hours 
8-144 
hour 
0-8 
hours 
8-144 
hour 
0-8 
hours 
8-144 hour 
Zero order Fr=k0t 
k0 6.5888 0.0664 4.654 0.062 6.000 0.0651 
r2 0.9279 0.8838 0.860 0.9203 0.9167 0.8972 
       
First order Ln(1- Fr)=-k1t 
k1 0.0965 0.0017 0.072 0.00014 0.1036 0.0021 
r2 0.9526 0.9398 0.9196 0.9217 0.9680 0.9116 
       
Higuchi 
model 
Fr =kHt
1/2 
kH 13.289 1.3123 17.641 0.9962 22.368 1.0542 
r2 0.9813 0.998 0.9998 0.9845 0.9796 0.9832 
       
Hixson-
Crowell 
model 
1-(1- Fr)
1/3=k1/3t 
k 1/3 0.0115 0.0002 0.0155 0.0002 0.02 0.0003 
r2 0.9279 0.8838 0.868 0.9203 0.9167 0.9662 
       
Korsmeyer-
Peppas 
model 
Fr = kk-p t
n 
kk-p 23.7137 40.7005 20.0309 47.1954 21.2716 55.2205 
n 0.365 0.0717 0.500 0.056 0.5408 0.054 
r2 0.9567 0.9885 0.9542 0.9861 0.9788 0.9815 
 
 
After mathematic modelling correction (described in 4.3.2), the corrected release data 
were fitted to different kinetic models (Table 4.2) as well to identify the possible drug 
release mechanism.  The highest r2 values were considered to the best fit model to 
demonstrate the behaviour of drug release. The release rates of drug from nanoparticles 
depend on either diffusion of dissolved drugs or biodegradation (erosion) of polymer 
matrix. The release data (after correction, Table 4.2) revealed that NHT-CS 
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nanoparticles followed Higuchi model (strong linearity, r2 = 0.9127-0.9990) that 
reflected the drug release from nanoparticles was controlled by diffusion. It has been 
reported that the prolonged release of water soluble drug from CS-based 
mico/nanoparticulate systems in PBS is associated with the diffusion of the dissolved 
drug through hydrated swollen matrix (Learoyd, Burrows, French, & Seville, 2008). 
Drug release from these formulations also showed good fitting with the first order 
kinetic in the initial phase (r2 = 0.9328-0.9755), which indicated the amount of initial 
drug release was a function of drug concentrations as demonstrated in Figure 4.3 and 
Figure 4.5. 
As it knows that diffusion is the main drug release mechanism in this study, the release 
data of NHT were fitted to  Korsmeyer-Peppas model to further understand the 
mechanism of diffusion from polymeric dosage forms such as Fickian (purely 
diffiusion) or non-Fickian (combined diffusion/polymer relaxation) behaviour. 
Specifically, during the initial phase, the drug release exponents (n values) for NHT-
CS 1:1 and NHT-CS 2:1 formulations were 0.33 and 0.42 respectively, suggesting that 
the drug release followed Fickian diffusion governed by purely diffusion as mostly 
NHT was encapsulated into CS nanoparticles and less NHT on the surface of CS 
nanoparticles regarding formulations of NHT-CS 1:1 and NHT-CS 2:1 (Hui Wang et 
al., 2017).  As drug loading increased, more NHT were loaded on the surface of CS 
nanoparticles as well as encapsulated into the CS nanoparticles.  As a result, the n 
values for NHT-CS 3:1 during initial phase was above 0.43, which is an indicative of 
non-Fickian diffusion governed by diffusion and polymer relaxation due to the rapid 
dissolution of surface or close to surface of adhered or entrapped NHT. After 8 hours, 
NHT which were on the surface of CS nanoparticles was washed away, which were 
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confirmed by SEM images presented in Figure 4.7. Therefore, prolonged drug release 
in the terminal phase followed Fickian diffusion.  
 
Compared with drug release data between before mathematic model correction (Table 
4.1) and after mathematic model correction (Table 4.2), the release constants after 
correction were lower than before correction except for Korsmeyer-Peppas model, 
which suggested the mathematic model used in this study was effective to correct 
delayed diffusion effect occurred by dialysis membrane.  However, linearity after 
correction was not as strong as that of before correction considering lower coefficients 
of determination after correction. There is no statistically significant difference in the 
cumulative drug release (Figure 4.6 a, b, c) between before and after mathematical 
model correction. It was interesting to note drug release of NHT-CS 2:1 during the 
burst release phase was dominated by diffusion and polymer relaxation before 
correction which n value for Korsmeyer-Peppas model was above 0.45, while the n 
value decreased to below 0.45 after correction governed by purely diffusion.  Thus it 
is suggested that drug loading of NHT-CS 2:1 was the critical limit between Fickian 
and non- Fickian. 
 
Overall, a variety of factors such as drug/CS ratios, concentration and molecular 
weight of the CS, type and concentration of crosslinking agent, particle size, degree of 
crosslinking and swelling behaviour of the crosslinked polymer affect the behaviour 
of drug release polymer nanoparticles. Therefore, it is not straightforward to predict 
the precise mechanism affecting drug release kinetics where complex processes are 
involved in releasing drug from nanoparticles. The drug release profiles from the CS 
nanoparticles with dialysis membrane technique were distinguishable to overcome 
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discrepancy of delayed drug release, although statistical significance was not detected. 
These in vitro studies demonstrated that the swellable CS nanoparticles developed in 
this study might have a potential for sustained lung delivery of NHT.   
Table 4.2 Release rate constants and correlation coefficients of NHT release from CS 
nanoparticles after correction 
 
models 1:1 2:1 3:1 
 Initial 
phase 
Terminal 
phase 
Initial 
phase 
Terminal 
phase 
Initial 
phase 
Terminal 
phase 
 0-8 
hours 
8-144 
hour 
0-8 
hours 
8-144 
hour 
0-8 
hours 
8-144 
hour 
Zero order Fr =k0t 
k0 3.4197 0.1001 4.5393 0.0725 5.8149 0.0998 
r2 0.7945 0.9851 0.9206 0.7874 0.9322 0.9774 
       
First order Ln(1- Fr)=-k1t 
k1 0.0531 0.0022 0.0729 0.0017 0.099 0.0033 
r2 0.9328 0.989 0.9605 0.7997 0.9755 0.9983 
       
Higuchi 
model 
Fr =kHt
1/2 
kH 13.218 1.2138 16.943 0.9073 21.558 1.4082 
r2 0.9127 0.9998 0.9861 0.9526 0.9852 0.999 
       
Hixson-
Crowell 
model 
1-(1- Fr)
1/3=k1/3t 
k 1/3 0.0114 0.0003 0.0151 0.0002 0.0194 0.0004 
r2 0.7945 0.9851 0.9206 0.7874 0.9322 0.9969 
       
Korsmeyer-
Peppas 
model 
Fr =kk-pt
n 
kk-p 25.5741 43.0923 22.9456 50.8159 21.1836 50.5126 
n 0.3362 0.0635 0.4207 0.0452 0.5221 0.0603 
r2 0.9594 0.9896 0.9897 0.9044 0.9835 0.9596 
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 SEM after Drug Release  
The morphology of the nanoparticles after drug release was determined by SEM in 
Figure 4.7. An amount of freeze-dried nanoparticles were put into dialysis membrane 
and PBS as release medium for a period of 6 days before SEM morphological 
investigation. Comparing drug loaded/unloaded pictures showed that the surface of CS 
nanoparticles after drug release was still smooth and spherical, though swelling of CS 
nanoparticles may occur during this process. Obvious differences in morphology of 
drug-loaded nanoparticles were observed between before and after NHT release. The 
most distinctive feature of SEM images in comparison between two stages is that a 
large amount of NHT was loaded onto the surface of CS nanoparticles regardless of 
mass ratios of NHT and CS before drug release study (Figure 3.3), while the CS 
particles showed a smoother and more rounded morphology after a 6-day release 
(Figure 4.7). It is worth noting that SEM images from CS nanoparticles without NHT 
did not show significant difference between before and after drug release study. The 
pictures also clearly showed that the porosity of nanoparticles became bigger after drug 
release visually at the corresponding drug-CS ratio. According to Figure 4.7, the size 
of nanoparticles was bigger compared with previous pictures (Figure 3.3) because 
NHT has formed a solid solution with the CS which causing swelling of CS particles 
to release the NHT and many of the particles looked to be fused together.  
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Figure 4.7 SEM images of nanoparticles after immersion in PBS for 6 days from (A) blank 
chitosan; (B) NHT-loaded CS (1:1); (C) NHT-loaded CS (2:1); (D) NHT-loaded CS (3:1) 
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 In Vitro Aerosolization Study 
 
Formulations without large carrier 
Using a twin-stage impinger (TSI), the dispersibility of blank and NHT loaded 
nanoparticles was investigated and the amount of NHT deposition was determined 
using both spectrophotometric and gravimetric methods. The relative particle 
depositions of different formulations were evaluated by parameters: RD, ED, FPF and 
FPD, which are presented in Table 4.3. Significant differences (p<0.05) in all 
deposition profiles of the aerosolized NHT-loaded CS nanoparticles with CS/NHT 
mass ratios of 1:1, 1:2 and 1:3 in RD, ED, FPF and FPD were observed. All the 
formulations exhibited RD ranging from 87.2 % to 92.9 %, which indicated about 
7.1% to 12.8% of the particles were lost during the process of evaluation of 
aerosolization. Some factors that may result in the loss of particles are: 1) adhesion of 
particles to the capsules and glass walls of the TSI chambers; 2) drug released from 
the particles in the PBS in case of NHT-loaded particles. The highest FPF of 
nanoparticles from the blank CS (30.1±0.2 %) which was significantly different (p = 
0.000013) from NHT-loaded CS of NHT: CS 2:1 (25.9±2.3%) and NHT: CS 3:1 
(24.4±1.5%). It was also observed that the FPF from formulation of NHT: CS of 1:1 
was higher than those of NHT-loaded CS formulations with mass ratios of NHT and 
CS of 2:1 and 3:1. The most significant difference (ANOVA, p= 0.000123) for FPF in 
blank CS nanoparticles (30.1±0.2 %) versus NHT: CS of 3:1 (24.4 ± 1.5%), followed 
by blank CS nanoparticles versus NHT/CS of 2:1 (p= 0.000884). No significant 
differences between the FPF of blank CS nanoparticles and NHT-loaded CS at a ratio 
of 1:1 were observed. There was no significant difference between mass ratios of drug-
loaded CS of 2:1 and 3:1. 
  
Chapter 4:  In Vitro Evaluation of NHT-loaded CS Formulations 134 
Although all drug-loaded CS nanoparticles showed similar ED (75-77%), the blank 
CS nanoparticles produced a significantly higher FPF than that of the drug-loaded CS 
nanoparticles (30% vs. 24%, Figure 4.8). It is possible that the CS polysaccharide 
backbone may contribute to the reduction in interparticle interaction and increase the 
FPF of the blank CS nanoparticles.  The reason behind this could be due to the higher 
intrinsic surface positive charge on the blank CS nanoparticles rendering less 
agglomeration due to the repulsive forces and this resulted in higher FPF of blank CS 
nanoparticles.  The decreased FPF of drug-loaded nanoparticles occurred when the 
mass ratios of NHT and CS increased. A fixed mass of nanoparticles (20 mg of blank 
and NHT-loaded) was used to aerosolise from the TSI, therefore, the number of 
nanoparticles reduced in the same mass of formulation (20 mg) with drug loaded 
nanoparticles. The masking of surface charge of nanoparticles by adsorbed drug on the 
surface reduced the FPF of NHT- loaded nanoparticles, although all of them have 
similar ED. 
Table 4.3 In vitro aerosolization of NHT-loaded /unloaded CS nanoparticles (data presented 
as mean ± SD., n = 5) 
 
Nanoparticle 
Formulations 
RD 
(%) 
ED 
(%) 
FPF 
(%) 
FPD 
(mg) 
Blank CS 87.2±2.4 75.5±0.3 30.1±0.2 
29.6±0.9 
- 
NHT- CS (1:1) 88.3±2.7 74.7±0.7 1.71±0.5 
NHT- CS (2:1) 92.5±2.9 76.9±2.3 25.9±2.3 2.5±0.24 
NHT- CS (3:1) 92.9±2.9 75.3±2.4 24.4±1.5 3.18±0.14 
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Figure 4.8 Fine Particle Fraction (FPF; red bars) and Fine Particles Dose (FPD; blue bars) of 
different formulations (data presented as mean ± SD., n = 5) 
 
Capillary forces are generated in the presence of moisture, which has a significant 
influence on the particle interaction through hydrogen bonding, and it eventually 
reduces the FPF of nanoparticles.  The observed reduction in FPF of drug-loaded 
nanoparticles was probably attributed to a higher agglomeration tendency caused by 
the capillary forces due to the presence of highly water soluble drug of NHT, adjoined 
on the particle surfaces with increased concentration of NHT. Addition of the 
hydrophilic drug to the CS microspheres that caused an increased agglomeration of 
particles due to the capillary forces has also been demonstrated (L. Lim & Wan, 1998). 
The higher amount of drug adjoined on the nanoparticles with high drug loading can 
be confirmed by SEM images (Figure 3.3, Chapter 3). 
Although the FPF of nanoparticles reduced after drug loading, increased FPD of NHT 
was obtained with increased concentration of NHT in the nanoparticles (Figure 4.8). 
Forces of particle interactions i.e. mechanical interlocking from surface roughness, 
capillary forces, electrostatic forces and van der Waals forces (Telko & Hickey, 2005) 
are the factors that control the effective aerosolization of nanoparticles. In most cases, 
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the physical interactions due to surface roughness or adhesive/cohesive forces are the 
dominant forces to obstruct particles aerosolization from the DPI formulations. In 
addition, surface morphology is an important factor that controls the dispersibility of 
particles from DPI formulations. The SEM images revealed that the surface 
smoothness of drug loaded nanoparticles reduced (i.e., roughness increased) with the 
increase of mass ratios of NHT to CS. Therefore, increased FPD of NHT from 
nanoparticles occurred due to the increased surface roughness, reduction in contact 
geometry and cohesion forces among particles. So, the higher FPD of drug loaded 
nanoparticles was attributed to these surface properties. The enhanced FPD of NHT-
loaded nanoparticles were further supported by the Carr’s compressibility index 
presented in Table 3.7 and Table 4.3.The Carr’s index of drug loaded CS has been 
found to be decreased with increasing drug loading, thereby improving the flow 
property of nanoparticles and increasing the FPD. Furthermore, the particle sizes of 
drug loaded nanoparticles increased with increased drug loading. The Carr’s index also 
supported the observation that the flow of particles increased with increasing particle 
size that enhanced the FPD. Increased dispersibility of powders due to increased 
particle size has been reported (Tuli, George, Dargaville, & Islam, 2012). This can be 
further explained by the facts that the amount of drug increased in the same mass of 
nanoparticles dose (20 mg), which indicated a fixed amount of dose contained reduced 
number of nanoparticles but higher amount of drug in the formulation that increased 
the FPD. As the total recovery of nanoparticles from the TSI was low, which affected 
the estimate of the true FPF of nanoparticles, it would be appropriate to take the FPD 
of nicotine into account rather than FPF of nanoparticles to demonstrate the practical 
application of the dispersibility data observed in this study. The calculated FPD of 
NHT increased from 1.71 mg to 3.18 mg (Table 4.3) with increasing concentration of 
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NHT in the nanoparticles. Since 1.0 g NHT is equivalent to 0.35 g nicotine base, these 
doses are equivalent to 0.60 mg to 1.12 mg nicotine base delivered into Stage 2 of TSI. 
Therefore, the FPD (equivalent to 0.60-1.12 mg pure nicotine base) obtained from 
NHT-loaded CS nanoparticles would be anticipated to deposit in the lower regions of 
the lung after inhalation, and then undergo initial burst release and subsequent 
sustained drug release. Thus, it offers the potential to reduce dosing frequency and 
improve patient compliance.  
The relationship between the FPF and zeta potential of nanoparticles was presented in 
Figure 4.9. The excellent linearity (r2 = 0.9849) of this figure clearly depicted that the 
FPF of nanoparticles increased with increasing zeta potential at measured pH. CS is a 
cationic polysaccharide and the glutaraldehyde cross-linked CS nanoparticles without 
NHT were positively charged (20.1 mV), which reduced (Figure 4.9) with increasing 
concentration of NHT. The NHT has a negative charge due to the presence of the 
tartaric acid salt so the positive charge due to protonation of the CS amino groups will 
be reduced with increased concentration of NHT in the formulation.  
Table 4.4 Comparison of zeta potential of nanoparticles at measured pH and fixed pH (data 
presented as mean ± SD., n = 3) 
 
Nanoparticles Measured 
pH 
Zeta potential  
(+ mV) 
Zeta potential 
(mV) at pH 6 
Blank CS 5.83 20.1±1.4 18.9±0.3 
NHT:CS (1:1) 4.55 19.0±1.2 -1.50±0.3 
NHT: CS (2:1) 3.83 14.2±0.7 -3.1±1.1 
 NHT: CS (3:1) 3.81 12.2±0.4 -4.5±1.9 
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Figure 4.9 Relationship between the zeta potential and FPF of NHT loaded CS nanoparticles 
(data presented as mean ± SD., n = 3) 
 
The higher FPF from blank CS nanoparticles could be due to the higher surface 
positive charge contributing to the electrostatic repulsive force among the particles. It 
is suggested that the intrinsic surface positive charge of CS nanoparticles will enhance 
the deagglomeration process of nanoparticles resulting in increased FPF with increased 
charge.  As presented in Table 4.4, surface charges of nanoparticles reduced with 
increased concentration of NHT and shifted to negative charge at a fixed pH 6. This 
result suggested that under conditions of reduced protonation of the CS the 
nanoparticles containing NHT tended to agglomerate since it was regarded that a low 
zeta potential (in this case -1.5 to -4.5 mV) would not favour dispersion of the 
nanoparticles. To further study the role of zeta potential on the nanoparticle 
dispersibility, the zeta potential of blank CS nanoparticles (fixed amount of 
glutaraldehyde) was measured at different pH levels. As Figure 3.7 presented, the zeta 
potential of nanoparticles was shown to be reduced with increased pH (r2 = 0.984). A 
fixed amount of glutaraldehyde was used for crosslinking so the number of available 
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amino groups on the CS for protonation was constant. The decrease in zeta potential 
therefore followed the reduction in the protonation as pH increased. The positive 
surface charge of CS in acidic medium due to protonation of the amine groups in CS 
showed repulsive forces (Kiang et al., 2004) between nanoparticles, which supported 
these findings. The large amount of drug accumulated on the particle surface resulted 
in reduced surface positive charge favouring agglomeration. Countering this, 
deagglomeration of CS-NHT nanoparticle agglomerates might be enhanced due to 
impaction on the internal wall of the device. Therefore, the significant reduction in 
FPF from the NHT loaded CS nanoparticles i.e., decreased particle repulsive forces, 
increased cohesion forces and likewise reduced dispersibility of nanoparticles was 
observed. This is because the accumulated drug in the nanoparticle reduced the 
positive zeta potential. 
In addition, the increased concentration of drug caused an increase in nanoparticle size 
(Table 3.2), which reduced the number of nanoparticles. The particle number (N) 
which gave the number of particles per unit weight of the sample was expressed by the 
equation:  
                                                          N=  
6
πρd3
                                                 Eq.  4.19  
where N is the particle number, d is the diameter of the spherical particle and ρ is the 
density of chitosan (1.54 gm/cm3).  
The reduction of particle number with reduced zeta potential in the same mass of 
formulation caused a reduction in the FPFs. As indicated earlier in the discussion, the 
loaded drug with higher concentration was likely to reduce the surface charge 
compared to the blank nanoparticles and thereby FPFs were reduced with increased 
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drug loading. This rationalizes the lowest FPF of NHT loaded CS nanoparticles at 
higher drug concentration (NHT: CS of 3:1).   
Very insignificant difference was observed between FPF and surface charges produced 
by the nanoparticles of CS and NHT-CS 1:1. The reason for this may the sum of two 
effects. The first is that the pH of the solution was higher in the case of the CS 
compared to the NHT: CS 1:1 nanoparticles so the degree of protonation was less. 
However, there was a reduced number of amino groups in the nanoparticles due to 
crosslinking and also the presence of the NHT which will have an overall negative 
charge. The net reduction in zeta potential is only 1mV. The reason behind this could 
be that the surface charge was not affected by 1:1 ratio of drug loading as most of 
drugs the NHT is encapsulated inside the polymer nanoparticles and this concentration 
was not high enough to cover the nanoparticles surface. The sudden drop of both the 
FPF and the surface charge produced by the NHT-CS 2:1 and 3:1, compared to the 
blank CS or NHT-CS 1:1 was probably due to masking more positive charges on 
nanoparticles by the increased concentration of drug. Additionally, it was possible that 
the higher agglomeration tendency was caused by the increased capillary forces due to 
the presence of large amount of highly water-soluble NHT, that were adjoined to the 
surface of CS nanoparticles. The tendency of increased agglomeration of CS-based 
microspheres upon the addition of a hydrophilic drug, propranolol hydrochloride has 
been reported (Lim and Wan, 1998), which supported this possibility.  The surface 
roughness had an impact on the dispersibility (Islam, Stewart, Larson, & Hartley, 
2005) of drug and accordingly higher FPF from NHT-loaded nanoparticles was 
expected as the surface irregularities/roughness increased with increased concentration 
of NHT. However, it appeared in this study that the surface irregularities or roughness 
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due to the increased drug loading did not play a dominant role in nanoparticle 
dispersion. 
Formulations with large carrier  
The nanoparticles of blank CS and NHT-loaded CS were mixed (10% w/w) with 
inhalation grade lactose microparticles (Inhalac 120, approximately 100 µm size) to 
see the impact of large carrier on nanoparticle dispersibility. The  FPF presented in 
Figure 4.11 (with carrier), where the large carrier based formulations produced a 
significant (p= 0.0001) elevation in FPF compared with those of carrier-free 
formulations. The surface charges demonstrated in Figure 4.9 were not seen to 
contribute to the dispersibility of nanoparticles from the carrier based formulations. 
The FPFs were slightly higher from samples with lower charge and increased with 
increasing drug loading in the nanoparticle, suggesting that the large carriers 
contributed to the reduction of the cohesive forces among the nanoparticles, giving 
improved de-agglomeration due to the collision effects (Islam, Stewart, Larson, & 
Hartley, 2004; Kho & Hadinoto, 2013). Because of higher mass of large carriers, the 
impaction effect was predominant over the charge effect as the charged nanoparticles 
on a carrier carry the same charge as the free nanoparticles (without carrier). It was 
explained previously that the intrinsic positive charge on CS nanoparticles led to the 
increased FPF of nanoparticles with increasing surface charge due to repulsive force 
among particles that formed loose agglomerates; however, the dispersibility from large 
carrier based formulation was not in conformity with this argument.   
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Figure 4.10 SEM images of CS nanoparticles with lactose carrier 
 
 
 
Figure 4.11  FPF of nanoparticles with or without large lactose carriers (data presented as mean 
± SD., n = 3) 
 
Once aerosolised the formulation, the agglomerates may be subjected to kinetic forces 
due to inspiratory flow and inhaler mechanical impaction forces or a combination of 
both for appropriate deagglomeration and subsequent dispersion (Al-Qadi et al., 2012; 
Leung et al., 2015; Papadimitriou et al., 2008). The SEM images in Figure 4.10 showed 
nanoparticles were distributed either as agglomerates or as a single particle on the large 
lactose carriers. It was suggested these nanoparticles (single or agglomerates) in the 
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mixture had limited cohesion forces among them and thereby easy detachment 
occurred due to high impaction. The momentum of any particle is dependent on the 
mass and the velocity of the carrier and as the larger particles will have greater mass 
there will be greater momentum transfer or high impaction to detach the surface 
particles. Therefore, significant mechanical forces were thought to be produced due to 
the carrier-carrier collisions or collisions between the carrier particles and the internal 
walls of the inhaler during aerosolization (Coates, Fletcher, Chan, & Raper, 2004).  
The geometry of the inhaler device, an important factor in drug dispersibility, has been 
reported to affect the extent of collisions occurring between the inhaler wall and the 
carrier particles (Coates et al., 2004). The nanoparticulate agglomerates that adhered 
on the large carriers might be detached as a whole, requiring a much lower velocity 
than the detachment of a single particle because of the significantly higher inertia for 
the agglomerates (De Boer, Chan, & Price, 2012).  In this study, lactose carriers, mixed 
with positively charged chitosan nanoparticles were aerosolized via a Rotahaler made 
of polyvinylchloride. On aerosolization, the lactose particles acquired positive specific 
surface charge with polyvinylchloride and polypropylene surfaces (Byron, Peart, & 
Staniforth, 1997; Rowley, 2001).  Therefore, the positive electrostatic charge 
developed on the lactose carrier (depending on the particle size and contact surface) 
due to the collision between the carriers and device surface during aerosolization 
probably influenced the overall dispersibility of nanoparticles by repulsive force 
between the large carriers and the cationic chitosan nanoparticles that resulted in 
higher FPF. However, this assumption was not supported by the zeta potential of NHT-
loaded CS nanoparticles, which showed increased FPF from large carrier based 
formulations with reduced zeta potential at higher concentration of drug loading (Table 
4.5). If the repulsive forces between large carriers with acquired positive surface 
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specific charge and CS nanoparticles were the contributing factor to increase the FPF, 
then the blank CS nanoparticles with highest zeta potential would have produced 
highest FPF and the highest NHT-loaded CS nanoparticles (NHT-CS 3:1) would have 
showed  the lowest FPF. However, the data presented in Table 4.5 showed the highest 
FPF from large carrier based formulation of nanoparticles with lowest zeta potential. 
Therefore, it can conclude that the impact of large carriers on FPF was independent of 
zeta potential.  
Table 4.5 Aerosolization studies of blank and nicotine-loaded chitosan nanoparticles 
with and without large lactose carriers (data presented as mean ± SD., n = 5) 
 
Formulations RD (%) ED (%) FPF (%) 
 
With 
carrier 
Without 
carrier 
With 
carrier 
Without 
carrier 
With 
carrier 
Without 
carrier 
Blank CS 81.4±3.0 90.0±1.4 66.6±3.6 75.5±0.2 33.4±1.4 30.8±0.2 
CS NHT (1:1) 81.6±6.1 88.3±2.7 65.3±1.6 74.7±0.7 33.5±2.2 29.6±0.9 
CS NHT (1:2) 81.3±3.8 92.5±2.9 71.5±2.6 76.9±2.3 34.9±0.5 25.9±2.3 
CS NHT (1:3) 79.0±3.3 92.9±2.9 63.0±2.2 75.3±2.4 38.0±1.8 24.4±1.5 
NHT 92.1±4.2 - 51.8±6.7 - 7.32±2.0 - 
 
Another possible factor to increase the FPF could be that the lactose carriers used in 
this study contained some associated fine particles of lactose (1.5% fine lactose 
<5µm), which were thought to form loose agglomerates with the nanoparticles that 
easily detached from the carrier surface, deagglomerated and higher dispersion 
occurred (Islam et al., 2004). Furthermore, the enhanced FPF of nanoparticles could 
have happened due to the surface roughness of lactose carriers as well as the 
nanoparticles. As seen in the SEM images, the nanoparticle surfaces were 
comparatively rougher with increased concentration of NHT loading and that surface 
roughness could have played a significant role in the detachment of nanoparticles from 
carrier surfaces due to limited contact and led to increase FPF. For example, the highest 
FPF (38.0 %) of NHT-CS 3:1 nanoparticles, which showed very rough surface that 
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probably experienced less adhesion forces on the lactose rough surface and easy 
detachment occurred. Although the actual mechanism of nanoparticle dispersion from 
formulation with or without large carriers was not absolutely clear, this study revealed 
some key points:  i.e., a) the CS nanoparticle dispersion without large carriers was 
dependent on the deagglomeration process controlled by the surface zeta potential of 
nanoparticles; b) the presence of large carriers in nanoparticlate DPI formulations 
accelerated the deagglomeration process by collision and high impaction and was 
independent of surface zeta potential.  
 Stability Test 
The stability of inhalation powders is crucial to maintain the aerosolization properties. 
Temperature and relative humidity during storage are two main factors to affect 
aerosol performance. Thus, long term stability is required to ensure the efficiency of 
aerosol performance.  
NHT-loaded CS nanoparticles as DPI formulation appeared that the NHT-CS powders 
remained in the powder form in the one year under conditions of 25°C, 60% RH. The 
colour of the powders stayed light yellow. SEM showed that the formulations stored 
for one year showed the same surface structure as those that were freshly prepared 
(Figure 4.12). In addition, the FPF of nanoparticles stored for up to one year did not 
show a statistically significant change during storage (Figure 4.13). It indicated that 
the powder was stable without significant deterioration of aerosolization performance 
during this period. In terms of drug loading after stability study, it was estimated based 
on the results of in vitro aerosolization study, which NHT-loaded CS nanoparticles 
were evaluated both gravimetrically and UV spectrophotometrically.  During one year 
storage, the amount of NHT in PBS from each stage of TSI  (data presented in 
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Appendix Table 1, P 219) did not vary significantly compared with freshly prepared 
particles, which indicated that composition of NHT in the nanoparticles did not change 
significantly. In other words, that drug loading of NHT-CS nanoparticles did not 
change significantly in comparison with nanoparticles that were freshly prepared. 
 
Figure 4.12 SEM of nanoparticles formulations between freshly made (A and C) and after 1 
year under room temperature storage and 60% RH (C and D).  (A) (B): blank CS nanoparticles; 
(C) (D): NHT-loaded CS (3:1) 
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Figure 4.13 In vitro aerosolization (FPF) of NHT-loaded CS nanoparticles by TSI in one year 
under storage condition of 25°C, 60% RH (data presented as mean ± SD., n = 3) 
 
4.5 SUMMARY 
This chapter showed that both manufacturing process and storage conditions could 
have a significant effect on effective delivered dose. The powders are a mixture of both 
individual nanoparticles and their microaggregates. According to in vitro drug release 
profile, NHT loaded CS nanoparticles established in Chapter 3 showed a prolonged 
drug release up to 4 days at the highest drug loading. Initial burst release is attributed 
to the rapid dissolution at the surface or close to the surface of adhered/entrapped drug 
in the nanoparticles, while the later slow release is because of the penetration of the 
release medium into the microaggregates and dissolution of the entrapped drug. On 
the basis of the in vitro drug release, conversion factor between NHT to nicotine base 
(1 mg NHT equals 0.35 mg nicotine base), drug loading, and FPD of NHT from the 
prepared nanoparticles, the predicted plasma concentration will be between 4-7 ng/mL 
from 1.7 to 3.2 mg of FPDs of the prepared formulations for therapeutic action. These 
values for NHT-CS 3:1 are similar or above the reported plasma concentrations of 
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nicotine obtained after inhalation via a device or cigarette smoking (Moyses et al., 
2015). FPF of NHT-loaded CS nanoparticles increased with increasing surface charge, 
which probably enhanced the deagglomeration of nanoparticles by repulsive forces.  
The use of a lactose carrier removed this effect and FPF of nanoparticles from the large 
carriers based formulations was significantly higher (p<0.001) than those of 
formulations without carriers and was surface charge independent. The results of this 
chapter suggest the mechanism of nicotine loaded CS nanoparticle dispersion without 
large carriers is dependent on the zeta potential, which is linked to the agglomeration 
or deagglomeration behaviour of nanoparticles.  Further comprehensive studies maybe 
warranted to develop an efficient DPI formulation by understanding the interactions 
between the charged particles and carriers, the impact of charged particles or 
agglomerates on the deagglomeration and dispersion.  Long term stability study 
showed the DPI formulations of NHT-loaded CS nanoparticles were stable at the 
storage condition of 25 °C/60 % RH. The outcomes of in vitro evaluations of prepared 
NHT loaded CS nanoparticles in this chapter are suitable to supply the effective 
therapeutic concentration after inhalation with sustained release and this provides a 
direction for in vivo animal evaluation tests in the following work. 
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In Vivo Assessments of NHT-loaded CS 
Formulations for Pulmonary Delivery    
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In this chapter NHT-CS nanoparticles are administered to mice lungs via a nose-only 
inhalation device to assess the drug activity and to determine the potential toxicity 
issues with pulmonary delivery of the formulations. First, the efficiency of a nose-only 
inhalation device is evaluated in vitro to determine the best parameters of flow rate 
and delivery period to deposit DPI formulations in the lungs of mice. Investigation of 
whether the formulation of NHT-CS (3:1) nanoparticle (developed in Chapter 3, 
designated here as nano-nicotine) has altered the activity of NHT by comparing the 
effect of the unmodified NHT in naïve mice (C57BL/6, 8-10 weeks old) through 
locomotor activity via a single subcutaneous injection (s.c) was performed. Next, the 
minimum required inhaled dose of nano-nicotine was determined which caused 
locomotor activity response similar to the injected (s.c.) dose of unmodified NHT. 
Finally, histological examination of lung tissues was performed to determine if 
inhalation of the nano-nicotine caused any lung damage.  
5.1 INTRODUCTION 
Locomotor activity in rodents is commonly used to investigate changes in spontaneous 
activity in response to pharmacological treatments. It is defined as the movement from 
one point to another in a specific time period. Nicotine is capable of altering locomotor 
activity. The locomotor response to nicotine is mediated by various neurotransmitters, 
producing either a stimulant or depressant motor activity depending on the mouse 
strain and dose administered (Clarke & Kumar, 1983; Domino, 2001). Stolerman 
reported locomotor stimulant and depressant effects of nicotine are due to different 
actions of different type of nicotinic acetylcholine receptors nAChRs (Stolerman, 
Garcha, & Mirza, 1995). The reinforcing effects of locomotor activity from nicotine is 
associated with the dopamine release to activate nAChRs subunits in the brain, and 
then nicotine increases nAChRs intensities through activating α4β2 nicotinic receptors 
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to modulate the release of several neurotransmitters (Lallemand, Ward, & De Witte, 
2007; Marubio et al., 2003). The depressant effect of nicotine is possibly due to 
blockage of neuronal nAChRs (Mineur & Picciotto, 2010), but the mechanism by 
which nicotine acts as an inhibitor remains obscure. Both effects of nicotine can be 
inhibited by the nicotinic antagonists such as mecamylamine (Clarke & Kumar, 1983; 
Stitzer, Morrison, & Domino, 1970). Therefore, the change in locomotor activity by 
nicotine exposure in non-tolerant mice is a primary step to predict pharmacological 
effects of our new nano-nicotine formulation in humans. On the other hand, chronic 
nicotine exposure in rodents would cause nicotine tolerance, as evidenced by a less 
depressant phase and a higher dose to induce stimulant locomotor  response (Clarke & 
Kumar, 1983). 
Different locomotor activities were observed among various strains due to distinct 
pharmacogenetic differences (Collins, Miner, & Marks, 1988).  In this study, we 
selected C57BL/6 mice, which are commonly used in bioassays during tobacco 
ingredient testing. Tsuji reported that mice of the C57 strain could inhale higher 
volume of smoke in the lungs in comparison to other strains under same exposure 
conditions in acute cigarette smoke inhalation studies (Tsuji et al., 2011).  
The aim of this chapter is to explore a series of optimum parameters in vitro to be 
applied on the nose-only inhalation device and determine the safety and efficacy of 
nano-nicotine as DPI formulation in mice models in vivo. The stimulatory dose of 
nano-nicotine which is comparable to the effects of free base is selected which is 
expected to mimic the effects of cigarette smoking.  
  
Chapter 5:  In Vivo Assessments of NHT-loaded CS Formulations for Pulmonary Delivery 152 
5.2 MATERIAL AND INSTRUMENTS 
 Animals  
The protocol was approved by the Queensland University of Technology Animal 
Ethics Committee and the University of Queensland Animal Ethics Committee, in 
accordance with the National Institutes of Health (NIH) guidelines for the care and use 
of laboratory animals. 
Male C57BL/6 naïve mice aged 8-10 weeks old (25.0 ±5.0 g) were obtained from the 
Australian Resource Centre (Perth, Australia). All animals in this study were nicotine 
naïve prior to the commencement of experimental protocols and were given at least 1 
week to habituate to the animal facilities prior to experiment commencement. Mice 
were single-housed in a clear, ventilated cage (Tecniplast) with unlimited access to 
food and water. The home cages are temperature controlled with a 12h normal 
light/dark cycle (lights on 7am: off 7pm). The mice were used only once, and they 
were sacrificed immediately after testing.  
 Drugs  
Nicotine hydrogen tartrate (NHT) powder was purchased from Sigma-Aldrich, 
Australia. It was ground into inhalable fractions of powders using mortar and pestle. 
All doses of nicotine in the following work are expressed as the free base of the 
nicotine (1 mg NHT equals 0.35 mg nicotine base). Based on the results of Chapter 4, 
to improve aerosolization of nanoparticle powders, both NHT and nano-nicotine were 
mixed with four times of inhalable grade lactose monohydrate (Inhalac® 120) (see 
3.1.1).    
 Nose-only Inhalation Device 
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Design of Device 
The nose-only inhalation device for administration of inhalation powder to multiple 
mice was modified from a previous report by Biswadip (Sinha & Mukherjee, 2012).  
The scheme of design is shown in Scheme 5.1. The main three parts of this inhalation 
device are: inhalation chamber, delivery chamber and dosing chamber.  
 
Scheme  5.1 Diagram of (A) inhalation chamber made of 50 mL tapered centrifuge tube; (B) 
delivery chamber; (C) dosing chamber 
 
Delivery chamber: A round box is in the middle as the delivery chamber with the fan 
assembled into it to deliver the formulations to the mouse nose and circulate the air. 
Two holes are made on the screwable cover of the delivery chamber, of which one is 
to connect the dosing chamber as the entry of the DPI delivery port; the other hole is 
to connect oxygen/air through pipeline.  There are twelve equal holes (exposure ports) 
across the outer face of delivery chamber to accommodate the mice holding containers, 
which are termed inhalation chambers.  
Inhalation chamber: Each exposure port is connected to an inhalation chamber that 
transfers aerosolized formulation to the animals.  Inhalation chamber are made of the 
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50mL tapered ends of centrifuge tubes. The tapered bottom of tubes is cut to make a 
small hole so that only the noses of the mice can tightly fit the holes. The silicone 
sealant was put between the tubes (inhalation chamber) and delivery chamber to 
prevent leakage of powder.  The other ends of the tapered centrifuge tubes were 
replaced with the plunger of syringe which is adjusted based on the size of the mouse 
to prevent the mouse from removing their nose from the inhalation port.  
Dosing chamber: Dosing chamber is made of 15 mL tapered end of the centrifuge 
tube. Two holes are punched on the wall of the tubes. A long plastic pipette was placed 
into the tube through the hole for pumping air to fluidize the powder. The other hole 
was connected to the dosing chamber to deliver the drug powder (nano-nicotine 
powder, NHT powder or blank CS nanoparticles). The dosing chamber from centrifuge 
tube was turned upside down when the experiment is in process to allow the drug 
powder to be delivered to delivery chamber. All the holes cut in this system were 
sealed tightly by adhesive to prevent air leaking from chambers.  
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Figure 5.1 Design of nose-only inhalation device 
 
5.3 METHODS 
 In Vitro Evaluation of Drug Deposition 
Efficiency of customised nose-only inhalation device was evaluated by in vitro drug 
deposition test. This procedure was aimed to choose the best aerosolization parameters 
to collect as much deposited drug on the inhalation ports of inhalation chamber as 
possible. The selected parameters (e.g. loading dose, delivery time, and flow rate) were 
applied in vivo animal study protocol design. The delivery chamber was connected to 
the dosing chamber by a rubber pipeline. The other side of dosing chamber was 
connected to the anaesthesia apparatus to allow control of oxygen flow rate. The 
loaded powders in the dosing chamber were fluidized after ventilating the oxygen from 
isoflurane apparatus (V3000PK, Parkland Scientific, Inc. USA). All the junctions of 
inhalation device were sealed appropriately to prevent the powders leaking and 
splashing during experiment.  
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The customised inhalation chamber can accommodate up to twelve mice. Six ports 
(port No: 2; 4; 6; 8; 10; 12) were blocked using syringe plungers. The other six ports 
were fixed to animal holder tubes (inhalation chamber) which were made of cut ends 
of tapered centrifuge tubes to test in vitro powder deposition. A weighed piece of 
cotton, which mimicked the nose of mice, was plugged in each port of animal holder 
tube. The collected amount of drug on the cotton plugs represented the inhaled amount 
of drug at the respective ports if the mice were placed into the inhalation tubes. Ground 
NHT was mixed with inhalation grade lactose monohydrate (Inhalac® 120) 
microparticles used as carriers to make binary interactive mixtures using hand mixing 
technique.  Amount of powder mixture (1:4 w/w ratio) of NHT (100mg) and lactose 
(Inhalac® 120) (400 mg) was loaded into dosing chamber. At the selected oxygen flow 
rate (0.6L/min; 0.9L/min), the powder was delivered to inhalation chamber for 3min 
or 5min. After powder dosing, the cotton pieces from each port were washed by PBS 
and collected separately. This process was repeated at least three times by rinsing 
cottons and squeezing them with a clean tweezers. The volume of the washing from 
each port was made up to 10 mL with PBS. After filtering through 0.22 µm filter 
(Millipore), the drug content was analysed by UV spectroscopy with proper dilution 
with PBS. The powder left in the delivery chamber and dosing chamber was also 
collected using cotton and PBS, followed by analysing by UV spectroscopy. The total 
recovered dose was sum of amount of powders in inhalation chamber, dosing chamber 
and delivery chamber to calculate the mass balance.  
 In Vivo Locomotion Behaviour Test 
5.3.2.1 General protocol of locomotor activity 
Locomotor activity was monitored with a 16 × 16 photo beam array located above the 
floor of the enclosure (Figure 5.2). The locomotor activity chambers were 40×40×38 
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cm divided into 4 enclosures with grid lines marked on the floor. Each enclosure can 
hold only 1 animal and up to 4 animals can be assessed at any one time. The locomotor 
activity chambers were monitored with an overhead-mounted video camera connected 
to a VCR to record mice behaviour which was analysed by Any-maze Software 
(Stoelting, Wood-dale, IL) which measured the distance the animal travelled every 5 
mins. 
 
Figure 5.2 The apparatus of locomotor activity chamber 
 
Locomotor studies were run 2 hours per day over four consecutive days. On day 1, 
mice were placed into the locomotor chamber for 2 hours (8:00am-10:00am, first 
round) in the morning and returned to home cage afterwards. No data was collected at 
day 1, allowing mice to acclimatize to the locomotor chamber. On days 2 and 3, mice 
were placed into the locomotor chamber to be habituated in the first hour, followed by 
being given a single s.c. injection of physiological (0.9%) saline (10 mL/kg) (Chapter 
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5.3.2.2) or placed in the nose-only inhalation chambers for 5 mins (Chapter 5.3.2.3).  
Mice were returned to locomotor chamber for another 1 hour. The purpose of day 2, 3 
were to habituate mice to the apparatus and injection or inhalation procedure before 
the drug test started. On day 4 (drug testing day), mice were placed in the locomotor 
activity chamber again for 60 min prior to the start of testing, when mice were given a 
single s.c. injection of drug treatment or placed into the nose-only inhalation chambers 
with drug treatments.  The mice were returned to the activity chamber immediately 
after the injections or inhalations, and the test sessions lasted for another one hour. 
After the each session, mice were returned to their home cage. Locomotor activity 
(distance travelled) was measured from the video recording using AnyMaze software. 
On the day 4 (drug testing day), travel distances of mice in the first hour were measured 
as baseline. Once stable baseline were established, changes in distance travelled in the 
second hour at day 4 with nicotine and nano-nicotine injections or inhalations were 
compared to the results with the vehicle alone to assess sensitization of nicotine and 
nano-nicotine in mice. Nicotine naïve mice received s.c. saline injections as a control 
group on basal activity throughout the experiment. Sensitization was evaluated by a 
significant increase or decrease in activity with drug administration compared with 
vehicle group, indicating doses defined in response to drug.  
The distance travelled induced by CS only injection was compared with control, 
determining whether CS only injection cause changes in locomotion behaviour in 
mice. Afterwards, the travel distance administered by nicotine injection compared to 
the control to observe the effects of acute injection of nicotine. The comparisons in 
travel distance by nano-nicotine injection and control to determine whether the 
bioactivity of nano-nicotine was altered during manufacture process.    In the study of 
in vivo locomotor activity by inhalation, the travel distance administered from CS only 
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inhalation was seen as control group. The distance travelled exposed to nicotine 
inhalation to determine the acute effects of nicotine inhalation. The minimum 
stimulant dose of nano-nicotine was selected from the highest travel distance induced 
by inhalation of nano-nicotine in comparison with control. 
5.3.3.2 Assessment of bioactivity of nano-nicotine via in vivo locomotor test by 
injection 
To determine whether the nano-nicotine had changed its bio-activity, the locomotor 
activity procedure was applied. Four different doses of nicotine test groups were set 
up. They were: 0.25 mg/kg; 0.5 mg/kg; 1.0 mg/kg, 1.5 mg/kg, which were equivalent 
to NHT powder as 0.71mg/kg; 1.42 mg/kg; 2.84 mg/kg; 4.26 mg/kg respectively. 
Meanwhile, four different formulated nano-nicotine groups were administered in 
accordance with nicotine-only groups. They were: 1.10 mg/kg; 2.19 mg/kg; 4.37 
mg/kg; 6.56 mg/kg. All drugs were prepared freshly prior to drug test every time in 
physiological saline (0.9%) and administered as subcutaneous (s.c.) injections in a 
volume of 10 mL/kg. Doses of nicotine are expressed as mg/kg and were administered 
using a pseudorandom Latin square design to create test batches and control for 
potential sources of inter-batch variation. 
The dose response curves were used to assess the bio-activity of the nano-nicotine and 
compared it to nicotine. Mice were randomLy assigned to one of four groups: vehicle 
(V), CS only (C), nicotine (N) and nano-nicotine (NN) (see Table 5.1). The procedure 
of locomotor activity test was as general protocol in Chapter 1.3.3.1. On day 4 (drug 
test day), mice were placed in the locomotor activity chamber for 60 min to collect the 
baseline prior to the start of testing, then mice were given a single s.c. injection of the 
assigned treatment: vehicle (n=10) or CS (1.5mg/kg; n=10) or nicotine (n=10) or nano-
nicotine (n=10).   Changes in distance travelled with CS only, nicotine and nano-
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nicotine injections were compared to vehicle as an indicator of whether the 
nanoparticle manufacture process has altered the activity of the compound. 
Table 5.1  Outline of experimental groups (e.g. dose=1 mg/kg) 
 
Treatment on days Day 1 Day 2 Day 3 Day 4 
First round  (8:00 am-10:00 am) 
Vehicle (V) n/a Sal  Sal  Sal  
Chitosan (C) n/a Sal Sal C 
NHT (N) n/a Sal  Sal  N 
Nana-nicotine (NN)  n/a Sal  Sal  NN 
 
Second round  (11:00 am-1:00pm) 
 
 
As above first round 
   
 
Third round (3:00 pm-5:00 pm) 
    As above first round   
“N”=one of 0.71mg/kg; 1.42 mg/kg; 2.84 mg/kg; 4.26 mg/kg NHT; “NN”=one of 1.10mg/kg; 2.19 
mg/kg; 4.37 mg/kg; 6.56 mg/kg formulated nano-nicotine. “C”=blank chitosan; Sal=0.9% saline. n/a 
means no injection. Three rounds per day.  
5.3.3.3 Assessment of viability of nano-nicotine via locomotor test following 
inhalation 
To determine the minimum stimulant dose required of nano-nicotine to alter mice 
locomotor activity and compare the inhalation efficiency of inhaled nano-nicotine with 
nicotine, the locomotor activity of naïve male mice (8-10 weeks old, C57BL/6) was 
measured following an acute inhalation administration dose of nano-nicotine or 
nicotine. Blank CS nanoparticle powders were used as the control. As described in the 
general protocol of locomotor test (1.3.3.1), the animals were habituated to the 
enclosure for one hour before the drug administration procedure. During the drug 
inhalation test, the mice were placed in the nose-only inhalation chambers for 5 mins 
instead of receiving an injection before being returned to the locomotor chamber. We 
tested blank CS nanoparticles and 3 doses of nicotine and nano-nicotine to determine 
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the lowest effective dose which was capable of altering locomotor activity using a 
Latin square design as described above. Four mice were tested per batch and three 
batches were tested per day. Different doses were loaded in the dosing chamber per 
batch, i.e 25mg, 50mg, 75mg NHT (labelled as 25N, 50N 75N), and 38.5mg, 76.9mg 
and 115.4mg nano-nicotine, which were equivalent to corresponding amount of NHT 
respectively (labelled as 25NN, 50NN 75NN). The test powder (NHT, nano-nicotine 
or blank CS) with four times of inhalable lactose powders were ground into inhalable 
grade powder and aerosolized under sufficient fluid pressure with flow rate of oxygen 
at 0.9L/min for 5 minutes in the 15 mL dosing chamber. In the following contents and 
figures in this chapter, the dose of nicotine per batch represented as 25N, 50 N, 75N; 
and equivalent dose of nano-nicotine per batch noted as 25 NN, 50 NN and 75 NN.  
5.3.3 Histopathological Evaluation and Lung Morphometry  
After completion of locomotor activity test, the mice were euthanized with carbon 
dioxide either immediately or 24 hours post exposure to assess the lungs for potential 
adverse effects of nicotine and nano-nicotine. The lungs were inflated with 2 mL of 
4% (w/v) paraformaldehyde (PFA), and then removed and fixed in a 4% PFA solution 
containing neutral PBS for at least 72 hours. After fixation, the lungs were stored in 
the PBS until processing. The specimens of all pulmonary lobes were embedded in 
paraffin. Sections at a thickness of 5 μm were stained with hematoxylin and eosin 
(H&E) to examine the histological structure using a brightfield slide scanner (Olympus 
VS120).  
Histological slides were assessed for unpigmented and pigmented macrophages in the 
alveolar lumen; pigmented macrophage nests in the alveolar lumen; lymphocytic 
infiltrates in the alveolar interstitium; lymphocytic infiltrates in the peri-vascular area; 
  
Chapter 5:  In Vivo Assessments of NHT-loaded CS Formulations for Pulmonary Delivery 162 
neutrophilic granulocytes in the alveolar lumen; pulmonary emphysema; and 
hyperplasia of the alveolar epithelium. One section per mouse by a cross section 
between a main stem bronchus and its branching bronchioles was assessed 
morphometrically. The area of morphometric assessment was selected randomLy 
using a xyz camera and processed with OlyVIA software (Olympus OlyVIA 2.4). 
5.3.4 Statistical Analysis 
All numerical data presented as mean ± SEM and statistically evaluated using 
GraphPad Prism 6 (GraphPad Software Co., USA). In the study of in vitro evaluation 
of nose-only inhalation device, comparison of means between oxygen flow rates of 0.6 
L/min and 0.9 L/min as a whole was performed with the unpaired t-test, while the 
comparison of inhalation port individually between flow rates of 0.6 L/min and 0.9 
L/min was processed with two-way ANOVA with Bonferroni’s post hoc test. The 
statistical analysis of the locomotion behaviour and the doses of drug treatment with 
time were performed as two-way ANOVA, followed by a Bonferroni post hoc 
analysis. Significant differences were taken into account if p was less than 0.05. 
5.4 RESULTS AND DISCUSSION 
 In Vitro Evaluation of Nose-Only Inhalation Device 
The flow rate is one of the most important factors to affect the drug deposition. The 
drug powder loaded into dosing chamber was forced to flow rapidly towards delivery 
chamber by sufficient fluid pressure, so the proper flow rate should be selected to 
aerosolize drug powders as much as possible. In addition, precise ventilation needs to 
be considered when designing an optimum nose-only inhalation device. The 
concentration of carbon dioxide in the inhalation chamber is increased with increased 
duration of animals into the chamber. The suggested ventilation of approaching animal 
each port is at least 2.5 times as much as that of animal’s minute  exhaled volume 
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(Fröhlich & Salar-Behzadi, 2014). The effect of flow rate on drug deposition was 
evaluated in vitro in this study by using 100mg NHT powder with 400 mg lactose as 
drug carriers. This choice was based on our previous study that the FPF of 10% NHT-
loaded CS nanoparticles with lactose carriers was improved significantly compared 
with the results from nanoparticles without lactose carriers (see section 4.4.4).  
After determination of NHT in the PBS by UV, it was found that 0.88±0.04 mg (mean 
± SEM) NHT was deposited on average across the six inhalation ports (port No: 1; 3; 
5; 7; 9; 11) at 0.6 L/min, while 1.20±0.05mg NHT was collected on average from the 
six ports at 0.9 L/min. The average deposition rate per port was 21.1% (0.88 
mg/port*12 ports/50 mg%100=21.1%) at the oxygen flow rate of 0.6 L/min and 28.8% 
at the oxygen flow rate of 0.9 L/min. The mean NHT deposition from 0.9L/min was 
significantly (t-test, p<0.01) higher than the mean NHT deposition from 0.6 L/min as 
presented in Figure 5.3 A.  Figure 5.3 B presents the amount of NHT deposited at each 
individual port of inhalation device. However, when comparison of individual 
inhalation ports was made between flow rate of 0.6 L/min and 0.9 L/min, the 
deposition at 0.9L/min was higher than that obtained from 0.6 L/min as a whole, but 
significance ( two-way ANOVA with Bonferroni’s post hoc test, p<0.05) was only 
seen in ports 1, 5 and 11.  It is worth noting that six of twelve ports (port No: 2; 4; 6; 
8; 10; 12) were blocked during the test process, resulting in lower drug deposition 
proportion, thus the actual total amount of powder collected from all ports were 
different from the theoretical amount. The actual mass balance details in the 
experimental procedure (such as total recovered dose, deposition percentage) have 
been listed in Appendix A. Consistent with the above findings, the drug deposition 
was enhanced dramatically with increased flow rate. 
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(A) 
 
 
 
(B) 
Figure 5.3 (A) comparison of mean drug deposition at different flow rate. Mean NHT 
deposition from the flow rate of oxygen of 0.9 L/min (grey) and mean NHT deposition from 
the flow rate of oxygen of 0.6 L/min (black). (data presented as mean ± SEM., n = 18) 
(Significant difference from group of 0.9L/min:  ****p<0.0001). (B) Comparison of effect of 
flow rate of oxygen on drug deposition at different individual port (data presented as mean ± 
SEM., n = 3) (Significant difference from group of 0.9L/min: *p<0.05, **p<0.01) 
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The nose-only inhalation device in this study was based on a reported design (Sinha & 
Mukherjee, 2012). A tapered tube was designed as DPI device in this study instead of 
conventional DPI devices which are available on the market, as generally DPI requires 
patients to inhale formulation actively, allowing formulation particles to reach the deep 
lungs properly. However, this definitely cannot be used for animals. In addition, 
compared to the current 6 mice at a time reported by other group (Sinha & Mukherjee, 
2012), the drug deposition rate of our group’s device was lower than the reported one 
(28.8 % vs. 42.67%), which suggested the efficiency of device could be improved 
potentially.  
As discussed above, the drug deposition from flow rate of 0.9 L/min performed much 
better than those of from 0.6 L/min at all the evaluation sides. The primary reason 
behind this is that air pressure was insufficient to force powder escaping from dosing 
chamber and to be delivered to delivery chamber.  Besides, more carbon dioxide with 
water was exhaled from mice when the less oxygen was delivered, causing the 
overproduction of moisture into the inhalation chambers, which may result in sticky 
powders to obstruct deaggregation impact events between particles. 
 Assessment of Bioactivity of Nano-nicotine via Locomotor Test by 
Injection 
To explore the effects of nicotine dose on naïve mice locomotor activity, the travel 
distance against dose of nicotine before and after drug administration was plotted in 
Figure 5.4. The locomotion distance of mice during habituation period (baseline) 
Figure 5.4 (A)] was analysed by one-way ANOVA with Bonferroni post hoc analysis, 
demonstrating no significant difference was observed among groups [F (5, 43) = 
0.2113, p>0.05 ]. It indicated that a stable baseline has been achieved, and any changes 
of locomotion activity after drug administration resulted from the treatments of drug 
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instead of some effect of particular locomotor chambers. Under this experimental 
condition, Figure 5.4 (B) presented the locomotor activity of mice after s.c. injection 
in the first hour. There was no significant difference between treatments of vehicle (V) 
and CS only (C) injection, suggesting CS injection did not affect the locomotion 
activity in mice. 
 The results of nicotine injections showed the dose of nicotine had the dual effects in 
locomotion distance with significant difference of treatments statistically [F (5, 42) = 
5.216, ***p=0.0008]. Compared with the vehicle group, s.c. injection of 0.25 N, in the 
similar level of CS injection, had no effects on locomotor activity, while 0.5 N 
administration boosted mice locomotor activity significantly (*p=0.0274); on the other 
hand, 1.0 N and 1.5 N decreased locomotor activity considerably visually, though these 
effects were not statistically significant from vehicle group (p>0.05), they were 
significant different from 0.5 N injection (p<0.05).  
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Figure 5.4 Total travel distance of mice in the period of (A) habituation (baseline); (B) nicotine 
test administered by s.c. injection (n=8-10 per group) (significant difference from group of 
vehicle: *p<0.05, significant difference from group of 0.5N: $p<0.05, $$p<0.01, $$$p<0.001)    
 
The doses of nicotine (0.5 mg/kg, 1.0mg/kg, 1.5 mg/kg) chosen in this study were 
based on the recommended nicotine dose in mice by Matta et.al (Matta et al., 2007). It 
was reported that the sensitivity of acute effects of nicotine in mice is less than that in 
rats. Median effective dose (ED50) dose for seizures in mice is 2-6 mg/kg depending 
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on strain (Matta et al., 2007). Regarding our study, the markedly depressant effects 
induced by acute s.c. injection were observed at 1.5 mg/kg, while the stimulant effects 
were at 0.5 mg/kg. The dose-response relationship between stimulant and depressant 
effects generally occurs in mice within a narrow dose range and the purpose of this 
section was to find the minimum nicotine dose in mice which had a stimulant effect. 
Thus, a lower nicotine dose of 0.25 mg/kg was introduced. The doses of nano-nicotine 
chosen were based on the drug loading (65%) of nicotine-loaded CS nanoparticles in 
accordance with corresponding nicotine doses. 
The results obtained in this study are agreement with previous reports (Stolerman, 
Fink, & Jarvik, 1973) (Clarke & Kumar, 1983) that locomotor stimulant effects were 
developed at low dose of nicotine, followed by a decrease at high dose of nicotine in 
its locomotor depressant effects, which is governed centrally mediated theoretically 
(Morrison et al., 1969).  The sensitized nicotine group (0.5 N) travelled longest in 
locomotor activity among all the nicotine test groups, which is supported by 
Schweitzer that low dose of intravenous nicotine suppresses spinal reflexes 
(Schweitzer & Wright, 1938), in contrast, the dose of 1.5 N showed sensitized 
depressant behaviour as high level of nicotine in the brain and blood would cause 
locomotion disturbances, which has been reported by Stolerman (Stolerman et al., 
1973). Overall, the nicotine locomotor stimulant and depressant characters in naïve 
mice are dose dependent due to the regulations of different types of nAChR on 
nicotine’s stimulant and depressant effects. 
 A stable baseline with no significant difference [F (5, 46) = 0.6652, p>0.05] was 
obtained during habituation period as shown in the Figure 5.5 (A) using one-way 
ANOVA test. The travel distances from different doses of nano-nicotine were graphed 
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in Figure 5.5 (B) with significant difference [F (5, 46) = 3.671, **p=0.0071] seen 
among treatment groups using one-way ANOVA with Bonferroni post hoc analysis. 
Compared with vehicle group, the injections of CS and 0.25 NN produced similar 
average travel distance in one hour without statistical difference (p>0.05). The 
treatment of 1.0 NN injection stimulated mice to the maximum average travel distance 
with significant difference (* p=0.0418) from vehicle group. The dose of 0.5NN 
increased travel distance, but the effect was not clearly as high as the dose of 1 NN 
when compared with vehicle group and no significant difference was detected 
statistically. Marked locomotor depression was observed at 1.5 NN though this effect 
was not statistically significant from the vehicle group (p>0.05).   
Furthermore, results were analysed statistically between doses. The travel distance 
from 1.0 NN injection was as comparator. The significant differences were observed 
at the treatments of 0.25 NN ($p=0.0292) and 1.5 NN ($$p=0.0014) from the group of 
1.0 NN.  
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Figure 5.5 Total travel distance of mice in the period of (A) habituation (baseline); (B) nano-
nicotine test administered by s.c. injection  (n=8-10 per group) (significant difference from 
group of vehicle: *p<0.05; significant difference from group of 1.0 NN: $p<0.05, $$p<0.01) 
 
The s.c. administration of nicotine induced an obvious dose-related effect in mice 
locomotor activity and their travel distance was analysed in every 5 minutes in the one 
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hour post drug injection (Figure 5.6).  Statistical analysis from two-way ANOVA with 
Bonferroni post hoc test showed that there was a main effect [F (55, 473) = 1.819; 
***p=0.0006] between factors of time [F (11, 473) = 51.92; p<0.0001] and treatment 
[F (5, 43) = 3.446; p=0.0105].  The travel distance in the first 5 minutes, the highest 
peak from all mice during one hour observation, was stimulated greatly by the dose of 
0.5 N (**p<0.01) and 1.0 N (*p<0.05) when compared with vehicle group. However, 
it is uncertain to conclude whether the hyperactivity during this session was as a result 
of test stress response or nicotine stimulation effects. In the second 5 minute session, 
the locomotor activity of all mice were reduced substantially, while the doses of 1.0 N 
(***p<0.001) and 1.5 N (***p<0.001) inhibited mice around zero movement with 
statistically significant decrease from vehicle group. This maybe an evidence to show 
acute nicotine administration in high dose could cause mice hypoactive and sleepy. In 
the following sessions, no significant differences between drug treatment groups were 
observed compared with vehicle group. This maybe because the nicotine was 
metabolized into cotinine in the mice bodies which was in agreement with the short 
half-life (t ½) around 5.9-6.5 minutes of nicotine in the mice (Petersen, Norris, & 
Thompson, 1984).  
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Figure 5.6 The effects of dose administrated by s.c. injection of nicotine on mice locomotor 
activity with time (n=8-10 per group) (Significant difference from vehicle group: *p<0.05, 
**p<0.01, ***p<0.001)        
 
Similarly, the locomotor activity of mice with different doses of nano-nicotine 
injection was analysed in the every 5 minutes by two-way ANOVA with Bonferroni 
post hoc test as shown in Figure 5.7. No interaction effect [F (55, 506) = 1.222; 
p=1.222], but significant differences in the effects of time [F (11, 506) = 44.87; 
****p<0.0001] and drug treatments [F (5, 46) = 3.671; **p=0.0071] were observed. 
Substantial increased travel distance was performed in the first five minutes regardless 
of the doses of nano-nicotine though no significant difference was detected in 
comparison with vehicle. In the second 5 minutes session, travel distance from all 
treatment groups reduced considerably, while both treatment groups of 0.5 NN 
(**p<0.01) and 1.5 NN (**p<0.01) produced decreased travel distance significant 
statistically compared with vehicle injection. However, it was interesting to note that 
mice administered with 1.0 NN came back to be hyperactive with statistical 
significance during test period between 30 (**p<0.01) and 40 (*p<0.05) minutes. It 
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suggested sufficient concentration of nicotine was available to stimulate releasing 
nicotinic acetylcholine receptors in the mice brain during this period, which modulated 
locomotion behaviour of mice.  It is supposed to be highly associated with slow and 
prolonged release system of NHT-CS nanoparticles. Afterwards, no significant 
differences were observed in the following sessions compared with vehicle group. 
 
Figure 5.7 The effects of dose administrated by s.c. injection of  nano-nicotine on mice 
locomotor activity with time.  (n=8-10 per group) (Significant difference from vehicle group: 
*p<0.05, **p<0.01, ***p<0.001)        
 
Furthermore, to compare the stimulant effects of nicotine and nano-nicotine in mice 
locomotor activity clearly, the graphs of 0.5 N and 1.0 NN, which were significantly 
different from vehicle group statistically, were plotted in Figure 5.8. A marked delayed 
stimulant response in the treatment of 1.0 NN occurred between 30 and 40 minutes, 
while no significant effect can be observed in the treatment of 0.5 N in the 5 minutes 
after s.c. injection was applied. Based on the discussions, it suggested multi doses of 
nano-nicotine may be required to achieve the same stimulant effect induced by nicotine 
at the first dose for smokers. However, the delayed stimulant effect of nano-nicotine 
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will be beneficial to be applied in the clinical practice to reduce side effects of tobacco 
smoking and maintain a consistent dosing and improve patient compliance.    
 
Figure 5.8 Comparison graph between 1.0 NN and 0.5 N administrated by s.c. injection on 
mice locomotor activity with time.  (n=8-10 per group) (Significant difference from vehicle 
group: *p<0.05, **p<0.01, ***p<0.001)        
 
Based on the results from locomotor activity test by s.c. injection, it is concluded that 
low dose of nicotine (0.5 N) stimulates hyperactivity in the naïve mice in locomotor 
sensitivity, while high dose nicotine (1.5 N) depresses locomotor activity. The 
bioactivity of nano-nicotine was not eliminated during the manufacture process, and 
the effects of nano-nicotine was  like nicotine administration with dual effects, but not 
as sensitive as nicotine in the naïve animals. This because the nicotine is released from 
NHT-CS nanoparticles slowly (eg. the cumulative drug release was just around 35% 
in one hour). Unfortunately, we did not observe the effect of nano-nicotine on naïve 
mice in a longer period due to the animal ethics concerns and actual operation 
difficulties.   
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 Assessment of Viabilitiy of Inhalation of Nano-nicotine via  Locomotor 
Test  
To determine the lowest dose required of the inhaled nano-nicotine to alter locomotor 
activity, three inhaled doses (25mg, 50mg, 75mg per batch) of nicotine, nano-nicotine 
and one dose of CS nanoparticles (50mg) as vehicle group were tested  on 8-10 weeks 
old naïve C57BL/6 male mice. 
According to the data of in vitro evaluation of drug deposition from the novel nose-
only inhalation device (section 5.4.1), we knew the flow rate of 0.9 mL/min is superior 
to 0.6 mL/min for drug deposition. 10.77±1.90mg of 100 mg NHT loaded in the dosing 
chamber deposited in the 6 delivery ports, so deposited NHT in each port was around 
1.8mg. We estimated that loading 100 mg nano-nicotine with 400 mg lactose carriers 
into the dosing chamber would result in 10.77 mg of NHT delivered to the 6 ports 
(drug loading=65%, 10.77*65%=7.0 mg) and each mouse will inhale about 1.2 mg 
(7.0mg/6 mice=1.2 mg) of NHT, which is converted to ~0.4 mg nicotine base (1 mg 
NHT is equivalent to 0.35 mg nicotine). According to in vitro aerosolization study 
result, FPF of this nano-nicotine formulation was 24.4%, so 97.6 µg of nicotine is 
expected to be deposited on mouse lung. The average mouse body weight is 25g, so 
the dose is approximately 4 mg/kg, which is twice as much as the guided dose for mice 
(Matta et al., 2007). Therefore, 25 mg, 50mg and 75 mg nicotine were chosen to ensure 
a safe dose was delivered to the mice.  
Figure 5.9 (A) showed the mice average total travel distance in the period of 
habituation (baseline) before nicotine exposure occurred, with no effect of treatment 
[F (3, 38) = 0.9177, p=0.4415] when analysed by one-way ANOVA with Bonferroni 
post hoc analysis test. It suggested that a stable baseline was obtained before drug test. 
Under this test condition, the acute inhalation of nicotine from different doses caused 
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a significant treatment effect [F (3, 37) =4.690, **p=0.0071] in mice activity [Figure 
5.9 (B)]. As seen in Figure 5.9 (B), the locomotor activity from a dose of 25N was at 
a similar level to that with vehicle alone (p>0.05). At the dose of 50N, the naïve mice 
were stimulated vigorously to reach the maximum increase in activity compared to the 
CS only group (p<0.05). At a higher dose of 75N the travel activity decreased visually 
without significant difference from vehicle group.  
Furthermore, comparisons were analysed between doses statistically. Though the 
groups of 25N, 75N were not significant different from vehicle group statistically, the 
treatments of 25N (*p<0.5) and 75N (**p<0.01) appeared significantly different from 
the group of 50N.  
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Figure 5.9 Total travel distance of mice with nose-only inhalation exposure in the period of 
(A) habituation (baseline); (B) nicotine test (n=8-10 per group) (significant difference from 
group of vehicle: *p<0.05; significant difference from group of 50N: $p<0.05, $$p<0.01).  
 
Figure 5.10 presented the total travel distance of mice between habituation (baseline) 
and nano-nicotine test. Habituation for 1 hour before drug test produced a stable 
baseline in mice activity, with no effect of treatment [F (3, 38) = 0.9692, p=0.4173] 
observed from one-way ANOVA with post hoc analysis by Bonferroni test. 
Administration of nano-nicotine caused significant differences in the mice locomotor 
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activity [F (3, 37) =9.872, ****p<0.0001]. The group of 75NN stimulated locomotor 
activity significantly (**p<0.01) compared with vehicle group. On the other hand, 
groups of 25 NN and 50 NN did not alter mice activity behaviour significantly (p>0.5) 
as compared with vehicle group.  
Travel distances from all doses of nano-nicotine were compared between doses. The 
highest travel distance from dose of 75NN was seen as comparator. Both doses of 25 
NN and 50 NN produced the similar level with vehicle group, which were much less 
than the comparator group with significant differences statistically.  
  
Chapter 5:  In Vivo Assessments of NHT-loaded CS Formulations for Pulmonary Delivery 179 
 
Figure 5.10 Total travel distance of mice with nose-only inhalation exposure in the period of 
(A) habituation (baseline), producing no differences in baseline activity; (B) nano-nicotine test 
(n=8-10 per group)(significant difference from group of vehicle: **p<0.01; significant 
difference from group of 75NN: $p<0.05, $$p<0.01, $$$p<0.001,  $$$$p<0.0001).  
 
Exposure to inhalable grade of nicotine, nano-nicotine and vehicle of CS nanoparticles 
powder (after mixing with four times the mass of lactose respectively) produced a dose 
related response in locomotor activity, which was significant with regards to dose and 
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treatment factors. To better understand the mechanism of nicotine and nano-nicotine 
affecting mice locomotion behaviour, the travel distances were plotted in Figure 5.11 
in every 5 minutes from all mice and analysed by two-way ANOVA with Bonferroni 
post hoc analysis test. After inhalation exposure, the first 5 minutes produced highest 
activity in mice as a result of the fear and stress emotionally from researcher’s 
handling, inhalation device and test process.  Hyperactive response induced from stress 
and fear are consistent with some researchers (Hefner & Holmes, 2007; Strekalova, 
Spanagel, Dolgov, & Bartsch, 2005).  The following activities decreased gradually to 
the zero at the end of test.  There was an interaction effect [F (66, 726) =1.351, *P= 
0.0380] on dose treatment [F (6, 66) = 4.562, ***p=0.0006] with time [F (11, 726) = 
84.04, ****p<0.0001]. Specifically, the treatments of 25N, 25NN, 50NN, 75N did not 
resulted in significant travel differences compared with the CS only group. 
Administration with 50N caused a significant increase (* p<0.05) in the locomotion 
activity at 15 minutes after inhalation exposure, but no significant differences were 
observed afterwards. This is mostly possible due to short half-life(t1
2⁄
 ) of nicotine in 
mice body. Petersen reported the half-life of nicotine in C57BL mice blood was 5.9-
6.9 min when the mice were administrated an i.p injection of nicotine 
(1.0mg/mL)(Petersen et al., 1984). In other words, smokers have to repeat cigarette 
smoking frequently to maintain the specific nicotine levels in the body to sustain the 
effect of the drug because of the rapid elimination rate of nicotine (N. L. Benowitz, 
2010). However, the duration of response to 75 NN was longer than 50N, and 
significant increases in the mice activity were observed at 15 min (**p<0.001), 25 min 
(**p<0.01) and 30 min (*p<0.05). This is because nicotine has been loaded into CS 
nanoparticles to achieve sustained and prolonged release, which is in accordance with 
my previous study in Chapter 4. 
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Figure 5.11 The effects of nicotine and nano-nicotine exposure and different levels of drug 
dose on mice locomotor activity with time. (n=8-10 per group) (Significant difference from 
CS control: *p<0.05, **p<0.01) (Effects of 50N and 75NN are enlarged on right corner).       
 
The response to nicotine in mice is more sensitive than to nano-nicotine, with a higher 
dose (75NN) being required to achieve the same level of behavioural activity. Apart 
from the slow release of nicotine from CS nanoparticles, the greater dose of nano-
nicotine that is required may be due to the deposition efficiency of nano-nicotine being 
lower than NHT powder as nano-nicotine DPI powder is made of floatable LMW 
chitosan powder. Also, the micro aggregates induced by strong inter-/intra- molecular 
forces among nanoparticles (see Chapter 3), may prevent nano-nicotine dispersion in 
high efficiency. The preliminary results in the present study showed inhalation of 
nicotine presents the dual pharmacological effects on mice locomotion behaviour with 
increased activity at a dose of 50N and inhibited activity at a dose of 75N, while nano-
nicotine exposure evoked dose-dependent increase in travel distance.  
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The reinforcing effects of locomotor activity from nicotine are associated with the 
activation of specific nicotine acetylcholine receptor subunits in the brain, resulting in  
elevated extracellular and synaptic dopamine concentrations (Lallemand et al., 2007). 
When the nicotine is above a specific concentration in the brain, nicotine stimulates an 
increase in nicotinic acetylcholine receptors intensities through activating α4β2 
nicotinic receptors to modulate the release of several neurotransmitters. Enhanced 
movement in the locomotor chamber randomLy without stereotypic behaviour was 
observed in around 10 minutes post exposure, followed by calm to normal spontaneous 
activity eventually, at which point travel distance was quantitated in one hour of 
recovery period by Any-maze software. 
Overall, all the mice got accustomed to the test chamber and maintained a stable 
activity prior to inhalation test.  Under the conditions of this study, acute 
administration of 50 N and 75 NN produced the significant increase in the mice 
locomotor activity. Comparing results of locomotor activity test between 1.0 NN by 
injection and 75 NN via inhalation, stimulant effects were observed at 30 min and 40 
min statistically significantly from 1.00 NN injections,   while stimulant effects were 
noted at 15 min, 25 min and 30 min via 75 NN inhalations. As a result, it is concluded 
that pulmonary drug delivery is faster and more efficient option to achieve therapeutic 
effects than injection. 
 
  Histopathological Analysis of Lung Tissues  
Representative histological images following acute inhalation exposure (after 1 hour 
and 24 hours) are presented in Figure 5.12. The section of mice healthy lung tissues 
(Figure 5.12 A, B) is composed of clear alveolar space, intra-alveolar vessel and thin 
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wall alveoli, including a single layer of squamous epithelium. Figure 5.12 C, D showed 
the mice lungs tissues after CS only exposure after 1 and 24 hours respectively. No 
obvious morphological changes were observed, indicating inhalation of CS 
nanoparticles with inhalable lactose carrier does not cause airway inflammation. 
Nicotine exposure in one hour (Figure 5.12 E) did not result in  any change, while 
minimal thickened alveolar wall, hyperplasia of bronchial epithelial cells, mixed 
inflammatory cell infiltrate (neutrophil, lymphocyte and macrophages) between intra-
alveolar vessels occurred post exposure in 24 hours. No lesion was observed after 
nano-nicotine exposure for one hour (Figure 5.12 G). Nano-nicotine exposure in 24 
hours (Figure 5.12 H) induced minimal increased squamous metaplasia, slight 
thickened alveolar wall and inflammatory infiltrates around the alveolar ducts and 
adjacent vasculature, which are the commonly observed lesions at the lungs after 
smoke exposure depending on nicotine concentration and exposure duration (Tsuji et 
al., 2013).  
In this study, we did not observe the severe lesions of lungs in nicotine and nano-
nicotine exposure within 24 hours. In the literature, most of the frequent lesions in 
cigarette smoke exposure using rodents are squamous metaplasia of respiratory 
epithelium, hyperplasia of metaplastic epithelium and respiratory epithelium, 
remarkable accumulation of pigmented macrophages in the lungs, and inflammatory 
cell infiltrates and perivascular lymphocytic infiltrates (Tsuji et al., 2015; Tsuji, Lee, 
et al., 2011). Tsuji reported emphysematous changes in alveolar ducts and adjacent 
alveoli occurred in some smoke-exposed mice. A few microscopic lesions were 
present in sections of other protocol-required tissues from smoke, air or cage control 
groups, with no clear evidence of a relationship to smoke exposure.  
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Figure 5.12 Histological changes of lung tissues from different groups (10×40, H&E staining, 
n=6). (A-B) healthy mice lungs; (C) CS exposure mouse in one hour; (D) CS exposure mouse 
in 24 hours; (E) nicotine exposure (50mg) mouse in one hour; (F) nicotine exposure (50 mg) 
mouse in 24 hours; (G) nano-nicotine exposure (75mg) mouse in one hour; (H) nano-nicotine 
exposure (75mg) mouse in 24 hours 
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5.5 SUMMARY  
In this chapter, the locomotor activity of male C57BL/6 naïve mice was examined 
following acute s.c. injection and inhalation at several concentrations of nicotine and 
nano-nicotine. During the experimental period, no adverse health effects were 
observed in any of the animals at any concentrations, nor was there any evidence for 
residual effects on s.c. injected administration and nose-only inhalation exposure 
sessions. In terms of experimental results by s.c. injection, nicotine and nano-nicotine 
produced significant increase in locomotor activity at intermediate concentrations. 
Minimally effective concentrations for activity increasing effects were 0.5 mg/kg 
(nicotine) and 1.0 mg/kg (nano-nicotine), respectively. Locomotion activity was 
decreased with higher concentrations because of blockage of neuronal nAChR. This 
indicated the formulation of nano-nicotine inhalation powder is bio-active after the 
process of manufacturing NHT-CS (3:1) particles. Similarly, biphasic effects of dose 
response on locomotor activity were observed in nicotine and nano-nicotine inhalation. 
Increased and decreased dose of nicotine and nano-nicotine as a function of exposure 
concentration play an important role in changing mice locomotion behaviours, which 
may reflect the CNS-depressant drug-like effects of nicotine. Lowest dose   for activity 
increasing effects were 50 mg per batch/ 4 mice (nicotine) and 75 mg per batch / 4 
mice (nano-nicotine), respectively. This suggested the nose-only inhalation device 
developed by our group is effective to deliver aerosolized powder to mice lungs, which 
confirmed the result from in vitro evaluation of inhalation device. In addition, the 
formulation of nano-nicotine is promising to develop as DPI formulation for lung 
delivery, which is a potential therapeutic strategy for better management of nicotine 
dependence as a kind of nicotine replacement therapies.   
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In the lung, minimal inflammatory cell infiltration (e.g., macrophages and neutrophils) 
was increased at the dose of nicotine (50mg) and nano-nicotine (75mg) exposed groups 
after 24hour exposure compared with healthy mice lungs. Based on the histological 
images, it is suggested that the exposure of 50mg nicotine per batch and 75 mg nano-
nicotine per batch was insufficient to induce the severe pulmonary inflammation 
associated with tobacco-related lung diseases, indicating that formulation of NHT-CS 
nanoparticles may be applicable for exposure studies under this study design in 
C57BL/6 mice, but it is still suggested to observe histopathological changes in a longer 
period. 
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Chapter 6:  
Conclusions  
  
Chapter 6: Conclusions 188 
6.1 OVERALL CONCLUSIONS 
The aim of this study was to develop a pulmonary drug delivery system using nicotine-
loaded CS nanoparticles as DPI formulations with the potential for the treatment of 
nicotine dependence with low dose and controlled release profiles. Thus, this thesis 
has focussed on discussion of strategies to develop a particulate NHT delivery system 
from DPI formulations (in Chapter 3), following in vitro evaluations of DPI 
formulations (in Chapter 4); and safety and efficiency tests of formulations on animal 
models demonstrated in Chapter 5. 
Firstly, an effective way to fabricate micro/nanoparticles of biodegradable polymer, 
CS, loaded with nicotine hydrogen tartrate (NHT) for pulmonary delivery of nicotine 
from DPI formulations was established. The prepared nanoparticles were 
characterized using a series of analytical techniques. The particles were spherical 
under SEM and TEM observations with size ranges between 167.6 and 411 nm by 
DLS analysis; however, Mastersizer showed aggregation between nanoparticles 
induced agglomerates between 3.73 and 4.73 µm in diameter due to high surface 
energy. Drug loading increased along with increase of mass ratios of NHT and CS, 
achieving highest loading rate at 66% for a ratio of 3:1. There was no surface 
enhancement of NHT on the nanoparticles since the amount of NHT measured on the 
surface of CS increased proportionally with increasing drug loading in the bulk 
according to the XPS analysis. DSC, XRD and FTIR suggested crystallinity of NHT 
was lost when encapsulated in the CS micro/nanoparticles. Specific surface area and 
surface charge were two main factors, which eventually affect the drug release and 
dispersibility of micro/nanoparticles as DPI formulations.  
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Secondly, in vitro drug release, aerosolization and long-term stability were studied to 
evaluate the DPI formulations of nicotine-loaded CS micro/nanoparticles as DPI 
formulations. In vitro drug release study from dialysis  membrane technique (to 
separate released NHT from the nanoparticles) showed an initial burst release for the 
first 8 hours followed by the sustained and prolonged release profiles of NHT released 
from CS particles matrix up to 4 days.  The maximum cumulative release (%) achieved 
was around 65% with respect to highest drug loading formulation.  The particles with 
bigger particle size experienced a slower initial burst release rate but longer sustained 
release period compared with smaller particles. A mathematical model allowed 
correction of the discrepancy during drug release measurement due to two diffusion 
barriers of the dialysis membrane. From TSI studies, the FPF of NHT-loaded CS 
nanoparticles reduced along with increase of mass ratios of NHT to CS, which is 
mainly dominated by the surface charge on the nanoparticle aggregates as measured 
by zeta potential. In contrast, increased FPD of NHT from 1.7 mg to 3.2 mg was 
obtained with increased concentration of NHT in the nanoparticles. However, 
dispersibility values of NHT-loaded CS particles with large lactose carriers increased 
significantly, which were independent of the effect of surface charge. In the long-term 
stability test, the formulations of NHT-CS inhalation particles were stable at the 
storage condition of 25°C/60% RH for a one-year observation.  
Thirdly, by using a mouse model, effective parameters of nose-only inhalation device 
were determined at 0.9L/min flow rate and inhalation duration for 5 minute. Safety of 
inhalation for mice lungs and efficiency to mediate mice locomotion behaviour 
following administration of NHT-loaded CS particles as DPI formulations were 
evaluated through locomotor activity test and histological observations. It was found 
NHT-loaded CS nanoparticles maintained bioactivity and delivered nicotine as 
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measured through locomotor activity test by injection. This was found to result in 
hyperactivity in mice at intermediate dose (s.c. single injection: 0.5 mg/kg for nicotine; 
1.0 mg/kg for NHT-CS nanoparticles vs. inhalation exposure: the groups of 50N for 
nicotine; 75 NN for NHT-CS nanoparticles) and, in contrast, hypoactivity at higher 
challenge doses. After inhalation exposure of NHT-CS particles to mice for 24 hours, 
there was no allergic airway inflammation observed by histological analysis of lung 
sections.  
In conclusion, this study has successfully established an effective and feasible way to 
develop NHT-loaded CS nanoparticles as DPI formulations although it involves 
organic solvent and crosslinking methods that are complex and time consuming. The 
outcomes of this study suggest that pulmonary delivery, after further work, may 
provide an alternative treatment approach for nicotine-mediated behaviours. It is 
anticipated that the advancement of knowledge on pulmonary drug delivery from the 
mouse model will translate to novel therapeutic strategies for the better management 
of patients with nicotine dependence in the future, and eventually it may offer a more 
targeted therapy approach for the significant number of Australians and smokers 
worldwide affected by smoking-related disorders. At the end of this work, it is 
expected this project will contribute to more effective medications for substance use 
disorders, reduce direct and indirect costs to society and make improvements to public 
health and safety and health care delivery. 
6.2 LIMITATIONS 
A successful nicotine replacement therapy requires delivery of sufficient nicotine in 
the blood of a smoker to reach the levels achieved from cigarette smoking. Based on 
this study i.e., in vitro drug release (Figure 4.5), conversion factor between NHT to 
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nicotine base (1 mg NHT equals 0.35 mg nicotine base), drug loading (Table 3.9), and 
FPD of NHT from the prepared nanoparticles (Table 4.3), the predicted peak plasma 
concentration will be between 4 and 7 ng/mL from 1.7 to 3.2 mg of FPDs of the 
prepared formulations in 8 h when the highest drug release was observed. Unlike 
cigarette smoking where nicotine reaches the brain within a few seconds from 
inhalation, in the nanoparticle system this will be delayed. As indicated in previous 
chapters, multiple capsules will likely be required to get the required pharmacological 
effect and that high dose of chitosan may cause an adverse effect.  
6.3 FUTURE DIRECTIONS 
Developing an effective treatment option from pulmonary delivery with reduced side 
effects for nicotine addiction is a long term and sustained work. This study is just the 
tip of an iceberg to explore a better therapeutical option for management of nicotine 
dependence. There are still many gaps due to complexity of the topic and limited 
available techniques. Although we have successfully developed a feasible way to 
prepare particles, it requires a number of studies to improve and optimise current 
powder formulation techniques and animal models for pulmonary drug delivery. Based 
on the outcomes to date and a deeper understanding of this project, a few challenges 
are suggested for future research directions.  
Chitosan nanoparticles have been used extensively as drug delivery vehicles due to 
their excellent bioavailability, better encapsulation, and controlled release with less 
toxic properties. Further studies could involve the use of derivatives of chitosan to 
provide better control of properties. However, currently most studies focus on the 
modifications of amino groups at the C2 position, while less attention is paid on the 
potential application of C6 modification (Islam & Ferro, 2016).  In the near future, 
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more conjugates of CS with drugs or other excipients at C6 or both C2 and C6 could 
be prepared for more practicable pharmacotherapeutic strategies. In addition, toxicities 
of derivatives of CS in human different organs have not been fully understood although 
a lot of studies have been reported based on in vivo animal models. However, there is 
no doubt that translation from animal models to humans is still difficult to achieve due 
to large differences of anatomical structures between animals and humans. 
Biodegradability is another safety issue to be considered in long term human health 
applications. In particular, the most current techniques involved in organic solvents 
and use chemical crosslinkers as well as high shear force. It is suggested that there is 
a need to develop more mild preparation techniques and search for less or non-toxic 
crosslinkers.  
Further comprehensive studies may be needed to develop an efficient DPI formulation 
by understanding the interactions between the charged particles and carriers, the 
impact of charged particles or agglomerates on the deagglomeration and dispersion, 
which will contribute to improving powders’ aerosolization performance and reducing 
adhesion force among particles.  
This study has addressed the safety and efficiency of nicotine-loaded CS particles as 
DPI formulation from the acute response in an animal model. Future investigations are 
suggested to consider measuring nicotine-mediated behaviours and clinically relevant 
blood levels of nicotine and cotinine to examine the efficacy of DPI formulations of 
NHT-loaded CS particles in reducing nicotine consumption in mice model for the long 
term.  
Further investigations are also suggested to explore more effective inhalation 
apparatus of dry powders in animal models. The research of DPI is growing fast in the 
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pharmaceutical studies and has achieved a significant success in the recent decades, 
but the equipment for studies in animal models is still not yet sufficient. Based on the 
current reviews (J. Kaur et al., 2008; Kwon et al., 2008), the inhalation devices 
designed for DPI studies either require tracheal intubation of the test animal under 
ambient pressure or positive pressure, which results in a large proportion of inhaled 
particles being deposited by physiological breathing rather than spontaneous 
respiration; or it requires whole-body exposure to achieve inhalation by spontaneous 
respiration, while the absorption routes are through percutaneous absorption  or 
orifices other than the nasopharynx. Some material is also toxic when retained on the 
fur of the animals. The nose-only exposure devices seem favourable for animal model 
studies, however, the duration of exposure is critical to consider carefully with 
variation of air flow rate, air pressure and aerosol concentration (Lebedová et al., 
2016). Therefore, it is essential to improve inhalation equipment further with joint 
collaborations from other disciplines such as mechanical engineering, chemistry, 
biology and neurology and so on.  
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Table 1. In vitro aerosolization study of blank and NHT-loaded CS nanoparticles by TSI in one 
year under storage condition of 25°C, 60% RH (data presented as mean ± SD., n = 3) 
 
 
Formulation Month R (mg) S1(mg) S2 (mg) RD (%) ED (%) FPF (%) 
Blank CS 0 5.6±0.1 7.4±0.1 5.6±0.1 90.0±1.4 69.9±0.2 30.8±0.2 
 1 6.2±0.4 6.1±0.7 5.4±0.1 88.8±3.6 64.8±2.2 30.3±1.1 
 2 8.5±0.5 7.5±0.3 6.9±0.2 92.1±0.5 62.9±1.8 30.1±0.6 
` 12 6.6±0.4 6.5±0.2 5.7±0.3 94.0±2.8 64.9±1.6 30.3±0.9 
NHT-CS 1:1 0 4.5±0.2 8.0±0.2 5.3±0.2 88.3±2.7 74.7±0.7 29.6±0.9 
 1 5.4±0.3 7.5±0.4 5.3±0.2 91.4±2.1 70.4±1.6 29.2±1.2 
 2 5.2±0.5 8.3±0.6 5.4±0.2 94.6±2.6 73.2±2.8 28.3±0.6 
 12 4.9±0.4 7.8±0.5 5.2±0.4 89.5±2.7 72.6±1.3 29.1±0.8 
NHT-CS 2:1 0 4.4±0.5 9.9±0.4 5.3±0.4 92.5±2.9 76.9±2.3 25.9±2.3 
 1 4.8±0.3 9.5±0.4 5.1±0.1 96.9±2.6 75.2±0.2 26.2±0.8 
 2 4.8±0.8 9.5±0.6 5.3±0.2 98.2±2.2 75.5±3.6 27.0±0.3 
 12 4.4±0.5 9.9±0.1 5.0±0.7 91.4±3.4 77.3±2.8 25.8±3.2 
NHT-CS 3:1 0 4.6±0.3 9.3±0.8 4.6±0.2 92.9±2.9 75.3±2.4 24.4±1.5 
 1 4.3±0.2 9.4±0.5 4.4±0.2 90.6±4.2 76.1±1.0 24.1±1.3 
 2 4.7±0.4 9.8±0.7 4.8±0.2 96.4±1.7 75.7±2.7 24.6±1.4 
 12 4.8±0.3 9.3±1.1 4.4±0.2 92.0±3.3 74.7±3.3 24.1±1.7 
 
NB: black CS nanoparticles were measured gravimetrically; NHT-loaded CS nanoparticles were 
measured gravimetrically and spectrophotometrically. 
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Table 2.  Mass balance between different flow rates (NHT loaded=100mg) (data presented as 
mean±SEM) 
 
Flow rate 
(L/min) 
Total recovered 
dose 
(mg) 
Total all ports 
collected 
(mg) 
Percentage of 
Deposition (%) 
0.6 27.15±1.14 8.72±0.92 9.03±1.40 
0.9 43.43±4.73 10.77±1.90 11.21±1.68 
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Figure 1.  Locomotor activity administrated by 0.25 mg/kg s.c. injection (n=8-10 per group; 
mean±SEM) (A) travel distance of naïve mice every 5 minutes for 2 hours; (B) travel distance 
during habituation period; (C) travel distance during one hour of drug test period; (D) the 
percentage of travel distance in the drug test hour of total travel distance in the two hours;  
NB: “N”=nicotine; “NN”=nano-nicotine; “V”=vehicle; “C”=Chitosan 
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Figure 2. Locomotor activity administrated by 0.5 mg/kg s.c. injection (n=8-10 per group; 
mean±SEM) (A) travel distance of naïve mice in every 5 minutes for 2 hours; (B) travel 
distance during habituation period; (C) travel distance during one hour of drug test period; (D) 
the percentage of travel distance in the drug test hour of total travel distance in the two hours. 
NB: “N”=nicotine; “NN”=nano-nicotine; “V”=vehicle; “C”=Chitosan 
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Figure 3. Locomotor activity administrated by 1.0 mg/kg s.c. injection (n=8-10 per group; 
mean±SEM) (A) travel distance of naïve mice in every 5 minutes for 2 hours; (B) travel 
distance during habituation period; (C) travel distance during one hour of drug test period; (D) 
the percentage of travel distance in the drug test hour of total travel distance in the two hours..  
NB: “N”=nicotine; “NN”=nano-nicotine; “V”=vehicle; “C”=Chitosan 
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Figure 4. Locomotor activity administrated by 1.5 mg/kg s.c. injection (n=8-10 per group; 
mean±SEM) (A) travel distance of naïve mice in every 5 minutes for 2 hours; (B) travel 
distance during habituation period; (C) travel distance during one hour of drug test period; (D) 
the percentage of travel distance in the drug test hour of total travel distance in the two hours;  
NB: “N”=nicotine; “NN”=nano-nicotine; “V”=vehicle; “C”=Chitosan 
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Figure 5. Locomotor activity inhalation exposure for 25mg dose (n=8-10 per group; 
mean±SEM) (A) travel distance of naïve mice in every 5 minutes for 2 hours; (B) travel 
distance during habituation period; (C) travel distance during one hour of drug test period; (D) 
the percentage of travel distance in the drug test hour of total travel distance in the two hours.  
NB: “N”=nicotine; “NN”=nano-nicotine; “C”=Chitosan/Vehicle 
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Figure 6. Locomotor activity inhalation exposure for 50 mg dose (n=8-10 per group; 
mean±SEM) (A) travel distance of naïve mice in every 5 minutes for 2 hours; (B) travel 
distance during habituation period; (C) travel distance during one hour of drug test period; (D) 
the percentage of travel distance in the drug test hour of total travel distance in the two hours.  
NB: “N”=nicotine; “NN”=nano-nicotine; “C”=Chitosan/Vehicle 
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Figure 7. Locomotor activity inhalation exposure for 75 mg dose (n=8-10 per group; 
mean±SEM) (A) travel distance of naïve mice in every 5 minutes for 2 hours; (B) travel 
distance during habituation period; (C) travel distance during one hour of drug test period; (D) 
the percentage of travel distance in the drug test hour of total travel distance in the two hours;  
NB: “N”=nicotine; “NN”=nano-nicotine; “C”=Chitosan/Vehicle 
 
 
 
